Exhibit 99.1
EXCHANGE AGREEMENT
dated as of
SEPTEMBER 25, 2005
by and among
SIRONA HOLDINGS LUXCO S.C.A.,
BLITZ 05-118 GMBH
and
▇▇▇▇▇▇ TECHNOLOGIES, INC.
TABLE OF CONTENTS
Page
ARTICLE 1 THE EXCHANGE.........................................................1
1.1 Authorization.......................................................1
1.2 The Exchange........................................................2
1.3 Closing.............................................................2
ARTICLE 2 REPRESENTATIONS AND WARRANTIES OF ▇▇▇▇▇▇.............................2
2.1 Organization; Standing and Power; Charter Documents; Subsidiaries...2
2.2 Capital Structure...................................................3
2.3 Authority; Non-Contravention; Necessary Consents....................4
2.4 Financial Statements; Indebtedness; Undisclosed Liabilities.........5
2.5 Absence of Certain Changes or Events................................6
2.6 Taxes...............................................................6
2.7 Intellectual Property...............................................7
2.8 Compliance with Laws; Permits.......................................7
2.9 Litigation..........................................................7
2.10 Material Contracts..................................................8
2.11 Benefit Plans; Labor................................................9
2.12 Property...........................................................10
2.13 Insurance..........................................................10
2.14 Related Party Transactions.........................................10
2.15 Environmental Matters..............................................11
2.16 Brokers' and Finders' Fees.........................................11
2.17 Filings with SEC...................................................11
2.18 The Proxy Statement; Disclosure....................................11
2.19 Board Approval.....................................................12
2.20 Opinion of Financial Advisor.......................................12
2.21 Delaware 203; Takeover Statute.....................................12
2.22 Investment Representations.........................................12
2.23 Exchanged Shares...................................................12
2.24 Disclosure.........................................................13
ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF SIRONA............................13
3.1 Organization; Standing and Power; Charter Documents; Subsidiaries..13
3.2 Capital Structure..................................................13
3.3 Authority; Non-Contravention; Necessary Consents...................15
3.4 Financial Statements; Indebtedness; Undisclosed Liabilities........16
3.5 Absence of Certain Changes or Events...............................16
3.6 Taxes..............................................................17
3.7 Intellectual Property..............................................17
3.8 Compliance with Laws; Permits......................................17
3.9 Litigation.........................................................18
3.10 Material Contracts.................................................18
3.11 Benefit Plans; Labor...............................................19
- i -
3.12 Property...........................................................20
3.13 Insurance..........................................................21
3.14 Related Party Transactions.........................................21
3.15 Environmental Matters..............................................21
3.16 Brokers' and Finders' Fees.........................................22
3.17 The Proxy Statement; Disclosure....................................22
ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF LUXCO.............................22
4.1 Organization; Power; Charter Documents.............................22
4.2 Authority; Non-Contravention; Necessary Consents...................22
4.3 Capital Structure..................................................23
4.4 Investment Representations.........................................24
4.5 Exchanged Shares and Note..........................................24
4.6 Disclosure.........................................................24
ARTICLE 5 COVENANTS RELATING TO CONDUCT OF BUSINESSES.........................24
5.1 Covenants of ▇▇▇▇▇▇................................................24
5.2 Covenants of Sirona................................................26
5.3 Advice of Changes; Government Filings..............................28
ARTICLE 6 ADDITIONAL AGREEMENTS...............................................29
6.1 ▇▇▇▇▇▇ Stockholders Meeting; Preparation of the Proxy Statement....29
6.2 Access to Information; Quarterly Financial Statements..............30
6.3 Approvals and Consents; Cooperation................................31
6.4 Alternative Proposals..............................................32
6.5 Fees and Expenses..................................................34
6.6 Current Public Information.........................................34
6.7 Listing............................................................34
6.8 Section 203 of the DGCL............................................35
6.9 Transfer of Restricted Securities..................................35
6.10 Public Announcements...............................................36
6.11 Tag-Along Rights...................................................36
6.12 Independent Directors..............................................37
6.13 Tax-Free Exchange..................................................37
6.14 Further Assurances.................................................38
ARTICLE 7 CONDITIONS PRECEDENT................................................38
7.1 Conditions to Each Party's Obligation to Effect the
Exchange Transactions..............................................38
7.2 Conditions to the Obligations of Luxco and Sirona to
Effect the Exchange Transactions...................................39
7.3 Conditions to the Obligations of ▇▇▇▇▇▇ to Effect the
Exchange Transactions..............................................40
ARTICLE 8 TERMINATION AND AMENDMENT...........................................41
8.1 Termination by Either ▇▇▇▇▇▇ or Luxco..............................41
8.2 Termination by Luxco...............................................42
- ii -
8.3 Termination by ▇▇▇▇▇▇..............................................42
8.4 Effect of Termination..............................................43
8.5 Amendment..........................................................44
8.6 Extension; Waiver..................................................44
ARTICLE 9 DEFINITIONS; INTERPRETATION.........................................44
9.1 Definitions........................................................44
9.2 Cross References...................................................49
9.3 Interpretation.....................................................51
ARTICLE 10 GENERAL PROVISIONS.................................................51
10.1 Non-Survival of Representations, Warranties and Agreements;
No Other Representations and Warranties............................51
10.2 Notices............................................................52
10.3 Counterparts.......................................................53
10.4 Entire Agreement; No Third Party Beneficiaries; Liability..........53
10.5 Governing Law; Jurisdiction........................................54
10.6 Severability.......................................................54
10.7 Succession and Assignment..........................................54
10.8 Enforcement........................................................55
INDEX OF EXHIBITS
Exhibit A - Transfer Deed
Exhibit B - Note Assignment Instrument and Consent
Exhibit C - Press Release
Exhibit D - Registration Agreement
Exhibit E - Amendment to Certificate of Incorporation
- iii -
EXCHANGE AGREEMENT
THIS EXCHANGE AGREEMENT, dated as of September 25, 2005 (this
"Agreement"), is made by and among Sirona Holdings Luxco S.C.A., a societe en
commandite par actions, organized under the laws of the Grand Duchy of
Luxembourg ("Luxco"), ▇▇▇▇▇ ▇▇-▇▇▇ ▇▇▇▇, a corporation organized under the laws
of the Federal Republic of Germany and to be renamed Sirona Holding GmbH
("Sirona") and a wholly owned subsidiary of Luxco, and ▇▇▇▇▇▇ Technologies,
Inc., a Delaware corporation ("▇▇▇▇▇▇"). Each of Luxco, Sirona and ▇▇▇▇▇▇ are
referred to herein individually as a "Party" and collectively as the "Parties."
Except as otherwise indicated herein, capitalized terms used herein are defined
in Section 9.1 hereof.
WHEREAS, Luxco owns 100% of the issued and outstanding share capital
of Sirona, which is divided into two shares (together, the "Sirona Shares");
WHEREAS, Luxco holds a Promissory Note, issued June 30, 2005 by
Sirona to Luxco, in the original principal amount of (euro)150,992,464 (the
"Sirona Note");
WHEREAS, Luxco and ▇▇▇▇▇▇ have each determined that it is in their
respective best interests for ▇▇▇▇▇▇ to acquire from Luxco all of the Sirona
Shares and the Sirona Note in exchange for ▇▇▇▇▇▇'▇ issuance to Luxco of
36,972,480 shares of common stock, par value $.01 per share, of ▇▇▇▇▇▇ ("Common
Stock"), upon the terms and subject to the conditions set forth in this
Agreement;
WHEREAS, Luxco and Sirona are unwilling to enter into this Agreement
unless, simultaneously with the execution and delivery of this Agreement,
certain beneficial and record stockholders of ▇▇▇▇▇▇ each enter into a separate
Voting Agreement and Irrevocable Proxy with Luxco (collectively, the "Voting
Agreements") providing for certain voting and other agreements relating to
certain of the shares of Common Stock owned by such stockholders; and
WHEREAS, the Exchange Transactions (as defined below) are intended
to constitute a tax-free exchange of property under applicable law.
NOW, THEREFORE, in consideration of the foregoing and the respective
representations, warranties, covenants and agreements set forth herein, and
intending to be legally bound hereby, the Parties agree as follows:
ARTICLE 1
THE EXCHANGE
1.1. Authorization. On the basis of the representations, warranties,
covenants and agreements and subject to the satisfaction or waiver of the
conditions set forth herein, at or prior to the Closing (as defined below),
▇▇▇▇▇▇ agrees to authorize the issuance to Luxco of 36,972,480 shares (as
equitably adjusted for any stock split, stock dividend or other recapitalization
of ▇▇▇▇▇▇ (whether by merger or otherwise) occurring after the date hereof and
prior to the Closing Date) of Common Stock (collectively, the "▇▇▇▇▇▇ Shares").
1.2 The Exchange. On the basis of the representations, warranties,
covenants and agreements and subject to the satisfaction or waiver of the
conditions set forth herein, at the
Closing, ▇▇▇▇▇▇ shall issue to Luxco, and Luxco shall acquire from ▇▇▇▇▇▇, the
▇▇▇▇▇▇ Shares free and clear of all Liens, and in exchange for such issuance,
Luxco shall transfer to ▇▇▇▇▇▇, and ▇▇▇▇▇▇ shall acquire from Luxco, the Sirona
Shares and the Sirona Note free and clear of all Liens (collectively, the
"Exchange Transactions"). At the Closing, (i) ▇▇▇▇▇▇ shall deliver to Luxco, one
or more certificates evidencing the ▇▇▇▇▇▇ Shares to be issued to Luxco
hereunder, registered in the name of Luxco or its nominee, subject to delivery
of the Sirona Shares and the Sirona Note to be exchanged therefor hereunder,
(ii) Luxco and ▇▇▇▇▇▇ shall execute and notarize before a German or Swiss notary
a German law governed transfer deed for the Sirona Shares in the form of Exhibit
A hereto (the "Transfer Deed"), subject to delivery of the ▇▇▇▇▇▇ Shares to be
exchanged therefor hereunder and (iii) Luxco, Sirona and ▇▇▇▇▇▇ shall execute
and deliver the Note Assignment Instrument and Consent in the form attached
hereto as Exhibit B with respect to the Sirona Note (the "Note Assignment"),
subject to delivery of the ▇▇▇▇▇▇ Shares to be exchanged therefor hereunder.
1.3 Closing. The closing of the Exchange Transactions (the
"Closing") shall take place at the offices of ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇ LLP, ▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇, commencing at 10:00 a.m. on the second
Business Day following the satisfaction or waiver of all conditions to the
obligations of the Parties to consummate the transactions contemplated hereby
(other than conditions with respect to actions the respective Parties will take
at the Closing itself), or at such other place or on such other date as may be
mutually agreeable to Luxco and ▇▇▇▇▇▇. The date and time of the Closing are
referred to herein as the "Closing Date."
ARTICLE 2
REPRESENTATIONS AND WARRANTIES OF ▇▇▇▇▇▇
▇▇▇▇▇▇ represents and warrants to Luxco and Sirona that the statements
contained in this Article 2 are true, correct and complete as of the date of
this Agreement and will be true, correct and complete as of the Closing Date,
subject to the limited exceptions specifically disclosed in writing in the
disclosure schedules supplied by ▇▇▇▇▇▇ to Luxco dated as of the date hereof,
certified by a duly authorized officer of ▇▇▇▇▇▇, as follows (it being
understood that whenever in this Article 2 a representation or warranty is made
in respect of ▇▇▇▇▇▇, it is also made in respect of each of ▇▇▇▇▇▇'▇ Significant
Subsidiaries):
2.1 Organization; Standing and Power; Charter Documents;
Subsidiaries.
(a) Organization; Standing and Power. ▇▇▇▇▇▇ and each of its
Subsidiaries is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation, have full
corporate power and authority to own, lease and operate their properties and to
carry on their businesses as now being conducted, except where the failure to
have such power and authority would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on ▇▇▇▇▇▇, and each is
duly qualified and in good standing to do business in each jurisdiction in which
the nature of its business or the ownership or leasing of its properties makes
such qualification necessary, except where the failure to be so qualified would
not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on ▇▇▇▇▇▇.
- 2 -
(b) Charter Documents. ▇▇▇▇▇▇ has made available to Luxco a
copy of the certificate of incorporation and bylaws of ▇▇▇▇▇▇, each as amended
to date (collectively, the "▇▇▇▇▇▇ Charter Documents") and the certificate of
incorporation and bylaws (or equivalent governing documents) of each of its
Significant Subsidiaries, each as amended to date (collectively, the "▇▇▇▇▇▇
Subsidiary Charter Documents") and all such instruments are in full force and
effect. Neither ▇▇▇▇▇▇ nor its Significant Subsidiaries are in default in any
material respect under or in violation in any material respect of any of the
provisions of the ▇▇▇▇▇▇ Charter Documents or the ▇▇▇▇▇▇ Subsidiary Charter
Documents, respectively.
(c) Subsidiaries. Set forth on Schedule 2.1(c) is a list
setting forth for each Subsidiary of ▇▇▇▇▇▇ its name, jurisdiction of
organization and a description of ▇▇▇▇▇▇'▇ ownership interest. Other than as set
forth on Schedule 2.1(c), ▇▇▇▇▇▇ has no Subsidiaries.
2.2 Capital Structure.
(a) Capital Stock. The entire authorized capital stock of
▇▇▇▇▇▇ (the "▇▇▇▇▇▇ Capital Stock") consists solely of (i) 50,000,000 shares
denominated as Common Stock of which 16,067,940 shares of Common Stock are
issued and outstanding and (ii) 2,500,000 shares of preferred stock, $.01 par
value, none of which is issued and outstanding. All of the issued and
outstanding shares of Common Stock have been duly authorized and validly issued,
are fully paid and non-assessable, and are free of any preemptive rights, rights
of participation, rights of maintenance or any similar rights. The issued and
outstanding shares of Common Stock were not issued in violation of the
preemptive rights of any Person or any Contract or Legal Requirement by which
▇▇▇▇▇▇ at the time of issuance was bound including federal and state securities
laws. As of the date hereof, there are no shares of ▇▇▇▇▇▇ Capital Stock held in
treasury by ▇▇▇▇▇▇. Except as set forth in Schedule 2.2(a): (i) none of the
outstanding shares of ▇▇▇▇▇▇ Capital Stock is subject to any right of first
refusal in favor of ▇▇▇▇▇▇ or any other Person, and (ii) there is no Contract
relating to the voting or registration of, or restricting any Person from
purchasing, selling, pledging or otherwise disposing of (or granting any option
or similar right with respect to), any shares of ▇▇▇▇▇▇ Capital Stock. ▇▇▇▇▇▇ is
not under any material obligation, nor is it bound by any material Contract
pursuant to which it may become obligated, to repurchase, redeem or otherwise
acquire any outstanding shares of ▇▇▇▇▇▇ Capital Stock.
(b) Other Securities. Except as otherwise set forth in
Schedule 2.2(b) or in the list described below in this Section 2.2(b), there are
not issued, outstanding or authorized any (i) securities, options, warrants,
calls, rights, commitments, agreements, arrangements or undertakings of any kind
to which ▇▇▇▇▇▇ or any Subsidiary of ▇▇▇▇▇▇ is a Party or by which it is bound
obligating ▇▇▇▇▇▇ or such Subsidiary to issue, deliver or sell, or cause to be
issued, delivered or sold, additional shares of ▇▇▇▇▇▇ Capital Stock or other
securities of ▇▇▇▇▇▇ or such Subsidiary, or obligating ▇▇▇▇▇▇ or such Subsidiary
to issue, grant, extend or enter into any such security, option, warrant, call,
right, commitment, agreement, arrangement or undertaking or that that would vest
or become exercisable as a result of the transactions contemplated hereby, (ii)
outstanding security, instrument or obligation that is or may become convertible
into or exchangeable for any shares of the ▇▇▇▇▇▇ Capital Stock or other
securities of ▇▇▇▇▇▇ or any Subsidiary of ▇▇▇▇▇▇, (iii) stockholder rights plan
(or similar plan commonly referred to as a "poison pill") or Contract under
which ▇▇▇▇▇▇ or any Subsidiary of ▇▇▇▇▇▇ is or may become obligated to sell or
otherwise issue any shares of its ▇▇▇▇▇▇ Capital Stock or any other securities
- 3 -
of ▇▇▇▇▇▇ or such Subsidiary, (iv) agreement to register any security of ▇▇▇▇▇▇
or any Subsidiary of ▇▇▇▇▇▇ on a come-along, drag-along or other basis, or (v)
other than the Transaction Dividend, dividends that have accrued but are unpaid
or which have been declared but are unpaid on the ▇▇▇▇▇▇ Capital Stock. By
e-mail dated August 22, 2005, ▇▇▇▇▇▇ provided to Luxco a correct and complete
list of each of the foregoing, and the record and beneficial owner thereof, a
description of the nature of such security, the amount of securities held, the
exercise, exchange or conversion rights relating thereto, including a schedule
of vesting, the exercise price per share, the term of each such security,
whether such security is intended to qualify as an incentive stock option under
applicable tax law, any restriction on exercise and the type and amount of
securities into which such securities are exchangeable, exercisable or
convertible. As of the date hereof, there are no outstanding options, warrants
or other rights or agreements to which ▇▇▇▇▇▇ or any of its Subsidiaries is a
party providing for the issuance, disposition or acquisition of ▇▇▇▇▇▇ Capital
Stock except options and warrants to acquire 4,435,816 shares of Common Stock in
the aggregate outstanding under the ▇▇▇▇▇▇ Option Plans and the ▇▇▇▇▇▇ Warrants.
(c) Stockholder Agreements. Except as set forth in Schedule
2.2(c), there are no stockholder agreements, voting trusts or other agreements
or understandings to which ▇▇▇▇▇▇ is a party or by which it is bound relating to
any shares of ▇▇▇▇▇▇ Capital Stock.
(d) Compliance with Legal Requirements. All outstanding shares
of ▇▇▇▇▇▇ Capital Stock and all outstanding options and warrants to acquire
▇▇▇▇▇▇ Capital Stock have been issued and granted in compliance in all material
respects with (i) all applicable Legal Requirements and (ii) all requirements
set forth in applicable Contracts.
2.3 Authority; Non-Contravention; Necessary Consents.
(a) Authority. The execution and delivery of this Agreement
and the other Transaction Documents to which ▇▇▇▇▇▇ is a party and the
consummation of the transactions contemplated hereby and thereby have been duly
authorized by all necessary corporate action on the part of ▇▇▇▇▇▇ and no other
corporate proceedings on the part of ▇▇▇▇▇▇ are necessary to authorize the
execution and delivery of this Agreement or the other Transaction Documents to
which ▇▇▇▇▇▇ is a party or to consummate the Exchange Transactions and the other
transactions contemplated hereby and thereby, other than the approval and
adoption of the Certificate Amendment, this Agreement and the Exchange
Transactions by ▇▇▇▇▇▇'▇ stockholders and the filing of the Certificate
Amendment pursuant to the DGCL, and any other corporate proceedings which may
be, or become, necessary by law or regulation. The Requisite Stockholder
Approval to approve and adopt the Certificate Amendment and this Agreement and
approve the Exchange Transactions are the only votes of the holders of any class
or series of ▇▇▇▇▇▇ Capital Stock necessary to approve and adopt the Certificate
Amendment, this Agreement and the other Transaction Documents and to consummate
the Exchange Transactions and the other transactions contemplated by this
Agreement. This Agreement and the other Transaction Documents to which ▇▇▇▇▇▇ is
a party have been duly executed and delivered by ▇▇▇▇▇▇ and, assuming the due
authorization, execution and delivery by Sirona and Luxco, constitute the valid
and binding obligations of ▇▇▇▇▇▇, enforceable against ▇▇▇▇▇▇ in accordance with
their respective terms subject to (i) laws of general application relating to
bankruptcy, insolvency and the relief of debtors, and (ii) rules of law
governing specific performance, injunctive relief and other equitable remedies.
- 4 -
(b) Non-Contravention. Except as set forth in Schedule 2.3(b),
the execution and delivery of this Agreement and the other Transaction Documents
to which ▇▇▇▇▇▇ is a party by ▇▇▇▇▇▇ do not, and performance of this Agreement
and the other Transaction Documents to which ▇▇▇▇▇▇ is a party by ▇▇▇▇▇▇ will
not (i) contravene or conflict with or constitute a violation of the ▇▇▇▇▇▇
Charter Documents or any resolution adopted by its stockholders, the ▇▇▇▇▇▇
Board or any committee of the ▇▇▇▇▇▇ Board, (ii) subject to (A) obtaining the
Requisite Stockholder Approval as contemplated by Section 6.1 and (B) compliance
with and filings under the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act and any additional consents and
filings under any foreign antitrust, competition, premerger notification or
trade regulation law, regulation or order, contravene or conflict with or
constitute a violation of any Legal Requirement applicable to ▇▇▇▇▇▇, (iii)
result in any material breach of or constitute a material default (or an event
that with notice or lapse of time or both would become a material default)
under, or impair ▇▇▇▇▇▇'▇ rights or alter the rights or obligations of any third
Person under, or give to others any rights of termination, amendment,
acceleration or cancellation of, or result in the creation of a Lien (other than
a Lien for taxes) on any of the assets of ▇▇▇▇▇▇ or any of its Significant
Subsidiaries pursuant to any Contract to which ▇▇▇▇▇▇ or any of its Significant
Subsidiaries is a party or (iv) contravene, conflict with or result in a
violation of any of the terms or requirements of, or give any Governmental
Entity the right to revoke, withdraw, suspend, cancel, terminate or modify any
▇▇▇▇▇▇ Permit, except where any of the foregoing in clauses (ii), (iii) or (iv)
would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect on ▇▇▇▇▇▇.
(c) Consents. Except as set forth in Schedule 2.3(c), no
consent, approval, failure to object, order or authorization of, or
registration, declaration or filing with any Governmental Entity or any other
Person is required to be obtained or made by ▇▇▇▇▇▇ in connection with the
execution and delivery of this Agreement or the consummation of the Exchange
Transactions and other transactions contemplated by this Agreement, except for
(i) any such consent, approval, failure to object, order or authorization of, or
registration, declaration or filing, the absence of which would not,
individually or in the aggregate, be reasonably expected to have a Material
Adverse Effect on ▇▇▇▇▇▇, (ii) the filing of the Certificate Amendment with the
Secretary of State of the State of Delaware, (iii) the applicable requirements,
if any, of the Securities Exchange Act, and (iv) compliance with and filings
under the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act and any additional consents and filings under
any foreign antitrust, competition, premerger notification or trade regulation
law, regulation or order.
2.4 Financial Statements; Indebtedness; Undisclosed Liabilities.
(a) ▇▇▇▇▇▇ Financial Statements. ▇▇▇▇▇▇ has filed a Quarterly
Report on Form 10-Q for the fiscal quarter ended June 30, 2005 and Annual Report
on Form 10-K for the fiscal years ended March 31, 2005 and 2004 containing its
consolidated financial statements (collectively, the "▇▇▇▇▇▇ Financials").
Except as set forth on Schedule 2.4(a), the ▇▇▇▇▇▇ Financials were (i) prepared
in accordance with U.S. GAAP (except as may be indicated in the notes thereto),
and (ii) fairly presented in all material respects the consolidated financial
position of ▇▇▇▇▇▇ and its consolidated Subsidiaries as at the respective dates
thereof and the consolidated results of their operations and cash flows for the
periods indicated (subject to in the case of any unaudited financial statements
to the absence of footnote disclosure and normal and recurring year-end
adjustments).
- 5 -
(b) Indebtedness. Except (i) as reflected in the ▇▇▇▇▇▇
Financials or in the notes thereto, (ii) for Indebtedness that has been incurred
by ▇▇▇▇▇▇ and its Subsidiaries since June 30, 2005 in the ordinary course of
business and (iii) as set forth in Schedule 2.4(b), none of ▇▇▇▇▇▇ or its
Significant Subsidiaries has, or is party to any Contracts relating to,
Indebtedness owed to any Person (other than to or among ▇▇▇▇▇▇ and any of its
Subsidiaries) in excess of $5,000,000 in the aggregate.
(c) Undisclosed Liabilities. Except as set forth on Schedule
2.4(c) or in any other Schedule to Article 2 or as reflected in the ▇▇▇▇▇▇
Financials or in the notes thereto, and except for normal or recurring
liabilities incurred since June 30, 2005 in the ordinary course of business,
▇▇▇▇▇▇ and its Significant Subsidiaries do not have any liabilities, either
accrued, contingent or otherwise of a nature required to be reflected in
financial statements in accordance with U.S. GAAP, and whether due or to become
due, which individually or in the aggregate are reasonably likely to have a
Material Adverse Effect with respect to ▇▇▇▇▇▇.
2.5 Absence of Certain Changes or Events. Except for the Transaction
Dividend and as set forth in Schedule 2.5, since June 30, 2005, ▇▇▇▇▇▇ and each
of its Significant Subsidiaries has conducted its respective business in all
material respects in the ordinary course of business. Since June 30, 2005,
▇▇▇▇▇▇ and each of its Significant Subsidiaries has, in all material respects,
preserved their respective business relationships with employees, suppliers,
creditors, customers and others transacting business with it. Without limiting
the generality of the foregoing, except for the Transaction Dividend or as set
forth in Schedule 2.5, since June 30, 2005, there has not occurred any of the
following: (a) any Material Adverse Change with respect to ▇▇▇▇▇▇; (b) any
declaration, setting aside for or payment of any dividend on, or other
distribution (whether in cash, stock or property) in respect of any ▇▇▇▇▇▇
Capital Stock, or any purchase, redemption or other acquisition by ▇▇▇▇▇▇ of any
▇▇▇▇▇▇ Capital Stock or any other securities of ▇▇▇▇▇▇ or any options, warrants,
calls or rights to acquire any such capital stock or other securities except for
purchases, redemptions or other acquisitions of securities from officers,
directors, employees or other services providers in the ordinary course of
business; (c) except as required by Financial Accounting Standards Board
pronouncements that become, or have become, effective as to ▇▇▇▇▇▇ after June
30, 2005, any material change in accounting methods, principles or practices
employed by ▇▇▇▇▇▇ or any of its Significant Subsidiaries; or (d) any action or
event that would have required the consent of Luxco pursuant to Section 5.1 of
this Agreement had such action or event occurred after the date of this
Agreement.
2.6 Taxes. Except as set forth on Schedule 2.6, ▇▇▇▇▇▇ and each of
its Significant Subsidiaries have (i) filed all federal, state, local and
foreign tax returns and reports required to be filed by them with respect to any
taxable period ending on or before the Closing Date (taking into account
extensions), (ii) paid or accrued all Taxes due and payable, and (iii) paid or
accrued all Taxes for which a notice of assessment or collection has been
received (other than amounts being contested in good faith by appropriate
proceedings), except in the case of clause (i), (ii) or (iii) for any such
filings, payments or accruals which are not reasonably likely, individually or
in the aggregate, to have a Material Adverse Effect with respect to ▇▇▇▇▇▇.
Except as set forth on Schedule 2.6, no taxing authority has asserted any claim
for Taxes which is unresolved, or to the Knowledge of ▇▇▇▇▇▇, is threatening to
assert any claims for Taxes, which claims, individually or in the aggregate, are
reasonably likely to have a Material Adverse Effect with respect to ▇▇▇▇▇▇.
▇▇▇▇▇▇ and each of its Significant Subsidiaries have withheld or collected and
paid over to the
- 6 -
appropriate governmental authorities (or are properly holding for such payment)
all Taxes required by applicable law to be withheld or collected, except for
amounts which are not reasonably likely, individually or in the aggregate, to
have a Material Adverse Effect with respect to ▇▇▇▇▇▇. There are no Liens for
Taxes upon the assets of ▇▇▇▇▇▇ or any of its Significant Subsidiaries (other
than Liens for Taxes that are not yet due or that are being contested in good
faith by appropriate proceedings), except for Liens which are not reasonably
likely, individually or in the aggregate, to have a Material Adverse Effect with
respect to ▇▇▇▇▇▇.
2.7 Intellectual Property. ▇▇▇▇▇▇ and its Significant Subsidiaries
own, or are licensed or otherwise possess legally enforceable rights to use, all
Intellectual Property that is necessary to the continued conduct of the business
of ▇▇▇▇▇▇ and its Significant Subsidiaries as currently conducted, subject to
such exceptions that would not be reasonably likely to have a Material Adverse
Effect with respect to ▇▇▇▇▇▇. Except as set forth on Schedule 2.7 hereto,
during the last three years, neither ▇▇▇▇▇▇ nor any of its Significant
Subsidiaries has received any written notice of infringement of or conflict with
asserted rights of others with respect to any material Intellectual Property
that is owned or used by, or licensed to, ▇▇▇▇▇▇ or any Significant
Subsidiaries.
2.8 Compliance with Laws; Permits.
(a) Compliance with Laws. Except as set forth on Schedule
2.8(a), ▇▇▇▇▇▇ and its Significant Subsidiaries have complied with, are not in
violation of, and have not received any notices of violation with respect to,
any applicable Legal Requirement with respect to the conduct of their
businesses, or the ownership or operation of their businesses, except for
failures to comply or violations which, individually or in the aggregate, have
not had and are not reasonably likely to have a Material Adverse Effect with
respect to ▇▇▇▇▇▇. There is no judgment, injunction, order or decree binding
upon ▇▇▇▇▇▇ or any Significant Subsidiary which has or would reasonably be
expected to have the effect of, in any material respect, prohibiting or
materially impairing any business practice of ▇▇▇▇▇▇ or such Significant
Subsidiary, any acquisition of property by ▇▇▇▇▇▇ or such Significant Subsidiary
or the conduct of business by ▇▇▇▇▇▇ or such Significant Subsidiary as currently
conducted. Neither ▇▇▇▇▇▇ nor any Significant Subsidiary has ever been or is now
subject to the United States Food and Drug Administration's Application
Integrity Policy.
(b) Permits. ▇▇▇▇▇▇ and its Significant Subsidiaries hold, to
the extent necessary under Legal Requirements, all Permits that are material to
and required for the operation of the business of ▇▇▇▇▇▇ or its Significant
Subsidiaries, as currently conducted, except where the failure to hold such
Permits would not reasonably be expected to have a Material Adverse Effect on
▇▇▇▇▇▇ (collectively, the "▇▇▇▇▇▇ Permits"). No suspension or cancellation of
any of the ▇▇▇▇▇▇ Permits is pending or, to the Knowledge of ▇▇▇▇▇▇, threatened.
▇▇▇▇▇▇ is in compliance in all material respects with the terms of the ▇▇▇▇▇▇
Permits.
2.9 Litigation.
(a) Litigation Disclosure. Except as set forth on Schedule
2.9(a), there is (i) no Proceeding pending or, to the Knowledge of ▇▇▇▇▇▇,
threatened against ▇▇▇▇▇▇ or any of its Significant Subsidiaries; and (ii) no
judgment, order, injunction, decree, stipulation or award
- 7 -
(whether rendered by a court, administrative agency, or by arbitration, pursuant
to a grievance or other procedure) against or relating to ▇▇▇▇▇▇ or any of its
Significant Subsidiaries which, in the case of either clause (i) above, if
adversely determined, or clause (ii) above, would reasonably be expected to
result in a loss to ▇▇▇▇▇▇ or any of its Significant Subsidiaries in excess of
$500,000 in each individual case.
(b) Indemnification Agreements. Schedule 2.9(b) identifies
each Contract and any Persons covered by such Contract to which ▇▇▇▇▇▇ or any of
its Significant Subsidiaries is a party providing that such Person will either
be indemnified or otherwise reimbursed in respect of claims that may be made
against such Person, and/or attorneys fees therefor, relating to such Person's
employment, officership or directorship with ▇▇▇▇▇▇ or such Significant
Subsidiary.
2.10 Material Contracts.
(a) Material Contracts. Except as otherwise set forth in
Schedule 2.10 and Contracts solely between or among ▇▇▇▇▇▇ and/or its
Subsidiaries, neither ▇▇▇▇▇▇ nor any of its Significant Subsidiaries is a Party
to or bound by any of the following (each, a "▇▇▇▇▇▇ Material Contract"):
(i) any material Contract providing for bonuses, stock,
options, stock purchases, profit sharing or the like;
(ii) any employment Contract or Contract for services
(other than for services by independent contractors) which requires the
payment of more than $250,000 annually in total cash compensation;
(iii) any Contract providing for severance or other
compensation or benefits in excess of $250,000 (x) in the event of a
termination of employment or in the event of termination of consulting or
similar services provided by any person who is a former employee, officer
or director of ▇▇▇▇▇▇ or any of its Significant Subsidiaries or (y) in
connection with the transactions contemplated by this Agreement;
(iv) any Contract (x) with a supplier (including any
service provider) that involves consideration in excess of $1,250,000 per
annum or (y) with any other Person that involves consideration in excess
of $2,000,000 per annum;
(v) any Contract containing covenants materially
limiting the freedom of ▇▇▇▇▇▇ or any Significant Subsidiary to compete in
any line of business or with any Person anywhere in the world;
(vi) any material partnership, joint venture or other
similar Contract; or
(vii) any Contract providing for the license of
Intellectual Property between ▇▇▇▇▇▇ or any Significant Subsidiary and any
third party that involves the exchange of consideration in excess of
$200,000 per annum.
- 8 -
(b) Breach of Contracts. All ▇▇▇▇▇▇ Material Contracts are
valid and in full force and effect except to the extent they have previously
expired in accordance with their terms or except if the failure to be in full
force and effect, individually or in the aggregate, would not reasonably be
expected to have a Material Adverse Effect on ▇▇▇▇▇▇. Neither ▇▇▇▇▇▇ nor any
Significant Subsidiary has violated any provision of, or committed or failed to
perform any act which with or without notice, lapse of time or both would
constitute a default under the provisions of, any ▇▇▇▇▇▇ Material Contract,
except in each case for those violations and defaults which, individually or in
the aggregate, would not reasonably be expected to have a Material Adverse
Effect with respect to ▇▇▇▇▇▇.
2.11 Benefit Plans; Labor.
(a) Benefit Plans. Schedule 2.11(a) lists each material
Employee Plan that ▇▇▇▇▇▇ or any of its Significant Subsidiaries maintains or to
which any of ▇▇▇▇▇▇ or its Significant Subsidiaries contributes or with respect
to which ▇▇▇▇▇▇ or any of its Significant Subsidiaries has any material
liability; provided that Schedule 2.11(a) need not list individual bonuses or
commissions paid or payable in the ordinary course of business. Each such
Employee Plan (and each related trust, insurance contract, or fund) has been
maintained, funded and administered in accordance with the terms of such
Employee Plan, except as would not have a Material Adverse Effect on ▇▇▇▇▇▇, and
complies in form and in operation in all respects with all applicable Legal
Requirements (either required as a matter of law or to obtain the intended tax
treatment and tax benefits), except where the failure to comply would not have a
Material Adverse Effect on ▇▇▇▇▇▇. Any material contributions (including all
employer contributions and employee salary reduction contributions), premiums or
other payments that are due have been made to or in respect of each such
Employee Plan and an accrual has been made on the books of ▇▇▇▇▇▇ or the
relevant Significant Subsidiary in accordance with U.S. GAAP for all material
benefits accrued and material contributions due as of the date hereof. Except as
set forth on Schedule 2.11(a), neither ▇▇▇▇▇▇ nor any of its Significant
Subsidiaries maintains, sponsors, contributes to or has any liability with
respect to any Employee Plan that is a "defined benefit plan," a "multiemployer
plan," a "multiple employer plan" or a "multiple employer welfare arrangement,"
within the meaning of applicable Legal Requirements. No director, officer,
employee or other fiduciary of ▇▇▇▇▇▇ or any Significant Subsidiary has
committed any material breach of fiduciary responsibility imposed by applicable
Legal Requirements with respect to the Employee Plans listed on Schedule
2.11(a). No material prohibited transaction (as defined in applicable Legal
Requirements) has occurred with respect to any Employee Plan of ▇▇▇▇▇▇ or any of
its Significant Subsidiaries. Neither ▇▇▇▇▇▇ nor any Significant Subsidiary has
any actual or potential material liability for death or medical benefits
following separation from employment, other than those benefits required by
applicable Legal Requirements.
(b) Labor. Except as set forth in Schedule 2.11(b), neither
▇▇▇▇▇▇ nor any of its Significant Subsidiaries is a party to or otherwise bound
by any material collective bargaining agreement, Contract or understanding with
a labor union or labor organization, nor is ▇▇▇▇▇▇ or any of its Significant
Subsidiaries the subject of any material Proceeding asserting that ▇▇▇▇▇▇ or any
of its Significant Subsidiaries has committed an unfair labor practice or is
seeking to compel it to bargain with any labor union or labor organization nor,
is there pending or, to the Knowledge of ▇▇▇▇▇▇, threatened, any material labor
strike, dispute, walkout, work stoppage, slow-down or lockout involving ▇▇▇▇▇▇
or any of its Significant Subsidiaries.
- 9 -
2.12 Property.
(a) Real Property. Neither ▇▇▇▇▇▇ nor any Subsidiary of ▇▇▇▇▇▇
owns any real property. Schedule 2.12(a) sets forth a list of all material real
properties leased or occupied by ▇▇▇▇▇▇ or its Significant Subsidiaries for the
operation of their respective business, including the address of each such
property (the "▇▇▇▇▇▇ Real Estate"). Other than any leases or occupancy
agreements solely between or among ▇▇▇▇▇▇ and/or its Subsidiaries, Schedule
2.12(a) identifies all of the material leases or other occupancy agreements with
respect to the ▇▇▇▇▇▇ Real Estate (the "▇▇▇▇▇▇ Leases") and any material
amendments or modifications to the ▇▇▇▇▇▇ Leases. Each ▇▇▇▇▇▇ Lease is in full
force and effect, and no material breach or default exists by ▇▇▇▇▇▇ or any
Significant Subsidiary (or, to the Knowledge of ▇▇▇▇▇▇, by any other party
thereto), nor has any event or condition occurred which could (with the giving
of notice or the passage of time or both) constitute a material breach or
default, under any ▇▇▇▇▇▇ Lease.
(b) Tangible Personal Property. Except as set forth on
Schedule 2.12(b) hereto, (i) ▇▇▇▇▇▇ and each Significant Subsidiary has good
title to all of the items of its tangible personal property reflected on the
June 30, 2005 balance sheet contained in the ▇▇▇▇▇▇ Financials, except as sold
or disposed of subsequent to the date thereof in the ordinary course of
business, and (ii) all such tangible personal property is owned free and clear
of all Liens, except for (A) Liens identified on Schedule 2.12(b), (B) Liens
which, individually or in the aggregate, do not materially detract from the
value, or materially interfere with the present use, of ▇▇▇▇▇▇'▇ or any of its
Significant Subsidiaries' aggregate tangible personal property (excluding any
Liens in favor of any Related Party), and (C) Permitted Liens.
2.13 Insurance. Except as set forth on Schedule 2.13, (i) all of
▇▇▇▇▇▇'▇ and its Significant Subsidiaries' material policies and contracts for
property, casualty and director's and officer's liability insurance or
substantially identical policies (in terms of scope and level of coverage) (the
"▇▇▇▇▇▇ Insurance Policies") are in full force and effect, (ii) the ▇▇▇▇▇▇
Insurance Policies are in full force and effect and will not lapse or be subject
to suspension, modification, revocation, cancellation, termination or
non-renewal by reason of the execution, delivery or performance of this
Agreement or of any transaction in connection with this Agreement, (iii) and are
sufficient in all material respects for compliance with all applicable Legal
Requirements, (iv) ▇▇▇▇▇▇ and its Significant Subsidiaries are current in all
premiums or other payments due under each ▇▇▇▇▇▇ Insurance Policy and have
otherwise performed in all material respects all of their respective obligations
thereunder, and (v) neither ▇▇▇▇▇▇ nor its Significant Subsidiaries have
received, during the past three years from any insurance carrier with which it
has carried any material insurance, any refusal of coverage or notice of
material limitation of coverage or any notice that a defense will not be
afforded or will be afforded with reservation of rights.
2.14 Related Party Transactions. Except as set forth in Schedule
2.14 or otherwise expressly disclosed in the notes to the ▇▇▇▇▇▇ Financials, no
Related Party of ▇▇▇▇▇▇ (other than ▇▇▇▇▇▇ and its Subsidiaries) (i) is a party
to any Contract with, or relating to the business or operations of, ▇▇▇▇▇▇ or
any of its Significant Subsidiaries; (ii) is a party to any Contract for or
relating to Indebtedness of ▇▇▇▇▇▇ or any of its Significant Subsidiaries (other
than loans to any employee in an aggregate amount less than $50,000 in the
ordinary course of business); (iii) who is an officer or director of ▇▇▇▇▇▇ or
any of its Subsidiaries has any Indebtedness to ▇▇▇▇▇▇ or any Subsidiary; or
(iv) owns or has the right to use any material
- 10 -
property (real, personal or mixed), tangible, or intangible, used or currently
intended to be used in, the business or operations of ▇▇▇▇▇▇ or any of its
Significant Subsidiaries. As of the Closing, no officer or director of ▇▇▇▇▇▇ or
any Subsidiary will have any Indebtedness owing to ▇▇▇▇▇▇ or any Subsidiary.
2.15 Environmental Matters. Except as set forth in Schedule 2.15,
and except for such matters that, individually or in the aggregate, are not
reasonably likely to have a Material Adverse Effect with respect to ▇▇▇▇▇▇: (i)
▇▇▇▇▇▇ and its Significant Subsidiaries have complied with all applicable
Environmental Laws; (ii) the properties currently owned or operated by ▇▇▇▇▇▇
and its Significant Subsidiaries (including soils, groundwater, surface water,
buildings or other structures) are not contaminated with any Hazardous
Substances; (iii) the properties formerly owned or operated by ▇▇▇▇▇▇ or any of
its Significant Subsidiaries were not contaminated with Hazardous Substances
during the period of ownership or operation by ▇▇▇▇▇▇ or any of its Significant
Subsidiaries; (iv) neither ▇▇▇▇▇▇ nor its Significant Subsidiaries are subject
to liability for any Hazardous Substance disposal or contamination on any third
party property; (v) neither ▇▇▇▇▇▇ nor any of its Significant Subsidiaries has
been associated with any release or threat of release of any Hazardous
Substance; (vi) neither ▇▇▇▇▇▇ nor any of its Significant Subsidiaries has
received any outstanding notice, demand, letter, claim or request for
information alleging that ▇▇▇▇▇▇ or any of its Significant Subsidiaries may be
in violation of or liable under any Environmental Law; (vii) neither ▇▇▇▇▇▇ nor
any of its Significant Subsidiaries is subject to any orders, decrees,
injunctions or other arrangements with any Governmental Entity or is subject to
any indemnity or other agreement with any third party relating to liability
under any Environmental Law or relating to Hazardous Substances; and (viii)
there are no circumstances or conditions involving ▇▇▇▇▇▇ or any of its
Significant Subsidiaries that could reasonably be expected to result in any
claims, liability, investigations, costs or restrictions on the ownership, use
or transfer of any property of ▇▇▇▇▇▇ pursuant to any Environmental Law.
2.16 Brokers' and Finders' Fees. Except for advisory fees payable to
UBS Securities LLC by ▇▇▇▇▇▇, neither ▇▇▇▇▇▇ nor any Subsidiary of ▇▇▇▇▇▇ has
incurred, or will incur, directly or indirectly, any liability for brokerage or
finders' fees or agents' commissions or any similar charges in connection with
this Agreement or any transaction contemplated by this Agreement.
2.17 Filings with SEC. Since January 1, 2001, ▇▇▇▇▇▇ has made all
filings with the SEC that it has been required to make under the Securities Act
and the Securities Exchange Act (collectively the "Public Reports"). As of their
respective dates, each of the Public Reports complied with the requirements of
the Securities Act or the Securities Exchange Act, as the case may be, in all
material respects. Except as set forth on Schedule 2.17, and to the extent
corrected prior to the date hereof by a subsequently filed Public Report, none
of the Public Reports, as of their respective dates, contained any untrue
statement of a material fact or omitted to state a material fact necessary in
order to make the statements made therein, in light of the circumstances under
which they were made, not misleading. ▇▇▇▇▇▇ has made available to Luxco a
correct and complete copy of each Public Report (together with all exhibits and
schedules thereto and as amended to date not otherwise available over the
Internet).
2.18 The Proxy Statement; Disclosure. The Proxy Statement will
comply with the Securities Exchange Act. None of the information supplied or to
be supplied by or on
- 11 -
behalf of ▇▇▇▇▇▇ for inclusion in the Proxy Statement to be filed with the SEC
will, at the time the Proxy Statement is mailed to the stockholders of ▇▇▇▇▇▇,
at the time of the ▇▇▇▇▇▇ Stockholders Meeting or as of the Closing Date,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they are made, not
misleading. Notwithstanding the foregoing, no representation or warranty is made
by ▇▇▇▇▇▇ with respect to statements made or incorporated by reference therein
about Luxco or Sirona supplied by Luxco or Sirona for inclusion or incorporation
by reference in the Proxy Statement.
2.19 Board Approval. The ▇▇▇▇▇▇ Board has, by resolutions duly
adopted at a meeting of all directors duly called and held and not subsequently
rescinded or modified in any way (i) determined that the Exchange Transactions
are consistent with and in furtherance of the long-term business interests of
▇▇▇▇▇▇ and fair to, and in the best interests of, ▇▇▇▇▇▇ and its stockholders
and declared the adoption of the Certificate Amendment, this Agreement and the
Exchange Transactions to be advisable, (ii) approved this Agreement, the
Certificate Amendment and the other Transaction Documents to which ▇▇▇▇▇▇ is a
party, and (iii) determined to recommend to the stockholders of ▇▇▇▇▇▇ that such
Stockholders approve and adopt this Agreement and the Certificate Amendment and
approve the Exchange Transactions at the ▇▇▇▇▇▇ Stockholders' Meeting.
2.20 Opinion of Financial Advisor. The financial advisor of ▇▇▇▇▇▇,
UBS Securities LLC, has delivered to the ▇▇▇▇▇▇ Board an opinion dated on or
about the date of this Agreement to the effect that, as of such date, the ▇▇▇▇▇▇
Shares to be issued by ▇▇▇▇▇▇ to Luxco in the Exchange Transactions, are fair
from a financial point of view to the holders of Common Stock.
2.21 Delaware 203; Takeover Statute. The ▇▇▇▇▇▇ Board has taken all
actions necessary to ensure that the restrictions contained in Section 203 of
the DGCL applicable to a "business combination" (as defined in such Section)
will not apply to the execution, delivery or performance of this Agreement or
any of the other Transaction Documents or the consummation of the transactions
contemplated hereby or thereby, including the issuance of the ▇▇▇▇▇▇ Shares. The
execution, delivery and performance of this Agreement or any of the other
Transaction Documents and the consummation of the transactions contemplated
hereby or thereby will not cause to be applicable to ▇▇▇▇▇▇ any "fair price,"
"moratorium," "control share acquisition" or other similar antitakeover statute
or regulation enacted under state or federal laws.
2.22 Investment Representations. ▇▇▇▇▇▇ is acquiring the Sirona
Shares pursuant hereto for its own account with the present intention of holding
such securities for purposes of investment, and it has no intention of selling
such securities in a public distribution in violation of the federal securities
laws or any applicable state securities laws. ▇▇▇▇▇▇ is an "accredited investor"
and a sophisticated investor for purposes of applicable U.S. federal and state
securities laws and regulations.
2.23 Exchanged Shares. Upon issuance in compliance with the
provisions of this Agreement, the ▇▇▇▇▇▇ Shares will be validly issued, fully
paid, and nonassessable, and will be free and clear of any Liens.
- 12 -
2.24 Disclosure. The representations and warranties of ▇▇▇▇▇▇
contained in this Agreement and in each certificate, schedule or exhibit
furnished or to be furnished by or on behalf of ▇▇▇▇▇▇ pursuant hereto, or in
connection with the transactions contemplated hereby, taken together, do not
contain and will not contain any untrue statement of a material fact and do not
or will not omit to state a material fact necessary to make the statements or
facts contained herein or therein, in light of the circumstances under which
they were made, not misleading.
ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF SIRONA
Sirona represents and warrants to ▇▇▇▇▇▇ that the statements contained in
this Article 3 are true, correct and complete as of the date of this Agreement
and will be true, correct and complete as of the Closing Date, subject to the
limited exceptions specifically disclosed in writing in the disclosure schedules
supplied by Sirona or Luxco to ▇▇▇▇▇▇ dated as of the date hereof, certified by
a duly authorized officer of Sirona or Luxco, as follows (it being understood
that whenever in this Article 3 a representation or warranty is made in respect
of Sirona, it is also made in respect of Sirona's Significant Subsidiaries):
3.1 Organization; Standing and Power; Charter Documents;
Subsidiaries.
(a) Organization; Standing and Power. Sirona and each of its
Subsidiaries is an entity duly organized and validly existing under the laws of
the jurisdiction of its organization, have full organizational power and
authority to own, lease and operate their properties and to carry on their
businesses as now being conducted, except where the failure to have such power
and authority would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on Sirona, and each is duly qualified
to do business in each jurisdiction in which the nature of its business or the
ownership or leasing of its properties makes such qualification necessary,
except where the failure to be so qualified would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on Sirona.
(b) Charter Documents. Sirona has made available to ▇▇▇▇▇▇ a
copy of its articles of association, as amended to date (the "Sirona Charter
Documents") and the articles of association (or equivalent governing documents)
of each of its Significant Subsidiaries, each as amended to date (collectively,
the "Sirona Subsidiary Charter Documents") and all such instruments are in full
force and effect. Neither Sirona nor its Significant Subsidiaries are in default
in any material respect under or in violation in any material respect of any of
the provisions of the Sirona Charter Documents or the Sirona Subsidiary Charter
Documents, respectively.
(c) Subsidiaries. Set forth on Schedule 3.1(c) is a list
setting forth for each Subsidiary of Sirona its name, jurisdiction of
organization and a description of Sirona's ownership interest. Other than as set
forth on Schedule 3.1(c), Sirona has no Subsidiaries.
3.2 Capital Structure.
(a) Capital Stock. The entire authorized capital stock of
Sirona (the "Sirona Capital Stock") consists solely of two shares, both of which
are issued and outstanding.
- 13 -
All of the issued and outstanding shares of Sirona Capital Stock have been duly
authorized and validly issued, are fully paid and non-assessable, and are free
of any preemptive rights, rights of participation, rights of maintenance or any
similar rights. The issued and outstanding shares of Sirona Capital Stock were
not issued in violation of the preemptive rights of any Person or any Contract
or Legal Requirement by which Sirona at the time of issuance was bound including
federal and state securities laws. As of the date hereof, there are no shares of
Sirona Capital Stock held in treasury by Sirona. Except as set forth in Schedule
3.2(a): (i) none of the outstanding shares of Sirona Capital Stock is subject to
any right of first refusal in favor of Sirona or any other Person, and (ii)
there is no Contract relating to the voting or registration of, or restricting
any Person from purchasing, selling, pledging or otherwise disposing of (or
granting any option or similar right with respect to), any shares of Sirona
Capital Stock. Sirona is not under any material obligation, nor is it bound by
any material Contract pursuant to which it may become obligated, to repurchase,
redeem or otherwise acquire any outstanding shares of Sirona Capital Stock.
(b) Other Securities. Except as otherwise set forth in
Schedule 3.2(b), there are not issued, outstanding or authorized any (i)
securities, options, warrants, calls, rights, commitments, agreements,
arrangements or undertakings of any kind to which Sirona or any Subsidiary of
Sirona is a Party or by which it is bound obligating Sirona or such Subsidiary
to issue, deliver or sell, or cause to be issued, delivered or sold, additional
shares of Sirona Capital Stock or other securities of Sirona or such Subsidiary,
or obligating Sirona or such Subsidiary to issue, grant, extend or enter into
any such security, option, warrant, call, right, commitment, agreement,
arrangement or undertaking or that that would vest or become exercisable as a
result of the transactions contemplated hereby, (ii) outstanding security,
instrument or obligation that is or may become convertible into or exchangeable
for any shares of the Sirona Capital Stock or other securities of Sirona or any
Subsidiary of Sirona, (iii) stockholder rights plan (or similar plan commonly
referred to as a "poison pill") or Contract under which Sirona or any Subsidiary
of Sirona is or may become obligated to sell or otherwise issue any shares of
its Sirona Capital Stock or any other securities of Sirona or such Subsidiary,
(iv) agreement to register any security of Sirona or any Subsidiary of Sirona on
a come-along, drag-along or other basis, or (v) dividends that have accrued but
are unpaid or which have been declared but are unpaid on the Sirona Capital
Stock. Schedule 3.2(b) sets forth a correct and complete list of each of the
foregoing, and the record and beneficial owner thereof, a description of the
nature of such security, the amount of securities held, the exercise, exchange
or conversion rights relating thereto, including a schedule of vesting, the
exercise price per share, the term of each such security, whether such security
is intended to qualify as an incentive stock option under applicable tax law,
any restriction on exercise and the type and amount of securities into which
such securities are exchangeable, exercisable or convertible.
(c) Stockholder Agreements. Except as set forth in Schedule
3.2(c), there are no stockholder agreements, voting trusts or other agreements
or understandings to which Sirona is a party or by which it is bound relating to
any shares of Sirona Capital Stock.
(d) Compliance with Legal Requirements. All outstanding shares
of Sirona Capital Stock and all outstanding options and warrants to acquire
Sirona Capital Stock have been issued and granted in compliance in all material
respects with (i) all applicable Legal Requirements and (ii) all requirements
set forth in applicable Contracts.
- 14 -
3.3 Authority; Non-Contravention; Necessary Consents.
(a) Authority. The execution and delivery of this Agreement
and the other Transaction Documents to which Sirona is a party and the
consummation of the transactions contemplated hereby and thereby have been duly
authorized by all necessary organizational action on the part of Sirona and no
other organizational proceedings on the part of Sirona are necessary to
authorize the execution and delivery of this Agreement or the other Transaction
Documents to which Sirona is a party or to consummate the Exchange Transactions
and the other transactions contemplated hereby and thereby other than any
organizational proceedings which may be, or become, necessary by law or
regulation. This Agreement and the other Transaction Documents to which Sirona
is a party have been duly executed and delivered by Sirona and, assuming the due
authorization, execution and delivery by ▇▇▇▇▇▇ and Luxco, constitute the valid
and binding obligations of Sirona, enforceable against Sirona in accordance with
their respective terms subject to (i) laws of general application relating to
bankruptcy, insolvency and the relief of debtors, and (ii) rules of law
governing specific performance, injunctive relief and other equitable remedies.
(b) Non-Contravention. Except as set forth in Schedule 3.3(b),
the execution and delivery of this Agreement and the other Transaction Documents
to which Sirona is a party by Sirona do not, and performance of this Agreement
and the other Transaction Documents to which Sirona is a party by Sirona will
not (i) contravene or conflict with or constitute a violation of the Sirona
Charter Documents or any resolution adopted by its stockholders, the Sirona
Board or any committee of the Sirona Board, (ii) subject to compliance with and
filings under the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act and any additional consents and filings
under any foreign antitrust, competition, premerger notification or trade
regulation law, regulation or order, contravene or conflict with or constitute a
violation of any Legal Requirement applicable to Sirona, (iii) result in any
material breach of or constitute a material default (or an event that with
notice or lapse of time or both would become a material default) under, or
impair Sirona's rights or alter the rights or obligations of any third Person
under, or give to others any rights of termination, amendment, acceleration or
cancellation of, or result in the creation of a Lien (other than a Lien for
taxes) on any of the assets of Sirona or any of its Significant Subsidiaries
pursuant to any Contract to which Sirona or any of its Significant Subsidiaries
is a party or (iv) contravene, conflict with or result in a violation of any of
the terms or requirements of, or give any Governmental Entity the right to
revoke, withdraw, suspend, cancel, terminate or modify any Sirona Permit, except
where any of the foregoing in clauses (ii), (iii) or (iv) would not,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Sirona.
(c) Consents. Except as set forth in Schedule 3.3(c), no
consent, approval, failure to object, order or authorization of, or
registration, declaration or filing with any Governmental Entity or any other
Person is required to be obtained or made by Sirona in connection with the
execution and delivery of this Agreement or the consummation of the Exchange
Transactions and other transactions contemplated by this Agreement, except for
(i) any such consent, approval, failure to object, order or authorization of, or
registration, declaration or filing, the absence of which would not,
individually or in the aggregate, be reasonably expected to have a Material
Adverse Effect on Sirona, (ii) the applicable requirements, if any, of the
Securities Exchange Act and (iii) compliance with and filings under
- 15 -
the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act and any additional consents and filings under any
foreign antitrust, competition, premerger notification or trade regulation law,
regulation or order.
3.4 Financial Statements; Indebtedness; Undisclosed Liabilities.
(a) Sirona Financial Statements. Attached to Schedule 3.4 are
the following financial statements: (i) the audited pro forma consolidated
financial statements of Sirona GmbH as of September 30, 2004 (the "Audited
Financials"); and (ii) the unaudited consolidated financial statements of Sirona
as of June 30, 2005 in the management account format, for the nine-month period
then ended, which are preliminary, estimated and pro forma as described on
Schedule 3.4(a) and any annexes thereto (the "Unaudited Financials", and
together with the Audited Financials, the "Sirona Financials"). Except as set
forth on Schedule 3.4(a), (i) the Sirona Financials were prepared in accordance
with German GAAP (except as may be indicated in the notes thereto) and (ii) the
Unaudited Financials fairly presented in all material respects the preliminary,
estimated, consolidated financial position in the management account format, as
described on Schedule 3.4 and the annexes thereto, and the Audited Financials
fairly presented in all material respects the pro forma consolidated financial
position of Sirona GmbH or Sirona and their respective consolidated
Subsidiaries, as the case may be, as at the respective dates thereof and the
results of Sirona GmbH's or Sirona's, as the case may be, operations and cash
flows for the periods indicated (subject to in the case of any unaudited
financial statements to the absence of footnote disclosure and normal and
recurring year-end adjustments).
(b) Indebtedness. Except (i) as reflected in the Sirona
Financials or in the notes thereto, (ii) for Indebtedness that has been incurred
by Sirona and its Subsidiaries since June 30, 2005 in the ordinary course of
business, (iii) as set forth in Schedule 3.4(b) and (iv) the Sirona Note, none
of Sirona or its Significant Subsidiaries has, or is party to any Contracts
relating to, Indebtedness owed to any Person (other than to or among Sirona and
any of its Subsidiaries) in excess of (euro)10,000,000 in the aggregate.
(c) Undisclosed Liabilities. Except as set forth on Schedule
3.4(c) or in any other Schedule to Article 3 or as reflected in the Sirona
Financials or in the notes thereto, and except for normal or recurring
liabilities incurred since June 30, 2005 in the ordinary course of business,
Sirona and its Significant Subsidiaries do not have any liabilities, either
accrued, contingent or otherwise of a nature required to be reflected in
financial statements in accordance with German GAAP, and whether due or to
become due, which individually or in the aggregate are reasonably likely to have
a Material Adverse Effect with respect to Sirona.
3.5 Absence of Certain Changes or Events. Except as set forth in
Schedule 3.5, since June 30, 2005, Sirona and each of its Significant
Subsidiaries has conducted its respective business in all material respects in
the ordinary course of business. Since June 30, 2005, Sirona and each of its
Significant Subsidiaries has, in all material respects, preserved their
respective business relationships with employees, suppliers, creditors,
customers and others transacting business with it. Without limiting the
generality of the foregoing, except as set forth in Schedule 3.5, since June 30,
2005, there has not occurred any of the following: (a) any Material Adverse
Change with respect to Sirona; (b) any declaration, setting aside for or payment
of any dividend on, or other distribution (whether in cash, stock or property)
in respect of any Sirona Capital Stock, or any purchase, redemption or other
acquisition by Sirona of any Sirona Capital Stock or
- 16 -
any other securities of Sirona or any options, warrants, calls or rights to
acquire any such capital stock or other securities except for purchases,
redemptions or other acquisitions of securities from officers, directors,
employees or other services providers in the ordinary course of business; (c)
except as required by the pronouncements of the Financial Accounting Standards
Board or the accounting standards bodies in Germany that become or have become,
effective as to Sirona after June 30, 2005, any material change in accounting
methods, principles or practices employed by Sirona or any of its Significant
Subsidiaries; or (d) any action or event that would have required the consent of
▇▇▇▇▇▇ pursuant to Section 5.2 of this Agreement had such action or event
occurred after the date of this Agreement.
3.6 Taxes. Except as set forth in Schedule 3.6, Sirona and each of
its Significant Subsidiaries have (i) filed all federal, state, local and
foreign tax returns and reports required to be filed by them with respect to any
taxable period ending on or before the Closing Date (taking into account
extensions), (ii) paid or accrued all Taxes due and payable, and (iii) paid or
accrued all Taxes for which a notice of assessment or collection has been
received (other than amounts being contested in good faith by appropriate
proceedings), except in the case of clause (i), (ii) or (iii) for any such
filings, payments or accruals which are not reasonably likely, individually or
in the aggregate, to have a Material Adverse Effect with respect to Sirona.
Except as set forth in Schedule 3.6, no taxing authority has asserted any claim
for Taxes which is unresolved, or to the Knowledge of Sirona, is threatening to
assert any claims for Taxes, which claims, individually or in the aggregate, are
reasonably likely to have a Material Adverse Effect with respect to Sirona.
Sirona and each of its Significant Subsidiaries have withheld or collected and
paid over to the appropriate governmental authorities (or are properly holding
for such payment) all Taxes required by applicable law to be withheld or
collected, except for amounts which are not reasonably likely, individually or
in the aggregate, to have a Material Adverse Effect with respect to Sirona.
There are no Liens for Taxes upon the assets of Sirona or any of its Significant
Subsidiaries (other than Liens for Taxes that are not yet due or that are being
contested in good faith by appropriate proceedings), except for Liens which are
not reasonably likely, individually or in the aggregate, to have a Material
Adverse Effect with respect to Sirona.
3.7 Intellectual Property. Sirona and its Significant Subsidiaries
own, or are licensed or otherwise possess legally enforceable rights to use, all
Intellectual Property that is necessary to the continued conduct of the business
of Sirona and its Significant Subsidiaries as currently conducted, subject to
such exceptions that would not be reasonably likely to have a Material Adverse
Effect with respect to Sirona. Except as set forth on Schedule 3.7 hereto,
during the last three years, neither Sirona nor any of its Significant
Subsidiaries has received any written notice of infringement of or conflict with
asserted rights of others with respect to any material Intellectual Property
that is owned or used by, or licensed to, Sirona or any Significant
Subsidiaries.
3.8 Compliance with Laws; Permits.
(a) Compliance with Laws. Except as set forth on Schedule
3.8(a), Sirona and its Significant Subsidiaries have complied with, are not in
violation of, and have not received any notices of violation with respect to,
any applicable Legal Requirement with respect to the conduct of their
businesses, or the ownership or operation of their businesses, except for
failures to comply or violations which, individually or in the aggregate, have
not had and are not
- 17 -
reasonably likely to have a Material Adverse Effect with respect to Sirona.
There is no judgment, injunction, order or decree binding upon Sirona or any
Significant Subsidiary which has or would reasonably be expected to have the
effect of, in any material respect, prohibiting or materially impairing any
business practice of Sirona or such Significant Subsidiary, any acquisition of
property by Sirona or such Significant Subsidiary or the conduct of business by
Sirona or such Significant Subsidiary as currently conducted. Neither Sirona nor
any Significant Subsidiary has ever been or is now subject to the United States
Food and Drug Administration's Application Integrity Policy.
(b) Permits. Sirona and its Significant Subsidiaries hold, to
the extent necessary under Legal Requirements, all Permits that are material to
and required for the operation of the business of Sirona or its Significant
Subsidiaries, as currently conducted, except where the failure to hold such
Permits would not reasonably be expected to have a Material Adverse Effect on
Sirona (collectively, the "Sirona Permits"). No suspension or cancellation of
any of the Sirona Permits is pending or, to the Knowledge of Sirona, threatened.
Sirona is in compliance in all material respects with the terms of the Sirona
Permits.
3.9 Litigation.
(a) Litigation Disclosure. Except as set forth on Schedule
3.9(a), there is (i) no Proceeding pending or, to the Knowledge of Sirona,
threatened against Sirona or any of its Significant Subsidiaries; and (ii) no
judgment, order, injunction, decree, stipulation or award (whether rendered by a
court, administrative agency, or by arbitration, pursuant to a grievance or
other procedure) against or relating to Sirona or any of its Significant
Subsidiaries which, in the case of either clause (i) above, if adversely
determined, or clause (ii) above, would reasonably be expected to result in a
loss to Sirona or any of its Significant Subsidiaries in excess of
(euro)1,000,000 in each individual case.
(b) Indemnification Agreements. Schedule 3.9(b) identifies
each Contract and any Persons covered by such Contract to which Sirona or any of
its Significant Subsidiaries is a party providing that such Person will either
be indemnified or otherwise reimbursed in respect of claims that may be made
against such Person, and/or attorneys fees therefor, relating to such Person's
employment, officership or directorship with Sirona or such Significant
Subsidiary.
3.10 Material Contracts.
(a) Material Contracts. Except as otherwise set forth in
Schedule 3.10 and Contracts solely between or among Sirona and/or its
Subsidiaries neither Sirona nor any of its Significant Subsidiaries is a Party
to or bound by any of the following (each, a "Sirona Material Contract"):
(i) any material Contract providing for bonuses, stock,
options, stock purchases, profit sharing or the like;
(ii) any employment Contract or Contract for services
(other than for services by independent contractors) which requires the
payment of more than (euro)250,000 annually in total cash compensation;
- 18 -
(iii) any Contract providing for severance or other
compensation or benefits in excess of (euro)250,000 (x) in the event of a
termination of employment or in the event of termination of consulting or
similar services provided by any person who is a former employee, officer
or director of Sirona or any of its Significant Subsidiaries or (y) in
connection with the transactions contemplated by this Agreement;
(iv) any Contract (x) with a supplier (including any
service provider) that involves consideration in excess of (euro)3,000,000
per annum or (y) with any other Person that involves consideration in
excess of (euro)5,000,000 per annum;
(v) any Contract containing covenants materially
limiting the freedom of Sirona or any Significant Subsidiary to compete in
any line of business or with any Person anywhere in the world;
(vi) any material partnership, joint venture or other
similar Contract; or
(vii) any Contract providing for the license of
Intellectual Property between Sirona or any Significant Subsidiary and any
third party that involves the exchange of consideration in excess of
(euro)500,000 per annum.
(b) Breach of Contracts. All Sirona Material Contracts are
valid and in full force and effect except to the extent they have previously
expired in accordance with their terms or except if the failure to be in full
force and effect, individually or in the aggregate, would not reasonably be
expected to have a Material Adverse Effect on Sirona. Neither Sirona nor any
Significant Subsidiary has violated any provision of, or committed or failed to
perform any act which with or without notice, lapse of time or both would
constitute a default under the provisions of, any Sirona Material Contract,
except in each case for those violations and defaults which, individually or in
the aggregate, would not reasonably be expected to have a Material Adverse
Effect with respect to Sirona.
3.11 Benefit Plans; Labor.
(a) Benefit Plans. Schedule 3.11(a) lists each material
Employee Plan that Sirona or any of its Significant Subsidiaries maintains or to
which any of Sirona or its Significant Subsidiaries contributes or with respect
to which Sirona or any of its Significant Subsidiaries has any material
liability; provided that Schedule 3.11(a) need not list individual bonuses or
commissions paid or payable in the ordinary course of business. Each such
Employee Plan (and each related trust, insurance contract, or fund) has been
maintained, funded and administered in accordance with the terms of such
Employee Plan, except as would not have a Material Adverse Effect on Sirona, and
complies in form and in operation in all respects with all applicable Legal
Requirements (either required as a matter of law or to obtain the intended tax
treatment and tax benefits), except where the failure to comply would not have a
Material Adverse Effect on Sirona. Any material contributions (including all
employer contributions and employee salary reduction contributions), premiums or
other payments that are due have been made to or in respect of each such
Employee Plan and an accrual has been made on the books of Sirona or the
- 19 -
relevant Significant Subsidiary in accordance with German GAAP for all material
benefits accrued and material contributions due as of the date hereof. Except as
set forth on Schedule 3.11(a), neither Sirona nor any of its Significant
Subsidiaries maintains, sponsors, contributes to or has any liability with
respect to any Employee Plan that is a "defined benefit plan," a "multiemployer
plan," a "multiple employer plan" or a "multiple employer welfare arrangement,"
within the meaning of applicable Legal Requirements. No director, officer,
employee or other fiduciary of Sirona or any Significant Subsidiary has
committed any material breach of fiduciary responsibility imposed by applicable
Legal Requirements with respect to the Employee Plans listed on Schedule
3.11(a). No material prohibited transaction (as defined in applicable Legal
Requirements) has occurred with respect to any Employee Plan of Sirona or any of
its Significant Subsidiaries. Neither Sirona nor any Significant Subsidiary has
any actual or potential material liability for death or medical benefits
following separation from employment, other than those benefits required by
applicable Legal Requirements.
(b) Labor. Except as set forth in Schedule 3.11(b), neither
Sirona nor any of its Significant Subsidiaries is a party to or otherwise bound
by any material collective bargaining agreement, Contract or understanding with
a labor union or labor organization, nor is Sirona or any of its Significant
Subsidiaries the subject of any material Proceeding asserting that Sirona or any
of its Significant Subsidiaries has committed an unfair labor practice or is
seeking to compel it to bargain with any labor union or labor organization nor,
is there pending or, to the Knowledge of Sirona, threatened, any material labor
strike, dispute, walkout, work stoppage, slow-down or lockout involving Sirona
or any of its Significant Subsidiaries.
3.12 Property.
(a) Real Property. Sirona and its Subsidiaries have good and
marketable title to the real properties set forth on Schedule 3.12(a) free and
clear of Liens, except for Permitted Liens and except for matters that would not
have a Material Adverse Effect with respect to Sirona. Schedule 3.12(a) sets
forth a list of all material real properties leased or occupied by Sirona or its
Significant Subsidiaries for the operation of their respective business,
including the address of each such property (the "Sirona Real Estate"). Other
than any leases or occupancy agreements solely between or among Sirona and/or
its Subsidiaries, Schedule 3.12(a) identifies all of the material leases or
other occupancy agreements with respect to the Sirona Real Estate (the "Sirona
Leases") and any material amendments or modifications to the Sirona Leases. Each
Sirona Lease is in full force and effect, and no material breach or default
exists by Sirona or any Significant Subsidiary (or, to the Knowledge of Sirona,
by any other party thereto), nor has any event or condition occurred which could
(with the giving of notice or the passage of time or both) constitute a material
breach or default, under any Sirona Lease.
(b) Tangible Personal Property. Except as set forth on
Schedule 3.12(b) hereto, (i) Sirona and each Significant Subsidiary has good
title to all of the items of its tangible personal property reflected on the
June 30, 2005 balance sheet contained in the Sirona Financials, except as sold
or disposed of subsequent to the date thereof in the ordinary course of
business, and (ii) all such tangible personal property is owned free and clear
of all Liens, except for (A) Liens identified on Schedule 3.12(b), (B) Liens
which, individually or in the aggregate, do not materially detract from the
value, or materially interfere with the present use, of Sirona's
- 20 -
or any of its Significant Subsidiaries' aggregate tangible personal property
(excluding any Liens in favor of any Related Party), and (C) Permitted Liens.
3.13 Insurance. Except as set forth on Schedule 3.13, (i) all of
Sirona's and its Significant Subsidiaries' material policies and contracts for
property, casualty and director's and officer's liability insurance or
substantially identical policies (in terms of scope and level of coverage) (the
"Sirona Insurance Policies") are in full force and effect, (ii) the Sirona
Insurance Policies are in full force and effect and will not lapse or be subject
to suspension, modification, revocation, cancellation, termination or
non-renewal by reason of the execution, delivery or performance of this
Agreement or of any transaction in connection with this Agreement, (iii) and are
sufficient in all material respects for compliance with all applicable Legal
Requirements, (iv) Sirona and its Significant Subsidiaries are current in all
premiums or other payments due under each Sirona Insurance Policy and have
otherwise performed in all material respects all of their respective obligations
thereunder, and (v) neither Sirona nor its Significant Subsidiaries have
received, during the past three years from any insurance carrier with which it
has carried any material insurance, any refusal of coverage or notice of
material limitation of coverage or any notice that a defense will not be
afforded or will be afforded with reservation of rights.
3.14 Related Party Transactions. Except as set forth in Schedule
3.14 or otherwise expressly disclosed in the notes to the Sirona Financials, no
Related Party of Sirona (other than Sirona and its Subsidiaries) (i) is a party
to any Contract with, or relating to the business or operations of, Sirona or
any of its Significant Subsidiaries; (ii) is a party to any Contract for or
relating to Indebtedness of Sirona or any of its Significant Subsidiaries (other
than loans to any employee in an aggregate amount less than (euro)50,000 in the
ordinary course of business); (iii) who is an officer or director of Sirona or
any of its Subsidiaries has any Indebtedness to Sirona or any Subsidiary; or
(iv) owns or has the right to use any material property (real, personal or
mixed), tangible, or intangible, used or currently intended to be used in, the
business or operations of Sirona or any of its Significant Subsidiaries. As of
the Closing, no officer or director of Sirona or any Subsidiary will have any
Indebtedness owing to Sirona or any Subsidiary.
3.15 Environmental Matters. Except as set forth in Schedule 3.15,
and except for such matters that, individually or in the aggregate, are not
reasonably likely to have a Material Adverse Effect with respect to Sirona: (i)
Sirona and its Significant Subsidiaries have complied with all applicable
Environmental Laws; (ii) the properties currently owned or operated by Sirona
and its Significant Subsidiaries (including soils, groundwater, surface water,
buildings or other structures) are not contaminated with any Hazardous
Substances; (iii) the properties formerly owned or operated by Sirona or any of
its Significant Subsidiaries were not contaminated with Hazardous Substances
during the period of ownership or operation by Sirona or any of its Significant
Subsidiaries; (iv) neither Sirona nor its Significant Subsidiaries are subject
to liability for any Hazardous Substance disposal or contamination on any third
party property; (v) neither Sirona nor any of its Significant Subsidiaries has
been associated with any release or threat of release of any Hazardous
Substance; (vi) neither Sirona nor any of its Significant Subsidiaries has
received any outstanding notice, demand, letter, claim or request for
information alleging that Sirona or any of its Significant Subsidiaries may be
in violation of or liable under any Environmental Law; (vii) neither Sirona nor
any of its Significant Subsidiaries is subject to any orders, decrees,
injunctions or other arrangements with any Governmental
- 21 -
Entity or is subject to any indemnity or other agreement with any third party
relating to liability under any Environmental Law or relating to Hazardous
Substances; and (viii) there are no circumstances or conditions involving Sirona
or any of its Significant Subsidiaries that could reasonably be expected to
result in any claims, liability, investigations, costs or restrictions on the
ownership, use or transfer of any property of Sirona pursuant to any
Environmental Law.
3.16 Brokers' and Finders' Fees. Except as set forth on Schedule
3.16, neither Sirona nor any Subsidiary of Sirona has incurred, or will incur,
directly or indirectly, any liability for brokerage or finders' fees or agents'
commissions or any similar charges in connection with this Agreement or any
transaction contemplated by this Agreement.
3.17 The Proxy Statement; Disclosure. None of the information
supplied or to be supplied by or on behalf of Sirona or Luxco for inclusion in
the Proxy Statement to be filed with the SEC will, at the time the Proxy
Statement is mailed to the stockholders of ▇▇▇▇▇▇, at the time of the ▇▇▇▇▇▇
Stockholders Meeting or as of the Closing Date, contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the
circumstances under which they are made, not misleading. Notwithstanding the
foregoing, no representation or warranty is made by Sirona with respect to
statements made or incorporated by reference therein about ▇▇▇▇▇▇ supplied by
▇▇▇▇▇▇ for inclusion or incorporation by reference in the Proxy Statement. The
representations and warranties of Sirona contained in this Agreement and in each
certificate, schedule or exhibit furnished or to be furnished by or on behalf of
Sirona pursuant hereto, or in connection with the transactions contemplated
hereby, taken together, do not contain and will not contain any untrue statement
of a material fact and do not or will not omit to state a material fact
necessary to make the statements or facts contained herein or therein, in light
of the circumstances under which they were made, not misleading.
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF LUXCO
Luxco represents and warrants to ▇▇▇▇▇▇ that the statements contained in
this Article 4 are true, correct and complete as of the date of this Agreement
and will be true, correct and complete as of the Closing Date, subject to the
limited exceptions specifically disclosed in writing in the disclosure schedules
supplied by Luxco or Sirona to ▇▇▇▇▇▇ dated as of the date hereof and certified
by a duly authorized officer of Luxco or Sirona, as follows:
4.1 Organization; Power; Charter Documents. Luxco is a societe en
commandite par actions, duly organized and validly existing under the laws of
the Grand Duchy of Luxembourg and has all organizational power and authority to
own, lease and operate its properties and to carry on its business as now being
conducted, except where the failure to have such power and authority would not,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Luxco. Luxco has made available to ▇▇▇▇▇▇ a copy of its
articles of association, as amended to date (the "Luxco Charter Documents"), and
such instruments are in full force and effect. Luxco is not in default in any
material respect under or in violation in any material respect of any of the
provisions of the Luxco Charter Documents.
4.2 Authority; Non-Contravention; Necessary Consents.
- 22 -
(a) Authority. The execution and delivery of this Agreement
and the other Transaction Documents to which Luxco is a party and the
consummation of the transactions contemplated hereby and thereby have been duly
authorized by all necessary organizational action on the part of Luxco and no
other organizational proceedings on the part of Luxco are necessary to authorize
the execution and delivery of this Agreement or the other Transaction Documents
to which Luxco is a party or to consummate the Exchange Transactions and the
other transactions contemplated hereby and thereby. This Agreement and the other
Transaction Documents to which Luxco is a party have been duly executed and
delivered by Luxco and constitute the valid and binding obligations of Luxco,
enforceable against Luxco in accordance with their respective terms subject to
(i) laws of general application relating to bankruptcy, insolvency and the
relief of debtors, and (ii) rules of law governing specific performance,
injunctive relief and other equitable remedies.
(b) Non-Contravention. Except as set forth in Schedule 4.2(b),
the execution and delivery of this Agreement and the other Transaction Documents
to which Luxco is a party by Luxco do not, and performance of this Agreement and
the other Transaction Documents to which Luxco is a party by Luxco will not (i)
contravene or conflict with or constitute a violation of the Luxco Charter
Documents or any resolution adopted by its securityholders, the Luxco Board or
any committee of the Luxco Board, or (ii) subject to compliance with and filings
under the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act and any additional consents and filings under
any foreign antitrust, competition, premerger notification or trade regulation
law, regulation or order, contravene or conflict with or constitute a violation
of any Legal Requirement applicable to Luxco, except where any of the foregoing
in clause (ii) would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on Luxco. Except as set forth in
Schedule 4.2(b), Luxco is not party to, or bound by, any Contract, Permit or
other instrument which would require consent as a result of the execution,
delivery and performance of this Agreement or the consummation of the
transactions contemplated by this Agreement, except as would not reasonably be
expected to have a Material Adverse Effect on Luxco.
(c) Consents. Except as set forth in Schedule 4.2(c), no
consent, approval, failure to object, order or authorization of, or
registration, declaration or filing with any Governmental Entity or any other
Person is required to be obtained or made by Luxco in connection with the
execution and delivery of this Agreement or the consummation of the Exchange
Transactions and other transactions contemplated by this Agreement, except for
(i) any such consent, approval, failure to object, order or authorization of, or
registration, declaration or filing, which would not, individually or in the
aggregate, be reasonably expected to have a Material Adverse Effect on Luxco and
(ii) compliance with and filings under the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act and any
additional consents and filings under any foreign antitrust, competition,
premerger notification or trade regulation law, regulation or order.
4.3 Capital Structure.
(a) Capital. The entire authorized capital of Luxco consists
of (euro)20,149,702.50 of which (euro)150,646.25 has been subscribed, consisting
of 120,517 ordinary shares of Luxco with a nominal value of (euro)1.25 each
("Luxco Capital Stock") which are issued. All of the issued shares of Luxco
Capital Stock have been duly authorized and validly issued, are
- 23 -
fully paid, and except as set forth in Schedule 4.3(a), are free of any
preemptive rights, rights of participation, rights of maintenance or any similar
rights. The issued shares of Luxco Capital Stock were not issued in violation of
the preemptive rights of any Person or any Contract or Legal Requirement by
which Luxco at the time of issuance was bound including federal and state
securities laws. As of the date hereof, there are no shares of Luxco Capital
Stock held in treasury by Luxco. Except as set forth in Schedule 4.3(a): (i)
none of the issued shares of Luxco Capital Stock is subject to any right of
first refusal in favor of Luxco or any other Person, and (ii) there is no
Contract relating to the voting or registration of, or restricting any Person
from purchasing, selling, pledging or otherwise disposing of (or granting any
option or similar right with respect to), any shares of Luxco Capital Stock.
Luxco is not under any material obligation, nor is it bound by any material
Contract pursuant to which it may become obligated, to repurchase, redeem or
otherwise acquire any outstanding shares of Luxco Capital Stock.
(b) Stockholder Agreements. Except as set forth in Schedule
4.3(b), there are no stockholder agreements, voting trusts or other agreements
or understandings to which Luxco is a party or by which it is bound relating to
the voting of any shares of Luxco Capital Stock. Except as set forth in Schedule
4.3(b), Luxco has made available to ▇▇▇▇▇▇ a true, correct and complete copy of
each agreement listed on Schedule 4.3(b).
4.4 Investment Representations. Luxco is acquiring the Restricted
Securities acquired pursuant hereto for its own account with the present
intention of holding such securities for purposes of investment, and has no
intention of selling such securities in a public distribution in violation of
the federal securities laws or any applicable state securities laws. Luxco is an
"accredited investor" and a sophisticated investor for purposes of applicable
U.S. federal and state securities laws and regulations. Notwithstanding the
foregoing, nothing contained herein shall prevent Luxco and subsequent holders
of Restricted Securities from transferring such securities in compliance with
the provisions of Section 6.9 hereof.
4.5 Exchanged Shares and Note. Except as set forth on Schedule 4.5,
Luxco owns the Sirona Shares and the Sirona Note to be transferred to ▇▇▇▇▇▇
pursuant to this Agreement, free and clear of all Liens.
4.6 Disclosure. The representations and warranties of Luxco
contained in this Agreement and in each certificate, schedule or exhibit
furnished or to be furnished by or on behalf of Luxco pursuant hereto, or in
connection with the transactions contemplated hereby, taken together, do not
contain and will not contain any untrue statement of a material fact and do not
or will not omit to state a material fact necessary to make the statements or
facts contained herein or therein, in light of the circumstances under which
they were made, not misleading.
ARTICLE 5
COVENANTS RELATING TO CONDUCT OF BUSINESSES
5.1 Covenants of ▇▇▇▇▇▇. Notwithstanding anything in this Agreement
to the contrary, ▇▇▇▇▇▇ shall be permitted to make and pay to its stockholders,
and its stockholders shall be permitted to accept the Transaction Dividend.
During the period from the date of this Agreement and continuing until the
earlier of the termination of this Agreement or the Closing Date (except as set
forth on Schedule 5.1 or as expressly contemplated or permitted by this
- 24 -
Agreement or except as required by a Governmental Entity or applicable law or to
the extent that Luxco shall otherwise consent in writing, which consent shall
not be unreasonably withheld or delayed):
(a) Ordinary Course. ▇▇▇▇▇▇ and its Subsidiaries shall carry
on their respective businesses in the ordinary course of business and shall use
reasonable best efforts to preserve intact their present business organizations
and their relationships with material customers, suppliers and others having
material business dealings with them.
(b) Dividends; Changes in Share Capital. Except for the
Transaction Dividend, ▇▇▇▇▇▇ shall not, and shall not permit any of its
Subsidiaries to, and shall not propose to, (i) declare or pay any dividends on
or make other distributions in respect of any of its capital stock (other than
dividends or distributions by any ▇▇▇▇▇▇ Subsidiary to any other ▇▇▇▇▇▇
Subsidiary or to ▇▇▇▇▇▇), (ii) split, combine or reclassify any of its capital
stock or issue or authorize or propose the issuance of any other securities in
respect of, in lieu of or in substitution for, shares of its capital stock or
(iii) repurchase, redeem or otherwise acquire any shares of its capital stock or
any securities convertible into or exercisable for any shares of its capital
stock except repurchases, redemptions or acquisitions from officers, directors,
employees or other service providers in the ordinary course of business.
(c) Issuance of Securities; Changes to Options. ▇▇▇▇▇▇ shall
not, and shall cause its Subsidiaries not to, issue, deliver or sell, or
authorize or propose the issuance, delivery or sale of, any shares of its
capital stock of any class, any of its Voting Debt or any securities convertible
into or exercisable for, or any rights, warrants or options to acquire, any such
shares or Voting Debt, or enter into any agreement with respect to any of the
foregoing. Except as expressly set forth in this Agreement, ▇▇▇▇▇▇ and the
▇▇▇▇▇▇ Board and any committee thereof shall not, and shall cause ▇▇▇▇▇▇'▇
Subsidiaries not to, grant, amend, modify, waive or take any action with respect
to any ▇▇▇▇▇▇ Options, ▇▇▇▇▇▇ Options Plans, or ▇▇▇▇▇▇ Warrants or agreements
pursuant to which any ▇▇▇▇▇▇ Warrants have been or could be issued (including
any actions that would trigger any anti-dilution or other adjustment provision
in any such plans or agreements) or accelerate the vesting of any ▇▇▇▇▇▇
Options. Notwithstanding anything in this Section 5.1(c) to the contrary, ▇▇▇▇▇▇
shall be permitted to issue shares of Common Stock upon the exercise, cashless
or otherwise, of ▇▇▇▇▇▇ Options and ▇▇▇▇▇▇ Warrants outstanding as of the date
hereof in accordance with their present terms or as their vesting may be
automatically accelerated in accordance with their present terms.
Notwithstanding anything else herein to the contrary, ▇▇▇▇▇▇ shall be permitted
to (i) make a loan after the date hereof to any employee of ▇▇▇▇▇▇ or its
Subsidiaries (other than any of the persons listed on Schedule 5.1(c)(i)) in an
amount not to exceed the exercise price of the outstanding vested options to
acquire Common Stock held by such employee (to the extent such options are set
forth on Schedule 2.4 or the letter referred to in Section 2.4); provided that
(x) any such loan shall have a maturity date that is not later than the earlier
of the date on which ▇▇▇▇▇▇ would be prohibited by law from having such loan be
outstanding or the date the Transaction Dividend is paid, (y) any such loan
shall be full recourse to such employee and shall be secured by the shares
received upon exercise of such option and (z) such loan shall be required to be
prepaid with any proceeds such employee may receive in connection with the
Transaction Dividend; provided further that the aggregate amount of all such
loans shall not exceed $2,500,000.
- 25 -
(d) Organizational Documents. Except to the extent required to
comply with their respective obligations hereunder or by applicable Legal
Requirements, ▇▇▇▇▇▇ and its Subsidiaries shall not amend or propose to amend
the ▇▇▇▇▇▇ Charter Documents or the ▇▇▇▇▇▇ Subsidiary Charter Documents.
(e) Indebtedness and Other Matters. ▇▇▇▇▇▇ shall not, and
shall not permit any of its Significant Subsidiaries to, (i) incur or become
obligated in respect of any Indebtedness in excess of $2,000,000 in the
aggregate other than (A) Indebtedness existing on the date hereof, (B)
Indebtedness for borrowed money under existing working capital facilities in the
ordinary course of business, (C) Indebtedness owed to ▇▇▇▇▇▇ or any of its
Significant Subsidiaries or (D) Indebtedness incurred to fund the Transaction
Dividend, (ii) make any loans or advances in excess of $1,000,000 in the
aggregate other than by ▇▇▇▇▇▇ or its Subsidiaries to or in ▇▇▇▇▇▇ or its
Subsidiaries or other than to customers for the purchase of products from ▇▇▇▇▇▇
or its Subsidiaries in the ordinary course of business, (iii) except for
acquisitions of cash equivalents and publicly traded securities or as set forth
on Schedule 5.1(e)(iii), make any capital contributions to, or investments in,
any other Person or group of related Persons (other than by ▇▇▇▇▇▇ or its
Subsidiaries to or in ▇▇▇▇▇▇ or its Subsidiaries) or form or acquire any new
Subsidiary or acquire any capital stock or equity securities in any business or
Person (other than ▇▇▇▇▇▇ or its Subsidiaries), in any case, with an aggregate
fair market value in excess of (x) $1,000,000, unless notice of such event is
provided to Sirona promptly following such event or (y) $3,000,000 (whether or
not subsequent notice is given), (iv) make or commit to make any capital
expenditures in excess of $500,000 in the aggregate in any one quarter, (v)
sell, lease, license or otherwise encumber or dispose of any assets or
properties (other than sales in the ordinary course of business and sales among
▇▇▇▇▇▇ and its Significant Subsidiaries) with an aggregate fair market value in
excess of (x) $500,000 unless notice of such event is provided to Sirona
promptly following such event or (y) $1,000,000 (whether or not subsequent
notice is given), or (vi) agree, or commit to agree, to take any of the actions
described in this Section 5.1(e). ▇▇▇▇▇▇ shall keep Sirona reasonably informed
on a timely basis with respect to any transactions that ▇▇▇▇▇▇ is permitted to
undertake pursuant the terms of Section 5.1(e)(iii).
(f) Benefit Plans and Other Employee Compensation. ▇▇▇▇▇▇
shall not, and shall not permit any of its Significant Subsidiaries to, (i)
establish, adopt, enter into, or amend in any material respect any material
Employee Plan of ▇▇▇▇▇▇ or its Significant Subsidiaries, except as required by
law or (ii) increase the compensation payable or to become payable to any of the
officers listed on Schedule 5.1(f) Part A hereto or any replacements therefor
or, except in the ordinary course of business consistent with prior practices,
other employees. Notwithstanding anything to the contrary herein, ▇▇▇▇▇▇ shall
be permitted to pay a special one-time bonus at the same time as the payment of
the Transaction Dividend in an aggregate amount not to exceed $2,176,367.60 to
the persons and in the amounts set forth on Schedule 5.1(f) Part B.
5.2 Covenants of Sirona. During the period from the date of this
Agreement and continuing until the earlier of the termination of this Agreement
or the Closing Date (except as set forth on Schedule 5.2 or as expressly
contemplated or permitted by this Agreement or except as required by a
Governmental Entity or applicable law or to the extent that ▇▇▇▇▇▇ shall
otherwise consent in writing, which consent shall not be unreasonably withheld
or delayed):
- 26 -
(a) Ordinary Course. Sirona and its Subsidiaries shall carry
on their respective businesses in the ordinary course of business and shall use
reasonable best efforts to preserve intact their present business organizations
and their relationships with material customers, suppliers and others having
material business dealings with them.
(b) Dividends; Changes in Share Capital. Sirona shall not, and
shall not permit any of its Subsidiaries to, and shall not propose to, (i)
declare or pay any dividends on or make other distributions in respect of any of
its capital stock (other than dividends or distributions (x) by any Sirona
Subsidiary to any other Sirona Subsidiary or to Sirona or (y) to Luxco to fund
repurchases, redemptions or acquisitions of equity securities from officers,
directors, employees or other service providers in the ordinary course of
business), (ii) split, combine or reclassify any of its capital stock or issue
or authorize or propose the issuance of any other securities in respect of, in
lieu of or in substitution for, shares of its capital stock or (iii) repurchase,
redeem or otherwise acquire any shares of its capital stock or any securities
convertible into or exercisable for any shares of its capital stock except
repurchases, redemptions or acquisitions from officers, directors, employees or
other service providers in the ordinary course of business.
(c) Issuance of Securities; Changes to Options. Sirona shall
not, and shall cause its Subsidiaries not to, issue, deliver or sell, or
authorize or propose the issuance, delivery or sale of, any shares of its
capital stock of any class, any of its Voting Debt or any securities convertible
into or exercisable for, or any rights, warrants or options to acquire, any such
shares or Voting Debt, or enter into any agreement with respect to any of the
foregoing. Except as expressly set forth in this Agreement, Sirona and the
Sirona Board and any committee thereof shall not, and shall cause Sirona's
Subsidiaries not to, grant, amend, modify, waive or take any action with respect
to any options, options plans, or warrants related to Sirona Capital Stock.
(d) Organizational Documents. Except to the extent required to
comply with their respective obligations hereunder or by applicable Legal
Requirements or as set forth on Schedule 5.2(d), Sirona and its Subsidiaries
shall not amend or propose to amend the Sirona Charter Documents or the Sirona
Subsidiary Charter Documents.
(e) Indebtedness and Other Matters. Sirona shall not, and
shall not permit any of its Significant Subsidiaries to, (i) incur or become
obligated in respect of any Indebtedness in excess of (euro)10,000,000 in the
aggregate other than (A) Indebtedness existing on the date hereof, (B)
Indebtedness for borrowed money under existing working capital facilities in the
ordinary course of business, or (C) Indebtedness owed to Sirona or any of its
Significant Subsidiaries, (ii) make any loans or advances in excess of
(euro)2,000,000 in the aggregate other than by Sirona or its Subsidiaries to or
in Sirona or its Subsidiaries or other than to customers for the purchase of
products from Sirona or its Subsidiaries in the ordinary course of business,
(iii) except for acquisitions of cash equivalents and publicly traded
securities, make any capital contributions to, or investments in, any other
Person or group of related Persons (other than by Sirona or its Subsidiaries to
or in Sirona or its Subsidiaries) or form or acquire any new Subsidiary or
acquire any capital stock or equity securities in any business or Person (other
than Sirona or its Subsidiaries), in any case, with an aggregate fair market
value in excess of (x) (euro)1,000,000, unless notice of such event is provided
to ▇▇▇▇▇▇ promptly following such event or (y) (euro)15,000,000 (whether or not
subsequent notice is given), (iv) make or commit to make any
- 27 -
capital expenditures in excess of (euro)4,000,000 in the aggregate in any one
quarter, (v) sell, lease, license or otherwise encumber or dispose of any assets
or properties (other than sales in the ordinary course of business and sales
among Sirona and its Significant Subsidiaries) with an aggregate fair market
value in excess of (x) (euro)5,000,000, unless notice of such event is provided
to ▇▇▇▇▇▇ promptly following such event or (y) (euro)10,000,000 (whether or not
subsequent notice is given), or (vi) agree, or commit to agree, to take any of
the actions described in this Section 5.2(e).
(f) Benefit Plans and Other Employee Compensation. Sirona
shall not, and shall not permit any of its Significant Subsidiaries to, (i)
establish, adopt, enter into, or amend in any material respect any material
Employee Plan of Sirona or its Significant Subsidiaries, except as required by
law or (ii) increase the compensation payable or to become payable to any of the
officers listed on Schedule 5.2(f) hereto or any replacements therefor or,
except in the ordinary course of business consistent with prior practices, other
employees.
5.3 Advice of Changes; Government Filings. Each of the Parties shall
(a) promptly advise the other in writing of (i) any representation or warranty
made by it contained in this Agreement that is qualified as to materiality
becoming untrue or inaccurate in any respect or any such representation or
warranty that is not so qualified becoming untrue or inaccurate in any material
respect, (ii) the failure by it (A) to comply with or satisfy in any respect any
covenant, condition or agreement required to be complied with or satisfied by it
under this Agreement that is qualified as to materiality or (B) to comply with
or satisfy in any material respect any covenant, condition or agreement required
to be complied with or satisfied by it under this Agreement that is not so
qualified as to materiality or (iii) any change, event or circumstance that has
had a Material Adverse Effect on such Party or materially and adversely affects
its ability to consummate the transactions contemplated hereby in a timely
manner, and (b) promptly notify each other of (i) any notice or other
communication from any Person alleging that the consent of such Person is or may
be required in connection with the transactions contemplated by this Agreement,
(ii) any notice or other communication from any Governmental Entity in
connection with the transactions contemplated by this Agreement, and (iii) any
actions, suits, claims, investigations or proceedings commenced or, to such
Party's Knowledge, threatened against, relating to or involving or otherwise
affecting ▇▇▇▇▇▇ or any of its Subsidiaries, on the one hand, or Luxco, Sirona
or any of their Subsidiaries, on the other hand, which relate to the
consummation of the transactions contemplated by this Agreement. Each such
notification pursuant to clause (a) or (b) of the prior sentence made with
respect to a matter or event first occurring after the date hereof and which was
not known by such Exchange Party on or prior to the date hereof (each, a
"Schedule Update") shall amend and supplement the appropriate Schedules to
Article 2, 3 or 4, as the case may be, delivered on the date hereof; provided,
however, that no Schedule Update shall be taken into account for the purposes of
Section 7.2(a) or Section 7.3(a) hereof; provided further that any notice that
is not a Schedule Update shall not have any effect on the representations and
warranties made herein or modify or update the appropriate Schedules. The
Parties shall file all reports (if any) required to be filed by each of them
with the SEC between the date of this Agreement and the Closing Date and shall
(to the extent permitted by law or regulation or any applicable confidentiality
agreement) deliver to the other Party copies of all such reports promptly after
the same are filed. Subject to applicable laws relating to the exchange of
information, each of ▇▇▇▇▇▇ and Luxco shall have the right to review in advance,
and to the extent practicable each will consult with the other, with respect to
- 28 -
all the information relating to the other Party and each of their respective
Subsidiaries, which appears in any filings, announcements or publications made
with, or written materials submitted to, any third party or any Governmental
Entity in connection with the transactions contemplated by this Agreement;
provided that confidential information in any such filings, announcements or
publications regarding Affiliates (other than Subsidiaries) of any Party need
not be disclosed to any other Party. In exercising the foregoing right, each of
the Parties agrees to act reasonably and as promptly as practicable. Each of
▇▇▇▇▇▇ and Luxco agrees that, to the extent practicable, it will consult with
the other Party with respect to the obtaining of all Permits, consents,
approvals and authorizations of all third parties and Governmental Entities
necessary or advisable to consummate the transactions contemplated by this
Agreement and each further agrees to keep the other apprized of the status of
matters relating to completion of the transactions contemplated hereby.
Notwithstanding anything to the contrary, nothing in this Agreement shall
require any Party or its Subsidiaries to disclose any forward product plans,
product specific cost information, pricing information, customer specific
information, merchandising information, or other similar competitively sensitive
information (collectively, "Competitively Sensitive Information") of such Party
or its Subsidiaries so long as such Party promptly notifies the other Parties in
writing of the nature of the specific Competitively Sensitive Information that
it has withheld in reliance on this sentence.
ARTICLE 6
ADDITIONAL AGREEMENTS
6.1 ▇▇▇▇▇▇ Stockholders Meeting; Preparation of the Proxy Statement.
(a) ▇▇▇▇▇▇ Stockholders Meeting. ▇▇▇▇▇▇ shall, as promptly as
practicable after the SEC shall have approved or declined to review the Proxy
Statement, duly call, give notice of, convene and hold a special meeting of its
stockholders (the "▇▇▇▇▇▇ Stockholders Meeting") for the purpose of obtaining
the Requisite Stockholder Approval, and subject to Section 6.4, the ▇▇▇▇▇▇ Board
shall recommend to the ▇▇▇▇▇▇ Stockholders the approval and adoption of the
Certificate Amendment, this Agreement and the Exchange Transactions (the
"Company Recommendation") and shall include such recommendation in the Proxy
Statement; provided, however, that the ▇▇▇▇▇▇ Board shall not be required to
make such Company Recommendation to the extent that it conflicts with a Company
Adverse Recommendation Change already made in accordance with Section 6.4(c).
▇▇▇▇▇▇ shall (i) use its reasonable best efforts to solicit from its
stockholders proxies in favor of the approval of the Certificate Amendment, the
Exchange Transactions and this Agreement and will take all other action
reasonably necessary or advisable to secure such vote or consent of its
stockholders and (ii) ensure that the ▇▇▇▇▇▇ Stockholders Meeting is called,
noticed, convened, held and conducted, and that all proxies solicited by it in
connection therewith are solicited in compliance with the DGCL, the ▇▇▇▇▇▇
Charter Documents and all other applicable Legal Requirements. The foregoing
shall be at ▇▇▇▇▇▇'▇ expense. Luxco shall vote or cause to be voted any of the
shares of Common Stock owned of record or beneficially by Luxco or any of its
Subsidiaries in favor of the Certificate of Amendment and this Agreement and the
transactions contemplated by this Agreement. Immediately following the Requisite
Stockholder Approval, ▇▇▇▇▇▇ shall file, and cause to become immediately
effective, the Certificate Amendment with the Secretary of State of the State of
Delaware in accordance with the DGCL.
- 29 -
(b) Proxy Statement. Subject to the terms and conditions of
this Agreement, as soon as practicable following the date of this Agreement,
▇▇▇▇▇▇ shall prepare and file with the SEC the Proxy Statement with respect to
the approval of the Certificate of Amendment and the Exchange Transactions and
the adoption of this Agreement at the ▇▇▇▇▇▇ Stockholders Meeting, and use its
reasonable best efforts to have the Proxy Statement cleared by the SEC and
mailed to ▇▇▇▇▇▇'▇ stockholders after the Proxy Statement has been cleared by
the SEC. The Parties shall cooperate with each other in the preparation of the
Proxy Statement. Sirona and Luxco shall at their own expense furnish all
information concerning them as may be required by law and the Exchange Act in
connection with the preparation, filing and distribution of the Proxy Statement,
which shall include, without limitation, Sirona's audited consolidated financial
statements for its two most recent fiscal years specified on Schedule 6.1(b)
(the "Sirona Audited U.S. GAAP Financials"), and any unaudited financial
statements for any interim period required by the U.S. federal securities laws,
in each case prepared in accordance with U.S. GAAP. Sirona shall use its
reasonable best efforts to deliver to ▇▇▇▇▇▇ the Sirona Audited U.S. GAAP
Financials and any unaudited financial statements for any such interim period as
promptly as practicable. In the event the Sirona Audited U.S. GAAP Financials
are not completed on or prior to December 15, 2005, Luxco shall reasonably
consult with ▇▇▇▇▇▇ promptly thereafter regarding the status of the Sirona
Audited U.S. GAAP Financials and the efforts that have been made prior to such
date with respect to the preparation thereof and shall allow ▇▇▇▇▇▇ to
reasonably meet and consult with the accountants preparing the Sirona Audited
U.S. GAAP Financials to a reasonable extent regarding the same. The Proxy
Statement shall comply as to form and content in all material respects with the
applicable provisions of the federal securities laws. Luxco and its counsel
shall be given a reasonable opportunity to review and comment upon the Proxy
Statement and any amendment or supplement thereto prior to the filing thereof
with the SEC, and ▇▇▇▇▇▇ shall consider any such comments in good faith. ▇▇▇▇▇▇
agrees to provide to Luxco and its counsel any comments which ▇▇▇▇▇▇ or its
counsel may receive from the staff of the SEC with respect to the Proxy
Statement promptly after receipt thereof. The Parties agree to promptly correct
any information provided by any of them for use in the Proxy Statement which
shall have become false or misleading in any respect, and ▇▇▇▇▇▇ further agrees
to use its reasonable best efforts to cause such Proxy Statement as so corrected
to be filed with the SEC and disseminated to ▇▇▇▇▇▇'▇ stockholders, in each case
as and to the extent required by the applicable provisions of the federal
securities laws. ▇▇▇▇▇▇ agrees to use its reasonable best efforts, after
consultation with the other parties hereto, to respond promptly to any comments
made by the SEC with respect to the Proxy Statement and any preliminary version
thereto or amendment thereof, filed by it. Each of Luxco and Sirona agree to use
its reasonable best efforts to promptly provide ▇▇▇▇▇▇ with any information
necessary to respond to any such comments made by the SEC. A copy of the opinion
of ▇▇▇▇▇▇'▇ financial advisor shall be included in the Proxy Statement.
6.2 Access to Information; Quarterly Financial Statements. Subject
to the provisions of this Section 6.2 and applicable laws relating to the
exchange of information and subject to attorney-client privilege, upon
reasonable notice, each Exchange Party shall (and shall cause its Subsidiaries,
to) afford to the officers, employees and other representatives of the other
Exchange Party reasonable access at reasonable times, during the period prior to
the Closing Date to each of its employees listed on Schedule 6.2 hereto;
provided that the foregoing shall not require any Exchange Party or its
Subsidiaries to disclose any Competitively Sensitive Information. ▇▇▇▇▇▇ shall
deliver to Sirona all of the quarterly financial statements for each of
- 30 -
the calendar quarters following June 30, 2005, within 30 days after the end of
each such quarter, that are prepared by or for ▇▇▇▇▇▇ in the ordinary course of
business. Sirona shall deliver to ▇▇▇▇▇▇ all of the quarterly financial
statements, in management account format, for each of the calendar quarters
following June 30, 2005, within 30 days after the end of each such quarter, that
are prepared by or for Sirona for its bank lenders in the ordinary course of
business. Notwithstanding the foregoing, from the date hereof until the earlier
of the Closing or a termination of this Agreement pursuant to and in accordance
with Article 8, except in the ordinary course of business, none of the Exchange
Parties, their respective Subsidiaries or any of their representatives, shall
contact, directly or indirectly, any customer, supplier, officer or employee
(other than any officers or employees listed on Schedule 6.2) or other
representative (other than any legal counsel and financial advisors of such
Exchange Party) of the other Exchange Party or its Subsidiaries with respect to
the transactions contemplated hereunder (including, without limitation, with
respect to any relationship post-Closing) except through coordinated meetings or
contacts consented to in writing by the other Exchange Party. All such
information delivered pursuant to this Section 6.2 shall be held in confidence
to the extent required by, and in accordance with, the provisions of the
Non-Disclosure and Confidentiality Agreement, dated June 8, 2005, between
▇▇▇▇▇▇, Beecken ▇▇▇▇▇ ▇'▇▇▇▇▇ & Company, Madison Dearborn Partners and Sirona
Dental Systems GmbH (the "Confidentiality Agreement"), which Confidentiality
Agreement shall remain in full force and effect.
6.3 Approvals and Consents; Cooperation. Each of ▇▇▇▇▇▇, Luxco and
Sirona shall cooperate with each other and use (and shall cause their respective
Subsidiaries to use) its reasonable best efforts to take or cause to be taken
all actions, and do or cause to be done all things, necessary, proper or
advisable on their part under this Agreement and applicable laws to consummate
and make effective the Exchange Transactions and the other transactions
contemplated by this Agreement as soon as practicable, including without
limitation (i) preparing and filing as promptly as practicable all documentation
to obtain each of the consents and approvals, with respect to ▇▇▇▇▇▇, set forth
on Schedule 6.3(a) and, with respect to Luxco and Sirona, set forth on Schedule
6.3(b) (collectively, the "Required Approvals") and (ii) taking all reasonable
steps as may be necessary to obtain all such Required Approvals. Without
limiting the generality of the foregoing, each of ▇▇▇▇▇▇, Luxco and Sirona agree
to make all necessary filings in connection with the Required Approvals as
promptly as practicable after the date of this Agreement, and to use its
reasonable best efforts to furnish or cause to be furnished, as promptly as
practicable, all information and documents requested with respect to such
Required Approvals, and shall otherwise cooperate with any applicable
Governmental Entity in order to obtain any Required Approvals in as expeditious
a manner as possible. Each of ▇▇▇▇▇▇, Luxco and Sirona shall use its reasonable
best efforts to resolve such objections, if any, as any Governmental Entity may
assert with respect to this Agreement and the transactions contemplated hereby
in connection with the Required Approvals. In the event that a suit is
instituted by a Person or Governmental Entity challenging this Agreement and the
transactions contemplated hereby as violative of applicable antitrust or
competition laws, each of ▇▇▇▇▇▇ and Luxco shall use its reasonable best efforts
to resist or resolve such suit. ▇▇▇▇▇▇ and Luxco each shall, upon request by the
other, furnish the other with all information concerning itself, its
Subsidiaries, Affiliates, directors, officers and stockholders and such other
matters as may reasonably be necessary or advisable in connection with the Proxy
Statement or any other statement, filing, Tax ruling request, notice or
application made by or on behalf of ▇▇▇▇▇▇, Luxco or any of their respective
Subsidiaries to any third party and/or any Governmental Entity in
- 31 -
connection with the Exchange Transactions or the other transactions contemplated
by this Agreement. Notwithstanding the foregoing, nothing in this Section 6.3 or
any other provision of this Agreement shall require, or be construed to require,
any Party to proffer to, or agree to, sell or hold separate and agree to sell,
before or after the Closing Date, any assets, businesses, or interest in any
assets or businesses of Schick, Luxco, Sirona or any of their respective
Affiliates (or to consent to any sale, or agreement to sell, any such assets or
businesses) or to agree to any material changes or restriction in the operations
of any such assets or businesses.
6.4 Alternative Proposals.
(a) From the date of this Agreement until the earlier of the
Closing Date or the termination of this Agreement in accordance with Article 8,
except as otherwise permitted hereby, each Exchange Party agrees that it will
not, nor shall it authorize or permit any of its officers and directors and it
will use its reasonable best efforts to cause its agents, affiliates, employees
and advisors not to, (i) solicit, initiate or knowingly encourage (including,
but not limited to, by way of furnishing nonpublic information) any inquiries or
the making of any proposal or offer (including, without limitation, any proposal
or offer to its stockholders) that constitutes, or is reasonably expected to
lead to, any Competing Transaction (as defined below), (ii) enter into or
maintain or continue discussions or negotiations with any Person in furtherance
of such inquiries or to obtain a Competing Transaction, (iii) agree to any
Competing Transaction or (iv) endorse any Competing Transaction; provided,
however, that notwithstanding anything to the contrary contained herein, prior
to the date of the Requisite Stockholder Approval, nothing in this Section 6.4
shall in any respect prohibit the ▇▇▇▇▇▇ Board or the officers, directors,
agents, affiliates, employees or advisors of ▇▇▇▇▇▇ or its Subsidiaries from
furnishing or disclosing information to, or engaging in discussions or
negotiations with, any Person that makes an unsolicited bona fide written
proposal to acquire ▇▇▇▇▇▇ pursuant to a Competing Transaction (a "Competing
Transaction Proposal"), if the ▇▇▇▇▇▇ Board acting in good faith determines (i)
after consultation with its financial advisor that such Competing Transaction
Proposal constitutes or is reasonably likely to result in a Superior Proposal
and (ii) after taking into account any revisions to the terms of the Exchange
Transactions or this Agreement proposed by Luxco after being notified pursuant
to Section 6.4(c), that doing so is necessary for the ▇▇▇▇▇▇ Board to comply
with its fiduciary duties to the ▇▇▇▇▇▇ Stockholders under applicable law. A
"Superior Proposal" shall mean any bona fide written Competing Transaction
Proposal for or in respect of the acquisition of at least a majority of the
outstanding shares of Common Stock or all or substantially all of ▇▇▇▇▇▇'▇ and
its Subsidiaries' assets (i) on terms that the ▇▇▇▇▇▇ Board determines in its
good faith judgment (after (w) consultation with, and taking into account the
advice of, a financial advisor of nationally recognized reputation and outside
legal counsel, (x) taking into account all the terms and conditions of such
Competing Transaction Proposal, including any break-up fees, expense
reimbursement provisions and conditions to consummation and (y) taking into
account any revisions to the terms of the Exchange Transactions or this
Agreement proposed by Luxco after being notified pursuant to Section 6.4(c)) are
more favorable to ▇▇▇▇▇▇ and its stockholders than the Exchange Transactions and
the other transactions contemplated hereby and (ii) that constitutes a
transaction that is reasonably likely to be consummated on the terms so
proposed, taking into account all legal, financial, regulatory and other aspects
of such proposal.
- 32 -
(b) ▇▇▇▇▇▇ shall promptly (within 24 hours) notify Luxco after
receipt by it (or any of its officers, directors, employees, agents or advisors
or other representatives) of any Competing Transaction Proposal or any request
for nonpublic information or inquiry which it reasonably believes could be
expected to lead to a Competing Transaction Proposal and shall provide to Luxco,
in writing, the terms and conditions of any such Competing Transaction Proposal,
or such request or inquiry and the identity of the person making the same. Prior
to ▇▇▇▇▇▇ furnishing information with respect to it, as permitted by Section
6.4(a) to any person making such a Competing Transaction Proposal, ▇▇▇▇▇▇ shall
enter into a confidentiality agreement with such person the terms of which are
not materially less restrictive than the Confidentiality Agreement, and all such
information (to the extent such information shall not have previously been
provided to Luxco) shall be provided or made available to Luxco at such time
such information is made available to such person.
(c) Notwithstanding the foregoing, the ▇▇▇▇▇▇ Board may, prior
to obtaining the Requisite Stockholder Approval, withdraw (or modify in a manner
adverse to Luxco) or publicly propose to withdraw (or modify in a manner adverse
to Luxco) once made, its recommendation in favor of this Agreement or the
transactions contemplated hereby and approve or recommend a Competing
Transaction Proposal (any action described in this subsection being referred to
as a "Company Adverse Recommendation Change") in connection with a Superior
Proposal if, but only if, and to the extent that all of the following conditions
are met prior to such Company Adverse Recommendation Change: (i) the Requisite
Stockholder Approval has not been obtained; (ii) the ▇▇▇▇▇▇ Board determines in
good faith (after consulting with its outside legal counsel) that failure to so
withdraw or modify the Company Recommendation would violate their fiduciary
duties to the ▇▇▇▇▇▇ Stockholders under applicable law; (iii) before taking any
such action, ▇▇▇▇▇▇ promptly gives Luxco written notice advising Luxco of the
decision of the ▇▇▇▇▇▇ Board to take such action, including the reasons
therefore and, in the event that such decision relates to a Competing
Transaction Proposal, such notice specifies the material terms and conditions of
such Competing Transaction Proposal and identifies the Person making such
Competing Transaction Proposal (and ▇▇▇▇▇▇ will also promptly give Luxco such a
notice with respect to any subsequent change in such proposal) and ▇▇▇▇▇▇ has
given Luxco at least five (5) Business Days after delivery of each such notice
to propose revisions to the terms of this Agreement (or to make another
proposal) in response to such Competing Transaction Proposal and has negotiated
in good faith with Luxco with respect to such proposed revisions or other
proposal, if any, (iv) such Competing Transaction Proposal constitutes a
Superior Proposal and has not been withdrawn, and (v) unless Luxco otherwise
agrees in writing, ▇▇▇▇▇▇ terminates this Agreement pursuant to Section 8.3(b)
within three Business Days following the five Business Day period referred to in
clause (iii) of this Section 6.4(c); provided, however, that notwithstanding any
Company Adverse Recommendation Change, ▇▇▇▇▇▇ shall nevertheless submit this
Agreement and the Exchange Transactions to the ▇▇▇▇▇▇ Stockholders for the
purpose of obtaining the Requisite Stockholder Approval at the ▇▇▇▇▇▇
Stockholders Meeting and nothing contained herein shall be deemed to relieve
▇▇▇▇▇▇ of such obligation, unless Luxco otherwise directs ▇▇▇▇▇▇ in writing or
this Agreement shall have been terminated in accordance with its terms prior to
the ▇▇▇▇▇▇ Stockholders Meeting.
(d) Notwithstanding the foregoing, the ▇▇▇▇▇▇ Board shall be
permitted to disclose to the stockholders of ▇▇▇▇▇▇ a position with respect to a
Competing Transaction
- 33 -
Proposal required by Rule 14e-2(a), Item 1012(a) of Regulation M-A or Rule 14d-9
promulgated under the Exchange Act.
(e) A "Competing Transaction" means any of the following
involving an Exchange Party and/or its Subsidiaries (other than the Exchange
Transactions and the other transactions contemplated by this Agreement): (i) a
merger, consolidation, share exchange, business combination, recapitalization,
liquidation, dissolution or other similar transaction; (ii) any acquisition,
purchase, sale, lease, exchange, transfer, issuance or disposition of a material
portion of the assets or debt or equity securities of such Person; and (iii) any
tender offer (including a self tender offer) or exchange offer for 20% or more
of any class of equity securities of such Exchange Party or any of its
Subsidiaries.
6.5 Fees and Expenses. Whether or not the Exchange Transactions are
consummated, all Expenses incurred in connection with this Agreement and the
transactions contemplated hereby (i) by ▇▇▇▇▇▇ shall be paid by ▇▇▇▇▇▇ or its
Subsidiaries and (ii) by Luxco or Sirona shall be paid by Sirona or its
Subsidiaries; provided that all fees and out-of-pocket expenses, other than
attorneys' fees, incurred in connection with the filing by any of the Parties
hereto or their respective Subsidiaries of any notice or other document under
any applicable antitrust Legal Requirement shall either be (A) paid 100% by
▇▇▇▇▇▇ or its Subsidiaries, in which case, Sirona or its Subsidiaries shall
promptly reimburse ▇▇▇▇▇▇ or its Subsidiaries for 50% of any such payments or
(B) paid to the applicable third party 50% by ▇▇▇▇▇▇ or its Subsidiaries and 50%
by Sirona or its Subsidiaries. However, in no event shall ▇▇▇▇▇▇ or its
Subsidiaries pay any amount directly to Luxco, Sirona or any of their respective
Subsidiaries pursuant to this Section 6.5 without Luxco's prior written consent.
For purposes of this Agreement, "Expenses" includes all out-of-pocket expenses
(including all fees and expenses of counsel, accountants, investment bankers,
financing sources and their counsel, experts and consultants to a Party and its
Affiliates) incurred by a Party or on its behalf in connection with or related
to the authorization, preparation, negotiation, execution and performance of
this Agreement and the transactions contemplated hereby, including the
preparation, printing, filing and mailing of the Proxy Statement and the
solicitation of stockholder approvals and all other matters related to the
transactions contemplated hereby.
6.6 Current Public Information. ▇▇▇▇▇▇ shall file all reports
required to be filed by it under the Securities Act and the Securities Exchange
Act and the rules and regulations adopted by the SEC thereunder and shall take
such further action as any holder or holders of Restricted Securities may
reasonably request, all to the extent required to enable such holders to sell
Restricted Securities pursuant to (i) Rule 144 adopted by the SEC under the
Securities Act (as such rule may be amended from time to time) or any similar
rule or regulation hereafter adopted by the SEC or (ii) as provided in the
Registration Agreement, a registration statement on Form S-2 or S-3 or any
similar registration form hereafter adopted by the SEC. Upon request, ▇▇▇▇▇▇
shall deliver to any holder of Restricted Securities a written statement as to
whether it has complied with such requirements.
6.7 Listing. In the event the Common Stock is listed on The Nasdaq
National Market, ▇▇▇▇▇▇ shall prepare and submit to The Nasdaq National Market a
listing application covering the ▇▇▇▇▇▇ Shares and shall obtain approval for the
listing of such shares.
- 34 -
6.8 Section 203 of the DGCL. The ▇▇▇▇▇▇ Board shall not adopt any
resolution containing any provisions, relating to the exemption from Section 203
of the DGCL granted to the Luxco Holders or their respective Affiliates which
would adversely affect or otherwise impair the rights of the Luxco Holders or
their Affiliates thereunder.
6.9 Transfer of Restricted Securities.
(a) Luxco and its assignees shall transfer Restricted
Securities only (i) pursuant to public offerings registered under the Securities
Act, (ii) pursuant to Rule 144 of the SEC (or any similar rule or rules then in
force) if such rule or rules are available, (iii) to a person whom the seller
reasonably believes is a "Qualified Institutional Buyer" (as defined in Rule
144A), (iv) outside of the United States in an offshore transaction in
accordance with Rule 904 of the Securities Act, and (v) subject to the
conditions specified in Section 6.9(b) below, any other legally available means
of transfer; provided that the conditions specified in Section 6.9(b) shall be
deemed to have been satisfied without any further action or evidence if the
holder of any Restricted Securities shall deliver to ▇▇▇▇▇▇ a written notice
stating that the holder is transferring Restricted Securities to another Luxco
Holder or an Affiliate of Luxco; provided that the holder thereof shall not
transfer the same until the prospective transferee has confirmed to ▇▇▇▇▇▇ in
writing its agreement to be bound by the provisions contained in this Section
6.9 and in Section 6.11.
(b) In connection with the transfer of any Restricted
Securities (other than a transfer described in Sections 6.9(a)(i) or (ii)
above), the holder thereof shall deliver written notice to ▇▇▇▇▇▇ describing in
reasonable detail the transfer or proposed transfer, together with an opinion of
counsel which (to ▇▇▇▇▇▇'▇ reasonable satisfaction) is knowledgeable in
securities law matters to the effect that such transfer of Restricted Securities
may be effected without registration of such Restricted Securities under the
Securities Act and any other documentation or certifications as ▇▇▇▇▇▇ or its
transfer agent may reasonably deem necessary under applicable law. In addition,
if the holder of the Restricted Securities delivers to ▇▇▇▇▇▇ an opinion of such
counsel that no subsequent transfer of such Restricted Securities shall require
registration under the Securities Act upon the receipt by ▇▇▇▇▇▇ or its transfer
agent of any other documentation or certification as it may reasonably deem
necessary under applicable law, ▇▇▇▇▇▇ shall promptly upon such contemplated
transfer deliver new certificates for such Restricted Securities which do not
bear the Securities Act legend set forth in Section 6.9(d). If ▇▇▇▇▇▇ is not
required to deliver new certificates for such Restricted Securities not bearing
such legend, the holder thereof shall not transfer the same until the
prospective transferee has confirmed to ▇▇▇▇▇▇ in writing its agreement to be
bound by the conditions contained in this Section 6.9 and in Section 6.11.
(c) Upon the request of Luxco, ▇▇▇▇▇▇ shall promptly supply to
Luxco or any subsequent holder of ▇▇▇▇▇▇ Shares or any of their respective
prospective transferees all information regarding ▇▇▇▇▇▇ required to be
delivered in connection with a transfer pursuant to Rule 144A of the Securities
Act. For the avoidance of doubt, any such transfer pursuant to Rule 144A shall
be subject to the requirements described in Section 6.9(b) above.
(d) Each certificate for Restricted Securities shall be
imprinted with a legend in substantially the following form:
- 35 -
"The securities represented by this certificate were originally issued on
[date of issuance] and have not been registered under the Securities Act
of 1933, as amended. The transfer of the securities represented by this
certificate is subject to the conditions specified in the Exchange
Agreement, dated as of September 22, 2005 by and among the issuer (the
"Company") and certain investors, and the Company reserves the right to
refuse the transfer of such securities until such conditions have been
fulfilled with respect to such transfer. A copy of such conditions shall
be furnished by the Company to the holder hereof upon written request and
without charge. Without limiting the generality of the foregoing, the
holder of the securities represented by this certificate agrees for the
benefit of the Company that (A) the securities may be transferred only (I)
pursuant to an effective registration statement under the Securities Act,
(II) to a person whom the seller reasonably believes is a "Qualified
Institutional Buyer" (as defined in Rule 144A of the Securities Act) in a
transaction meeting the requirements of Rule 144A, (III) outside of the
United States in an offshore transaction in accordance with Rule 904 of
the Securities Act, (IV) pursuant to an exemption from registration under
the Securities Act provided by Rule 144 thereunder (if available) or (V)
in any other transactions exempt from the registration requirements of the
Securities Act, and (B) the holder will, and each subsequent holder is
required to, notify any purchaser of the securities from it of the resale
restrictions referred to in (A) above."
6.10 Public Announcements. Except with respect to any Company
Adverse Recommendation Change, each of the Parties shall consult with each other
before issuing, and give each other the reasonable opportunity to review and
comment upon, any press release or other public statements (other than routine
employee communications) with respect to the transactions contemplated by this
Agreement, including the Exchange Transactions and shall not issue any such
press release or make any such public statement prior to such consultation,
except as such party may in its good faith judgment conclude may be required by
law, court process or by obligations pursuant to any listing agreement with any
national securities exchange or national securities quotation system, in which
case the issuing Party shall use its reasonable best efforts to consult with the
other party before issuing any such release or making any such public statement.
The Parties agree that the initial press release to be issued with respect to
the transactions contemplated by this Agreement shall be in the form attached
hereto as Exhibit ▇. ▇▇▇▇▇▇ will report the execution of this Agreement on SEC
Form 8-K, in a form reasonably acceptable to Luxco, and will attach a copy of
the main body of this Agreement to that report.
6.11 Tag-Along Rights. Luxco hereby agrees that, from and after the
Closing and until the earlier to occur of (a) the date that is 18 months after
the Closing Date and (b) such date as neither Luxco nor any group (within the
meaning of Section 13(d)(3) of the Securities Exchange Act) of beneficial owners
of Luxco as of the date hereof (collectively, the "Luxco Group") together own at
least 50% of the issued and outstanding shares of Common Stock, in the event
that the Luxco Group proposes to consummate a Tag-Along Sale (as defined below),
it shall not consummate such Tag-Along Sale unless, in connection therewith,
Luxco causes the proposed acquirors in such Tag-Along Sale to make, as soon as
practicable after the closing of the Tag-Along Sale, an offer to purchase from
each other stockholder of ▇▇▇▇▇▇ (by merger, tender offer or otherwise) an
Equivalent Percentage (as defined below) of the shares of Common
- 36 -
Stock held by such other stockholder, on terms no less favorable than those
received by the Luxco Group in the Tag-Along Sale. "Tag-Along Sale" shall mean a
sale by the Luxco Group of Common Stock acquired pursuant to this Agreement, in
a privately negotiated transaction (other than to or among the Luxco Group) to
any Person or group of related Persons in any transaction or series of related
transactions in which (a) a number of shares of Common Stock exceeding 50% of
the issued and outstanding Common Stock would be sold by the Luxco Group to such
Person or group of related Persons and (b) the sale price per share of Common
Stock received by the Luxco Group exceeds the average closing trading price of
the Common Stock for the ten consecutive days prior to the date of announcement
of the proposed Tag-Along Sale. "Equivalent Percentage" shall mean the
percentage of the number of shares of Common Stock sold by the Luxco Group in
the Tag-Along Sale bears to their total holdings of Common Stock immediately
prior to such sale. For the avoidance of doubt, notwithstanding anything herein
to the contrary, this Section 6.11 shall terminate and be of no further force
and effect upon the first to occur of (a) the date that is 18 months after the
Closing Date and (b) the date on which the Luxco Group own less than 50% of the
issued and outstanding shares of Common Stock.
6.12 Independent Directors. Luxco hereby agrees that, from and after
the Closing and until such date as neither Luxco nor the Luxco Group together
own at least 50% of the issued and outstanding shares of Common Stock, at each
annual or special meeting of the stockholders of ▇▇▇▇▇▇ at which action is to be
taken with respect to the election of directors of ▇▇▇▇▇▇, Luxco shall vote all
of the ▇▇▇▇▇▇ Shares acquired pursuant to this Agreement then owned by it in
favor of the election of individuals to the ▇▇▇▇▇▇ Board in order that at least
three Independent Directors will serve on the ▇▇▇▇▇▇ Board at any point in time
and shall use its reasonable best efforts to cause, to the extent within its
reasonable control, such nominations to the ▇▇▇▇▇▇ Board as may be required in
order to effectuate the foregoing. For the purposes of this Section 6.12,
"Independent Director" shall mean any individual who does not own, directly or
indirectly, an equity interest in Luxco or any of its Affiliates (other than
▇▇▇▇▇▇ or any Subsidiary thereof) and is not an officer, director or employee of
Luxco or any of its Affiliates (other than ▇▇▇▇▇▇ or any Subsidiary thereof),
including, without limitation, any officer, employee or consultant of ▇▇▇▇▇▇ or
its Subsidiaries that does not own any equity interest in Luxco.
6.13 Tax-Free Exchange. For United States of America federal income
tax purposes, the Exchange Transactions are intended to be treated as the
exchange of the stock of Blitz F04-506 GmbH, to be renamed Sirona Dental
Services GmbH, and Sirona Dental Systems Ltd. solely for ▇▇▇▇▇▇ voting stock,
qualifying as "B" reorganizations within the meaning of Code Section
368(a)(1)(B). For the Grand Duchy of Luxembourg tax purposes, the Exchange
Transactions are intended to be treated as an exchange of the stock of Sirona
for ▇▇▇▇▇▇ voting stock, qualifying as tax-free under article 22 bis of the
Corporate Income Tax. The Parties agree to report the Exchange Transactions
consistent with such intended tax treatment. None of the Parties will take or
cause to be taken any action which would prevent the Exchange Transactions from
qualifying for such intended tax treatment. In furtherance and not in limitation
of the foregoing, if the Closing occurs, except with the prior written consent
of Luxco, neither ▇▇▇▇▇▇ nor Sirona shall, for a period of two years following
the Closing Date, cause or permit Sirona, Blitz F04-506 GmbH, to be renamed
Sirona Dental Services GmbH, or Sirona Dental Systems Ltd. to liquidate,
dissolve, or merge with another entity.
- 37 -
6.14 Further Assurances. At and after the Closing, each Party shall
execute and deliver such further instruments of conveyance and transfer and take
such additional action as any other Party may reasonably request to effect,
consummate, confirm, or evidence the consummation of the transactions
contemplated hereby or to carry out the purposes of this Agreement.
ARTICLE 7
CONDITIONS PRECEDENT
7.1 Conditions to Each Party's Obligation to Effect the Exchange
Transactions. The respective obligations of Luxco, Sirona and ▇▇▇▇▇▇ to effect
the transactions contemplated by this Agreement are subject to the satisfaction
or waiver on or prior to the Closing Date of the following conditions:
(a) Stockholder Approval. ▇▇▇▇▇▇ shall have obtained the
Requisite Stockholder Approval;
(b) No Injunctions or Restraints, Illegality. No temporary
restraining order, preliminary or permanent injunction or other order issued by
a court or other Governmental Entity of competent jurisdiction shall be in
effect and have the effect of making the Exchange Transactions illegal or
otherwise prohibiting consummation of the Exchange Transactions;
(c) Prohibitions to Transactions. There shall not have been
any action or proceeding brought or threatened in writing by a Governmental
Entity of competent jurisdiction or a statute, rule, regulation, executive order
or other action promulgated, enacted, taken or threatened by a Governmental
Entity of competent jurisdiction which would have the effect of (i) restraining
or prohibiting the making or consummation of the Exchange Transactions and the
other transactions contemplated by this Agreement, (ii) prohibiting or
restricting the ownership or operation by Luxco or ▇▇▇▇▇▇ (or any of their
respective Affiliates or Subsidiaries) of any portion of ▇▇▇▇▇▇'▇ or Sirona's
business or assets, or compelling Luxco or ▇▇▇▇▇▇ (or any of their respective
Affiliates or Subsidiaries) to dispose of or hold separate any portion of
▇▇▇▇▇▇'▇ or Sirona's business or assets, (iii) imposing material limitations on
the ability of Luxco or ▇▇▇▇▇▇ (or any of their respective Affiliates or
Subsidiaries) effectively to acquire or to hold or to exercise full rights of
ownership of the ▇▇▇▇▇▇ Shares or the Sirona Shares, as the case may be,
including, without limitation, in the case of Luxco, the right to vote on all
matters properly presented to the stockholders of ▇▇▇▇▇▇, (iv) imposing any
material limitations on the ability of Luxco or ▇▇▇▇▇▇ (or any of their
respective Affiliates or Subsidiaries) effectively to control in any material
respect the business and operations of ▇▇▇▇▇▇ or Sirona, as the case may be, or
(v) obtaining material damages from Luxco or ▇▇▇▇▇▇ or any of their respective
Affiliates in connection with the making or consummation of the Exchange
Transactions and there shall not be in effect any injunction, order, decree,
judgment or ruling issued by a court of competent jurisdiction having any effect
set forth in clauses (i) through (v) above; and
(d) Consents. Any waiting period (and any extension thereof)
applicable to the consummation of the exchange transactions under the
▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act shall have
- 38 -
expired or been terminated and any consents by a non-U.S. Governmental Entity
that are material and are required to be obtained under anti-competition laws
shall have been obtained.
7.2 Conditions to the Obligations of Luxco and Sirona to Effect the
Exchange Transactions. The respective obligations of Luxco and Sirona to effect
the transactions contemplated by this Agreement are subject to the satisfaction
or waiver on or prior to the Closing Date of the following conditions:
(a) Representations and Warranties. The representations and
warranties of ▇▇▇▇▇▇ set forth in Article 2 of this Agreement (without giving
effect to any Schedule Updates) shall be true and correct (i) as to any
representation or warranty which addresses matters as of a particular date, as
of the date referred to therein and (ii) as to all other representations and
warranties, as of the date of this Agreement and as of the Closing Date as if
made on the Closing Date, unless the inaccuracies under such representations and
warranties, do not, individually or in the aggregate, result in or constitute a
Material Adverse Effect with respect to ▇▇▇▇▇▇; provided that for purposes of
determining whether any representation or warranty is not true and correct under
this condition, all references to materiality and Material Adverse Effect shall
be ignored;
(b) Performance. ▇▇▇▇▇▇ shall have performed all obligations
and complied in all material respects with all agreements or covenants to be
performed or complied with by it under this Agreement;
(c) No Material Adverse Change. There shall not have occurred
and be continuing any Material Adverse Change with respect to ▇▇▇▇▇▇ since the
date hereof;
(d) Certificate Amendment. ▇▇▇▇▇▇ shall have filed the
Certificate Amendment with the Secretary of State of the State of Delaware in
accordance with the DGCL and the Certificate Amendment shall have become
effective;
(e) Board Resignations and Appointments. Except as otherwise
specified in writing by Luxco to ▇▇▇▇▇▇ prior to the Closing Date, (A) all of
the directors on the ▇▇▇▇▇▇ Board other than ▇▇▇▇▇▇▇ ▇. ▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
and ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ shall have resigned and such resignations shall be
effective no later than the Closing Date and the resulting vacancies shall not
have been filled except to the extent required by this Section 7.2(e), (B) the
▇▇▇▇▇▇ Board shall have authorized a change in the number of directors
constituting the entire ▇▇▇▇▇▇ Board to be ten directors, and (C) the ▇▇▇▇▇▇
Board shall have elected, effective as of the day following the Closing Date, to
be Class A Directors, Class B Directors or Class C Directors, such classes to be
designated in writing (consistent with the classes available to the positions to
be vacant) by Luxco to ▇▇▇▇▇▇ at least 10 days prior to the filing of the Proxy
Statement and otherwise in accordance with the ▇▇▇▇▇▇ Charter Documents, ▇▇▇▇▇▇▇
▇. ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
▇▇▇▇▇▇▇, Jr., ▇▇▇▇ ▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇▇▇▇ or such other persons as designated
by Luxco prior to the Closing to fill the foregoing vacancies and to serve as
directors of ▇▇▇▇▇▇ until the earlier of their death, resignation or removal;
- 39 -
(f) Third Party Consents and Approvals. Luxco shall have
received, in form and substance reasonably satisfactory to it, each of the third
party consents and approvals set forth on Schedule 7.2(f);
(g) Registration Agreement. ▇▇▇▇▇▇ shall have executed and
delivered to Luxco the Registration Agreement, in substantially the form of
Exhibit D hereto (the "Registration Agreement"), and the Registration Agreement
shall be in full force and effect as of the Closing; and
(h) Other Deliveries. On or before the Closing, ▇▇▇▇▇▇ shall
have delivered to Luxco all of the following:
(i) the original stock certificate(s) evidencing the
▇▇▇▇▇▇ Shares;
(ii) the Transfer Deed and Note Assignment executed by
▇▇▇▇▇▇;
(iii) a certificate from an officer of ▇▇▇▇▇▇ in a form
reasonably satisfactory to Luxco, dated the Closing Date, stating that the
preconditions specified in Sections 7.2(a) through (e) have been
satisfied;
(iv) a copy of the resolutions of the ▇▇▇▇▇▇ Board and
the stockholders of ▇▇▇▇▇▇ approving the transactions contemplated by this
Agreement, certified by an officer of ▇▇▇▇▇▇;
(v) the notice to the notary for the Transfer Deed
contemplated by the Transfer Deed executed by ▇▇▇▇▇▇; and
(vi) certificates from appropriate authorities, dated as
of or about the Closing Date, as to the good standing and qualification to
do business of ▇▇▇▇▇▇ in each jurisdiction where it is so qualified.
7.3 Conditions to the Obligations of ▇▇▇▇▇▇ to Effect the Exchange
Transactions. The obligations of ▇▇▇▇▇▇ to effect the transactions
contemplated by this Agreement are subject to the satisfaction or waiver
on or prior to the Closing Date of the following conditions:
(a) Representations and Warranties. The representations and
warranties of Sirona and Luxco set forth in Articles 3 and 4, respectively, of
this Agreement (without giving effect to any Schedule Updates) shall be true and
correct (i) as to any representation or warranty which addresses matters as of a
particular date, as of the date referred to therein and (ii) as to all other
representations and warranties, as of the date of this Agreement and as of the
Closing Date as if made on the Closing Date, unless the inaccuracies under such
representations and warranties, do not, individually or in the aggregate, result
in a Material Adverse Effect with respect to Luxco or Sirona; provided that for
purposes of determining whether any representation or warranty is not true and
correct under this condition, all references to materiality and Material Adverse
Effect shall be ignored;
- 40 -
(b) Performance. Luxco and Sirona shall have performed all
obligations and complied in all material respects with all agreements or
covenants to be performed or complied with by them under this Agreement;
(c) No Material Adverse Change. There shall not have occurred
and be continuing any Material Adverse Change with respect to Luxco or Sirona,
since the date hereof;
(d) Third Party Consents and Approvals. ▇▇▇▇▇▇ shall have
received, in form and substance reasonably satisfactory to it, each of the third
party consents and approvals set forth on Schedule 7.3(d); and
(e) Other Deliveries. On or before the Closing, Luxco shall
have delivered to ▇▇▇▇▇▇ all of the following:
(i) the Sirona Note;
(ii) the Transfer Deed executed by Luxco;
(iii) the Note Assignment executed by Luxco and Sirona;
(iv) a certificate from officers of Luxco or Sirona, as
applicable, in a form reasonably satisfactory to ▇▇▇▇▇▇, dated the Closing
Date, stating that the preconditions specified in Sections 7.3(a) through
(c) have been satisfied;
(v) a copy of the resolutions of the Luxco Board
approving the transactions contemplated by this Agreement, certified by an
officer of Luxco; and
(vi) the notice to the notary for the Transfer Deed
contemplated by the Transfer Deed executed by Luxco.
ARTICLE 8
TERMINATION AND AMENDMENT
8.1 Termination by Either ▇▇▇▇▇▇ or Luxco. This Agreement may be
terminated at any time prior to the Closing Date as follows:
(a) by the mutual written consent of Luxco and ▇▇▇▇▇▇ duly
authorized, by the Luxco Board and the ▇▇▇▇▇▇ Board;
(b) by either ▇▇▇▇▇▇ or Luxco, if any Governmental Entity
shall have issued an order, decree or ruling or taken any other action
permanently restraining, enjoining or otherwise prohibiting the transactions
contemplated by this Agreement, and such order, decree, ruling or other action
shall have become final and nonappealable; provided, however, that the
provisions of this Section 8.1(b) shall not be available to any Party whose
failure to fulfill its obligations in any material respect under this Agreement
shall have been the cause of, or shall have resulted in, such order, decree,
ruling or other action;
- 41 -
(c) by either ▇▇▇▇▇▇ or Luxco, on written notice to the other,
if the Closing has not occurred on or before May 31, 2006 (the "Termination
Date"); provided, however, that the provisions of this Section 8.1(c) shall not
be available to any Party whose failure to fulfill any of its obligations in any
material respect under this Agreement has been the cause of, or resulted in, the
failure of the Closing to occur on or before the Termination Date; or
(d) by either ▇▇▇▇▇▇ or Luxco, on written notice to the other,
if the required adoption of this Agreement by the ▇▇▇▇▇▇ stockholders as
contemplated by this Agreement shall not have been obtained by reason of the
failure to obtain the required vote at the ▇▇▇▇▇▇ Stockholders Meeting duly
convened therefore or at any adjournment thereof; provided, however that the
right to terminate this Agreement under this Section 8.1(d) shall not be
available to any Party where the failure to obtain the Requisite Stockholder
Approval shall have arisen from the action or failure to act of such Party and
such action or failure to act constitutes a material breach by such Party of
this Agreement.
8.2 Termination by Luxco. This Agreement may also be terminated by
Luxco at any time prior to the Closing Date on written notice to ▇▇▇▇▇▇ upon a
material breach of any covenant or agreement on the part of ▇▇▇▇▇▇ set forth in
this Agreement, or if (i) any representation or warranty of ▇▇▇▇▇▇ set forth
herein that is qualified as to materiality shall have become untrue or (ii) any
such representation or warranty of ▇▇▇▇▇▇ that is not so qualified shall have
become untrue in any material respect, unless in the case of the foregoing
clauses (i) and (ii), the inaccuracies in such representations and warranties do
not, individually or in the aggregate, result in a Material Adverse Effect with
respect to ▇▇▇▇▇▇ (a "Terminating ▇▇▇▇▇▇ Breach"); provided, however, that, if
such Terminating ▇▇▇▇▇▇ Breach is reasonably capable of being cured by ▇▇▇▇▇▇ no
later than thirty (30) calendar days after Luxco has furnished ▇▇▇▇▇▇ with
written notice of such Terminating ▇▇▇▇▇▇ Breach through the exercise of
reasonable best efforts to cure such breach, so long as ▇▇▇▇▇▇ continues to
exercise such reasonable best efforts, Luxco may not terminate this Agreement
under this Section 8.2 prior to the expiration of such thirty-day period (it
being understood that Luxco may not terminate this Agreement pursuant to this
Section 8.2 if it shall have materially breached this Agreement or if such
breach by ▇▇▇▇▇▇ is cured within such thirty-day period).
8.3 Termination by ▇▇▇▇▇▇. This Agreement may also be terminated by
▇▇▇▇▇▇ at any time prior to the Closing Date on written notice to Luxco:
(a) upon a material breach of any covenant or agreement on the
part of Luxco or Sirona set forth in this Agreement, or if (i) any
representation or warranty of Luxco or Sirona set forth herein that is qualified
as to materiality shall have become untrue or (ii) any such representation or
warranty of Luxco or Sirona that is not so qualified shall have become untrue in
any material respect, unless in the case of the foregoing clauses (i) and (ii),
the inaccuracies in such representations and warranties do not individually or
in the aggregate, result in a Material Adverse Effect with respect to Luxco or
Sirona (a "Terminating Luxco Breach"); provided, however, that, if such
Terminating Luxco Breach is reasonably capable of being cured by Luxco or
Sirona, as the case may be, no later than thirty (30) calendar days after ▇▇▇▇▇▇
has furnished Luxco with written notice of such Terminating Luxco Breach,
through the exercise of reasonable best efforts to cure such breach, so long as
Luxco or Sirona, as the case may be, continues to exercise such reasonable best
efforts, ▇▇▇▇▇▇ may not terminate this Agreement under this
- 42 -
Section 8.3(a) prior to the expiration of such thirty-day period (it being
understood that ▇▇▇▇▇▇ may not terminate this Agreement pursuant to this Section
8.3(a) if it shall have materially breached this Agreement or if such breach by
Luxco is cured within such thirty-day period);
(b) on written notice to Luxco in connection with a Company
Adverse Recommendation Change in the manner set forth in Section 6.4(c);
provided, however, that (A) ▇▇▇▇▇▇ shall have complied with the terms of Section
6.4 in all material respects and (B) this Agreement may not be terminated
pursuant to this Section 8.3(b) unless concurrently with such termination,
▇▇▇▇▇▇ pays to Luxco the Termination Fee (as hereinafter defined) less any
Expense Payment (as hereinafter defined) previously paid; or
(c) if ▇▇▇▇▇▇ shall not have received from Sirona the Sirona
Audited U.S. GAAP Financials by February 15, 2006; provided that ▇▇▇▇▇▇ may not
exercise its termination right pursuant to this Section 8.3(c), if any, unless
such right is exercised on or before February 28, 2006.
8.4 Effect of Termination.
(a) In the event of termination of this Agreement by either
▇▇▇▇▇▇ or Luxco as provided in this Article 8, this Agreement shall forthwith
become void and there shall be no liability or obligation on the part of Luxco,
Sirona or ▇▇▇▇▇▇ or their respective officers, directors, partners,
stockholders, Affiliates, representatives, agents, employees or advisors;
provided, however, that (i) with respect to Luxco, Sirona and ▇▇▇▇▇▇, Section
6.5, this Section 8.4, and Articles 9 and 10, shall remain in full force and
effect and survive any termination of this Agreement and (ii) nothing herein
shall relieve any party from liability for the intentional breech of any of its
representations or warranties or covenants or agreements set forth in this
Agreement.
(b) ▇▇▇▇▇▇ shall (provided that neither Luxco nor Sirona is
then in material breach of its obligations under this Agreement) upon the
termination of this Agreement pursuant to Section 8.1(d), promptly, but in no
event later than two Business Days following such termination, reimburse Luxco
and Sirona their Expenses in cash in an amount not to exceed $1.5 million (the
"Expense Payment").
(c) In the event that this Agreement is terminated pursuant to
Section 8.3(b), ▇▇▇▇▇▇ shall pay to Luxco, by wire transfer of immediately
available funds to an account designated by Luxco concurrently with the
effectiveness of such termination, an amount equal to $13.5 million (the
"Termination Fee"), less any Expense Payment previously paid.
(d) If all of the following events have occurred:
(i) (A) a Competing Proposal with respect to ▇▇▇▇▇▇ or
its Subsidiaries is publicly disclosed or publicly proposed to ▇▇▇▇▇▇ or
its stockholders at any time on or after the date of this Agreement but
prior to any termination of this Agreement and (B) this Agreement is
terminated pursuant to Section 8.1(c), 8.1(d) or 8.2; and
- 43 -
(ii) thereafter, within 12 months of the date of such
termination, ▇▇▇▇▇▇ or its Subsidiaries enters into a definitive agreement
with respect to, or consummates, such Competing Proposal referred to in
the foregoing clause (i); then, ▇▇▇▇▇▇ shall pay to Luxco, concurrently
with the earlier of the execution of such definitive agreement or the
consummation of such Competing Proposal, an amount equal to the
Termination Fee (less any Expense Payment previously paid).
(e) ▇▇▇▇▇▇ acknowledges that the agreements contained in
Sections 8.4(b), (c) and (d) are an integral part of the transactions
contemplated by this Agreement, and that, without these agreements, Luxco and
Sirona would not enter into this Agreement.
8.5 Amendment. This Agreement may be amended by the Parties, by
action taken or authorized by the ▇▇▇▇▇▇ Board and the Luxco Board, at any time
before or after adoption of this Agreement by ▇▇▇▇▇▇'▇ stockholders. This
Agreement may not be amended except by an instrument in writing signed on behalf
of each of the Parties.
8.6 Extension; Waiver. At any time prior to the Closing Date, the
Parties, by action taken or authorized by their respective boards of directors
(or equivalent governing body), may, to the extent legally allowed, (i) extend
the time for the performance of any of the obligations or other acts of the
other Parties, (ii) waive any inaccuracies in the representations and warranties
contained herein or in any document delivered pursuant hereto and (iii) waive
compliance with any of the agreements or conditions contained herein. Any
agreement on the part of a Party to any such extension or waiver shall be valid
only if set forth in a written instrument signed on behalf of such Party. No
delay on the part of any Party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof, nor shall any waiver on the part of
any Party of any right, power or privilege hereunder operate as a waiver of any
other right, power or privilege hereunder, nor shall any single or partial
exercise of any right, power or privilege hereunder preclude any other or
further exercise thereof or the exercise of any other right, power or privilege
hereunder. Unless otherwise provided, the rights and remedies herein provided
are cumulative and are not exclusive of any rights or remedies which the parties
hereto may otherwise have at law or in equity. The failure of any Party to
assert any of its rights under this Agreement or otherwise shall not constitute
a waiver of those rights.
ARTICLE 9
DEFINITIONS; INTERPRETATION
9.1 Definitions. When used in this Agreement, the following terms
have the meanings set forth below:
"Affiliate" of any particular Person means any other Person
controlling, controlled by, or under common control with such particular Person,
where "control" means the possession, directly or indirectly, of the power to
direct the management and policies of a Person whether through the ownership of
voting securities, contract, or otherwise.
"Business Day" means any day (other than a Saturday or Sunday or
legal holiday) on which banks in ▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇,
▇▇▇▇▇▇ ▇▇▇▇▇▇ of America, Frankfurt, Federal Republic of Germany and London,
United Kingdom are open for business.
- 44 -
"Certificate Amendment" means the amendment to the Certificate of
Incorporation of ▇▇▇▇▇▇, in substantially the form of Exhibit E hereto.
"Class A Director" means a director whose term, pursuant to ▇▇▇▇▇▇'▇
certificate of incorporation, is scheduled to end in the second half of calendar
year 2006.
"Class B Director" means a director whose term, pursuant to ▇▇▇▇▇▇'▇
certificate of incorporation, is scheduled to end in the second half of calendar
year 2007.
"Class C Director" means a director whose term, pursuant to ▇▇▇▇▇▇'▇
certificate of incorporation, is scheduled to end in the second half of calendar
year 2008 or thereafter.
"Code" means the Internal Revenue Code of 1986, as amended, and the
rules and regulations promulgated thereunder.
"Contract" shall mean any written, oral or other agreement,
contract, subcontract, lease, binding understanding, instrument, note, bond,
indenture, option, warranty, purchase order, license, sublicense, insurance
policy, benefit plan or legally binding commitment or undertaking of any nature.
"DGCL" means the General Corporation Law of the State of Delaware,
as amended.
"director" means, with respect to a Person, a member of the board of
directors or equivalent governing body of such Person.
"Employee Plan" shall mean with reference to any Person any plan,
program, policy, practice, contract, agreement or other arrangement providing
for performance awards, stock or stock-related awards, fringe benefits, pension,
supplemental pension, retirement compensation, profit sharing, bonus or
incentive compensation, deferred compensation, medical benefits or other
employee benefits of any kind, whether written or unwritten or otherwise, funded
or unfunded, contributed to or required to be contributed by such party for the
benefit of any employee of such Person or with respect to which such Person has
or may have any liability or obligation, including all international benefit
plans of such Party; provided, however, that the definition of "Employee Plan"
shall not include any employment agreements.
"Environmental Law" means any federal, state, local or foreign law,
regulation, order, decree, permit, authorization, opinion, common law or agency
requirement relating to: (A) the protection, investigation or restoration of the
environment, health and safety, or natural resources, (B) the handling, use,
presence, disposal, release or threatened release of any Hazardous Substance or
(C) noise, odor, wetlands, pollution, or contamination.
"Exchange Party" shall mean each of ▇▇▇▇▇▇ and Luxco.
"German GAAP" means Federal Republic of Germany generally accepted
accounting principles as in effect from time to time, consistently applied.
- 45 -
"Governmental Entity" shall mean any supranational, national, state,
provincial, municipal, local or foreign government, any instrumentality,
subdivision, court, administrative agency or commission or other governmental
authority or instrumentality, or any quasi-governmental or private body
exercising any regulatory, taxing, importing or other governmental or
quasi-governmental authority.
"▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act" means the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Antitrust
Improvements Act of 1976, as amended, and the rules and regulations promulgated
thereunder.
"Hazardous Substance" means any substance that is: (A) listed,
classified, prohibited or regulated pursuant to any Environmental Law; (B) any
petroleum product or by-product, asbestos-containing material, lead-containing
paint or plumbing, polychlorinated biphenyls, radioactive materials or radon; or
(C) any other substance which is the subject of regulatory action by any
Governmental Entity pursuant to any Environmental Law.
"Indebtedness" of any Person means, without duplication: (a)
indebtedness for borrowed money or for the deferred purchase price of property
or services in respect of which such Person is liable, contingently or
otherwise, as obligor or otherwise (other than trade payables and other current
liabilities incurred in the ordinary course of business), and any commitment by
which such Person assures a creditor against loss, including contingent
reimbursement obligations with respect to letters of credit; (b) indebtedness
guaranteed in any manner by such Person, including a guarantee in the form of an
agreement to repurchase or reimburse; and (c) obligations under capitalized
leases in respect of which such Person is liable, contingently or otherwise, as
obligor, guarantor or otherwise, or in respect of which obligations such Person
assures a creditor against loss.
"Intellectual Property" means patents, trademarks, trade names,
service marks, copyrights, and any applications for such patents, trademarks,
trade names, service marks and copyrights, know-how, computer software programs
or applications and tangible or intangible proprietary information or material.
"Knowledge" means, with respect to a Party, the actual knowledge of
the officers and senior management of such Party and its Significant
Subsidiaries, as the case may be, including (i) in the case of ▇▇▇▇▇▇, ▇▇▇▇▇▇▇
▇. ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇ and ▇▇▇ ▇▇▇▇▇▇ and (ii) in the case of Luxco or Sirona,
▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ and ▇▇▇▇ ▇▇▇▇▇▇.
"Legal Requirements" means, with respect to a Person, all foreign
and United States federal, state and local laws, statutes, codes, rules,
regulations, ordinances, judgments, orders, decrees, injunctions, awards,
permits, licenses and the like of any Governmental Entity that are applicable to
such Person. Each reference in this Agreement to any Legal Requirement shall be
deemed to include such Legal Requirements as in effect as of the Closing Date or
at such other time on or before the Closing Date material to the provision of
this Agreement using the term "Legal Requirement."
"Lien" means any mortgage, pledge, lien, encumbrance, charge, or
other security interest of any kind or nature whatsoever.
- 46 -
"Luxco Board" means the board of Sirona Holdings S.A., a societe
anonyme organized under the laws of the Grand Duchy of Luxembourg, the general
partner of Luxco.
"Luxco Holders" means the holders of securities issued by Luxco.
"Material Adverse Effect" or "Material Adverse Change" means, with
respect to any Party hereto, any change, event, development, violation,
inaccuracy, circumstance or effect that has had or is reasonably likely to have
a material adverse effect on the business, assets (including intangible assets),
results of operations, or financial condition of such Party and its Subsidiaries
taken as a whole; provided, however, that any changes or effects (A) caused by
changes in general economic conditions, (B) that affect the industry in which
such Party and its Subsidiaries operate in general, except in any such case, to
the extent such effect on any such Party and its Subsidiaries is materially
disproportionate, (C) directly and primarily resulting from the announcement, or
proposed consummation of the transactions contemplated by, this Agreement, or
(D) resulting from compliance with the terms and conditions of this Agreement,
shall not be considered to be a Material Adverse Effect or Material Adverse
Change.
"Permit" means all permits, licenses, certificates, variances,
exemptions, orders and approvals from Governmental Entities.
"Permitted Liens" means, with respect to a Party, (a) Liens arising
by operation of law and securing the payment of Taxes which are not yet due and
payable or for Taxes that the taxpayer is contesting in good faith through
appropriate proceedings; (b) with respect to any property leased by such Party
or its Subsidiaries as lessee, the interest of the lessor in such property; (c)
Liens on properties to secure claims for labor, material or supplies in respect
of obligations not yet overdue; (d) Liens of carriers, warehousemen, mechanics
and materialmen in respect of obligations not yet overdue; (e) purchase money
security interests on personal property incurred in connection with the
acquisition of such property, which security interests cover only the personal
property so acquired; and (f) liens securing rental payments under capital lease
arrangements; provided, however, that any Lien in favor of a Related Party shall
not constitute a Permitted Lien.
"Person" means an individual, a partnership, a limited partnership,
a limited liability partnership, a corporation, a limited liability company, an
association, a joint stock company, a trust, a joint venture, an unincorporated
organization, any other business entity, or a governmental entity (or any
department, agency, or political subdivision thereof).
"Proceeding" means any claim, suit, action, investigation,
indictment or information or proceeding by or before any Governmental Entity or
any arbitrator.
"Proxy Statement" means the definitive proxy materials relating to
the ▇▇▇▇▇▇ Stockholders Meeting.
"Related Party" means, with respect to a Person, any current or
former officer, director, Affiliate or holder or group of related holders of 5%
or more of the outstanding voting securities of such Person or such Person's
Significant Subsidiaries, or any spouse or descendant (whether natural or
adopted) of any such individual or any entity in which any of the foregoing
Persons owns a 5% or greater direct or indirect beneficial interest.
- 47 -
"Requisite Stockholder Approval" means the affirmative vote of the
holders of a majority of the issued and outstanding Common Stock in favor of the
Certificate Amendment, this Agreement and the Exchange Transactions.
"Restricted Securities" means (i) the ▇▇▇▇▇▇ Shares issued hereunder
and (ii) any securities issued with respect to the securities referred to in
clause (i) above by way of a stock dividend or stock split or in connection with
a combination of shares, recapitalization, merger, consolidation or other
reorganization. As to any particular Restricted Securities, such securities
shall cease to be Restricted Securities when they have (a) been effectively
registered under the Securities Act and disposed of in accordance with the
registration statement covering them, (b) become eligible for sale pursuant to
Rule144(k) (or any similar provision then in force) under the Securities Act or
(c) been otherwise transferred and new certificates for them not bearing the
Securities Act legend set forth in Section 6.9(d) have been delivered by ▇▇▇▇▇▇
in accordance with Section 6.9(b). Whenever any particular securities cease to
be Restricted Securities, the holder thereof shall be entitled to receive from
▇▇▇▇▇▇, without expense, new securities of like tenor not bearing a Securities
Act legend of the character set forth in Section 6.9(d).
"▇▇▇▇▇▇ Board" means the Board of Directors of ▇▇▇▇▇▇.
"▇▇▇▇▇▇ Option Plans" means ▇▇▇▇▇▇'▇ 1996 Stock Option Plan, as
amended, and ▇▇▇▇▇▇'▇ 1997 Option Plan for Non-Employee Directors, as amended,
in each case, as in effect on the date of this Agreement.
"▇▇▇▇▇▇ Options" means any and all of the options to purchase shares
of Common Stock under the ▇▇▇▇▇▇ Option Plans or duly adopted agreements of
▇▇▇▇▇▇ or resolutions of the ▇▇▇▇▇▇ Broad.
"▇▇▇▇▇▇ Warrants" means the warrants to purchase shares of Common
Stock listed on Schedule 2.2(b).
"SEC" means the United States Securities and Exchange Commission.
"Securities Act" means the Securities Act of 1933, as amended, and
the rules and regulations promulgated thereunder.
"Securities Exchange Act" means the Securities Exchange Act of 1934,
as amended, and the rules and regulations promulgated thereunder.
"Significant Subsidiary" means (i) with respect to Sirona, Sirona
Dental Systems GmbH, a corporation organized under the laws of the Federal
Republic of Germany, Sirona Immobilien GmbH, a corporation organized under the
laws of Germany, Sirona Dental Systems LLC, a Delaware limited liability company
and Blitz F04-506 GmbH, a corporation organized under the laws of the Federal
Republic of Germany and to be renamed Sirona Dental Services GmbH and (ii) with
respect to ▇▇▇▇▇▇, ▇▇▇▇▇▇ Technologies, Inc., a New York corporation.
"Sirona Board" means any of the Managing Directors of Sirona.
- 48 -
"Sirona GmbH" means Sirona Dental Systems Beteiligungs- und
Verwaltungsgesellschaft mbH, a limited liability company formerly organized
under the laws of the Federal Republic of Germany, which was merged with and
into Blitz F04-506 GmbH, a corporation organized under the laws of the Federal
Republic of Germany and to be renamed as Sirona Dental Services GmbH.
"Subsidiary" means, with respect to any Person, any corporation,
limited liability company, partnership, association, or business entity of which
(i) if a corporation, a majority of the total voting power of shares of stock
entitled (without regard to the occurrence of any contingency) to vote in the
election of directors, managers, or trustees thereof is at the time owned or
controlled, directly or indirectly, by that Person or one or more of the other
Subsidiaries of that Person or a combination thereof, or (ii) if a limited
liability company, partnership, association, or other business entity (other
than a corporation), a majority of the ownership interest of such organization
(other than a corporation) is at the time owned or controlled, directly or
indirectly, by that Person or one or more Subsidiaries of that Person or a
combination thereof and for this purpose, a Person or Persons owns a majority
ownership interest in such organization (other than a corporation) if such
Person or Persons shall be allocated a majority of such organization's gains or
losses or shall be or control any managing director or general partner of such
organization (other than a corporation). The term "Subsidiary" shall include all
Subsidiaries of such Subsidiary.
"Tax" or, collectively, "Taxes," shall mean any and all federal,
state, local and foreign taxes, assessments and other governmental charges,
duties, impositions and liabilities, including taxes based upon or measured by
gross receipts, income, profits, sales, use and occupation, and value added, ad
valorem, transfer, franchise, withholding, payroll, recapture, employment,
excise and property taxes, together with all interest, penalties and additions
imposed with respect to such amounts, and any obligations with respect to such
amounts arising as a result of being a member of an Affiliated, consolidated,
combined or unitary group for any period or under any agreements or arrangements
with any other person and including any liability for taxes of a predecessor
entity.
"Transaction Dividend" means the cash dividend by ▇▇▇▇▇▇ to its
stockholders, declared after the date hereof and prior to the Closing and
payable prior to or after the Closing, in an amount not to exceed $2.50 per
share of Common Stock. "Transaction Documents" means this Agreement, the Voting
Agreements, the Registration Agreement, the Transfer Deed and the Note
Assignment.
"U.S. GAAP" means United States of America generally accepted
accounting principles as in effect from time to time, consistently applied.
"Voting Debt" means, with respect to a Person, any bonds,
debentures, notes or other indebtedness of such Person having, or convertible
into other securities having, the right to vote on any matters on which
stockholders of such Person may vote.
9.2 Cross References. The following terms are defined in the
following Sections of this Agreement:
- 49 -
Term Section
---- -------
Agreement Preamble
Audited Financials 3.4(a)
Closing 1.3
Closing Date 1.3
Common Stock Preamble
Company Adverse Recommendation Change 6.4(c)
Company Recommendation 6.1(a)
Competing Transaction 6.4(e)
Competing Transaction Proposal 6.4(a)
Competitively Sensitive Information 5.3
Confidentiality Agreement 6.2
Equivalent Percentage 6.11
Exchange Transactions 1.2
Expenses 6.5
Expense Payment 8.4(b)
Independent Directors 6.12
Luxco Preamble
Luxco Capital Stock 4.3(a)
Luxco Charter Documents 4.1
Luxco Group 6.11
Note Assignment 1.2
Party; Parties Preamble
Public Reports 2.17
Registration Agreement 7.2(g)
Required Approvals 6.3
Schedule Update 5.3
▇▇▇▇▇▇ Preamble
▇▇▇▇▇▇ Capital Stock 2.2(a)
▇▇▇▇▇▇ Charter Documents 2.1(b)
▇▇▇▇▇▇ Financials 2.4(a)
▇▇▇▇▇▇ Insurance Policies 2.13
▇▇▇▇▇▇ Leases 2.12(a)
▇▇▇▇▇▇ Material Contract 2.10(a)
▇▇▇▇▇▇ Permits 2.8(b)
▇▇▇▇▇▇ Real Estate 2.12(a)
▇▇▇▇▇▇ Shares 1.1
▇▇▇▇▇▇ Stockholders Meeting 6.1(a)
▇▇▇▇▇▇ Subsidiary Charter Documents 2.1(b)
Sirona Preamble
Sirona Audited U.S. GAAP Financials 6.1(b)
Sirona Capital Stock 3.2(a)
Sirona Charter Documents 3.1(b)
Sirona Financials 3.4(a)
Sirona Insurance Policies 3.13
- 50 -
Sirona Leases 3.12(a)
Sirona Material Contract 3.10(a)
Sirona Note Preamble
Sirona Permits 3.8(b)
Sirona Real Estate 3.12(a)
Sirona Shares Preamble
Sirona Subsidiary Charter Documents 3.1(b)
Superior Proposal 6.4(a)
Tag-Along Sale 6.11
Termination Date 8.1(c)
Termination Fee 8.4(c)
Terminating Luxco Breach 8.3(a)
Terminating ▇▇▇▇▇▇ Breach 8.2
Transfer Deed 1.2
Unaudited Financials 3.4(a)
Voting Agreements Preamble
9.3 Interpretation. When a reference is made in this Agreement to
Sections, Exhibits or Schedules, such reference shall be to a Section of or
Exhibit or Schedule to this Agreement unless otherwise indicated. The table of
contents, cross references and headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. Whenever the words "include," "includes" or
"including" are used in this Agreement, they shall be deemed to be followed by
the words "without limitation." Whenever the words "ordinary course of business"
are used in this Agreement, "ordinary course of business" shall be deemed to be
followed by the words "consistent with past practice." Unless otherwise
specified, all references to "$" in this Agreement refer to United States
dollars and all references to "(euro)" in this Agreement refer to Euros. The
Parties have participated jointly in the negotiation and drafting of this
Agreement. In the event an ambiguity or question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the parties
and no presumption or burden or proof shall arise favoring or disfavoring any
party by virtue of the authorship of any of the provisions of this Agreement.
Any reference to any federal, state, local or foreign statute or law shall be
deemed also to refer to all rules and regulations promulgated thereunder, unless
the content requires otherwise. It is understood and agreed that neither the
specifications of any dollar or Euro amount in this Agreement nor the inclusion
of any specific item in the Schedules or Exhibits is intended to imply that such
amounts or higher or lower amounts, or the items so included or other items, are
or are not material, and neither party shall use the fact of setting of such
amounts or the fact of the inclusion of such item in the Schedules or Exhibits
in any dispute or controversy between the parties as to whether any obligation,
item or matter is or is not material for purposes hereof.
ARTICLE 10
GENERAL PROVISIONS
10.1 Non-Survival of Representations, Warranties and Agreements; No
Other Representations and Warranties. None of the representations, warranties,
covenants and other agreements in this Agreement, including the Transfer Deed
and the Note Assignment,
- 51 -
or in any certificate or instrument delivered pursuant to this Agreement,
including any rights arising out of any breach of such representations,
warranties, covenants and other agreements, shall survive the Closing Date,
except for those covenants and agreements contained herein and therein that by
their terms apply or are to be performed in whole or in part after the Closing
Date and/or the provisions of this Article 10. Each party hereto agrees that,
except for the representations and warranties contained in this Agreement, none
of ▇▇▇▇▇▇, Luxco or Sirona or any of their respective Subsidiaries makes any
other representations or warranties, and each hereby disclaims any other
representations and warranties made by itself or any of its officers, directors,
employees, agents, financial and legal advisors or other representatives, with
respect to the execution and delivery of this Agreement, the documents and the
instruments referred to herein, or the transactions contemplated hereby or
thereby, notwithstanding the delivery or disclosure to the other party or the
other party's representatives of any documentation or other information with
respect to any one or more of the foregoing.
10.2 Notices. All notices and other communications hereunder shall
be in writing and shall be deemed duly given (a) on the date of delivery if
delivered personally, (b) on the first Business Day following the date of
dispatch if delivered by a nationally recognized next-day courier service, (c)
on the third Business Day following the date of mailing if delivered by
registered or certified mail, return receipt requested, postage prepaid or (d)
if sent by facsimile transmission, as the date of confirmation of receipt. All
notices hereunder shall be delivered as set forth below, or pursuant to such
other instructions as may be designated in writing by the party to receive such
notice:
if to Luxco or, prior to the Closing, Sirona:
Sirona Holdings Luxco S.C.A.
▇-▇▇, ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇
Facsimile: ▇▇▇▇ ▇▇▇-▇▇▇
and
Sirona Holdings Luxco S.C.A.
c/o Madison Dearborn Partners
Three First ▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
with copies to:
▇▇▇▇▇▇▇▇ & ▇▇▇▇▇ LLP
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. Perl, P.C.
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
- 52 -
and
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇, LLP
▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
if to ▇▇▇▇▇▇ or, after the Closing, Sirona:
▇▇▇▇▇▇ Technologies, Inc.
▇▇-▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
with a copy to:
▇▇▇▇▇▇ & Whitney LLP
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇ ▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
10.3 Counterparts. This Agreement may be executed in two or more
counterparts (including by means of telecopied signature pages), all of which
shall be considered one and the same agreement and shall become effective when
two or more counterparts have been signed by each of the parties and delivered
to the other parties, it being understood that all parties need not sign the
same counterpart.
10.4 Entire Agreement; No Third Party Beneficiaries; Liability.
(a) This Agreement (including the Schedules and Exhibits) and
the other Transaction Documents constitutes the entire agreement among the
Parties and supersedes all prior agreements and understandings, both written and
oral, among the parties and their respective Subsidiaries with respect to the
subject matter hereof, other than the Confidentiality Agreement, which shall
survive the execution and delivery of this Agreement.
(b) This Agreement shall be binding upon and inure solely to
the benefit of each Party and their permitted successors and assigns, and
nothing in this Agreement, express or implied, is intended to or shall confer
upon any other Person any right, benefit or remedy of any nature whatsoever
under or by reason of this Agreement.
(c) No Affiliate, officer, director or stockholder of any
Party shall have any liability hereunder.
- 53 -
10.5 Governing Law; Jurisdiction. This Agreement shall be governed
and construed in accordance with the laws of the State of Delaware, without
regard to the laws that might be applicable under conflicts of laws principles.
Each of ▇▇▇▇▇▇, Luxco and Sirona irrevocably agrees that any legal action or
proceeding with respect to this Agreement or for recognition and enforcement of
any judgment in respect hereof brought by the other party hereto or its
successors or assigns may be brought and determined in the Chancery or other
Courts of the State of Delaware, and each of ▇▇▇▇▇▇, Luxco and Sirona hereby
irrevocably submits with regard to any such action or proceeding for itself and
in respect to its property, generally and unconditionally, to the exclusive
jurisdiction of the aforesaid courts. Each of ▇▇▇▇▇▇, Luxco and Sirona hereby
irrevocably waives, and agrees not to assert, by way of motion, as a defense,
counterclaim or otherwise, in any action or proceeding with respect to this
Agreement, (a) any claim that it is not personally subject to the jurisdiction
of the above-named courts for any reason other than the failure to lawfully
serve process, (b) that it or its property is exempt or immune from jurisdiction
of any such court or from any legal process commenced in such courts (whether
through service of notice, attachment prior to judgment, attachment in aid of
execution of judgment, execution of judgment or otherwise), and (c) to the
fullest extent permitted by applicable law, that (i) the suit, action or
proceeding in any such court is brought in an inconvenient forum, (ii) the venue
of such suit, action or proceeding is improper and (iii) this Agreement, or the
subject matter hereof, may not be enforced in or by such courts.
10.6 Severability. If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any law or public policy,
all other terms and provisions of this Agreement shall nevertheless remain in
full force and effect so long as the economic or legal substance of the
transactions contemplated hereby is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision
is invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible in an acceptable manner in order
that the transactions contemplated hereby are consummated as originally
contemplated to the greatest extent possible. Any provision of this Agreement
held invalid or unenforceable only in part, degree or certain jurisdictions will
remain in full force and effect to the extent not held invalid or unenforceable.
To the extent permitted by applicable law, each party waives any provision of
law which renders any provision of this Agreement invalid, illegal or
unenforceable in any respect.
10.7 Succession and Assignment. Subject to the provisions of this
Section 10.7, this Agreement will be binding upon, inure to the benefit of and
be enforceable by the parties and their respective successors and assigns.
Neither this Agreement nor any of the rights, interests or obligations hereunder
shall be assigned by any of the Parties, in whole or in part (whether by
operation of law or otherwise), without the prior written consent of the other
Parties, and any attempt to make any such assignment without such consent shall
be null and void; provided, however, that (i) following the Closing, Luxco and
its permitted assigns may assign their respective rights and obligations
hereunder to any subsequent acquiror(s) of all or part of the ▇▇▇▇▇▇ Shares and
(ii) the rights and obligations of Luxco under this Agreement and the agreements
contemplated hereby may be assigned by Luxco at any time, in whole or in part,
to any investment fund managed by Madison Dearborn Partners LLC or MDP Global
Investors Limited or any of their respective successors; and provided, further,
that as a condition to any such assignment, such assignee shall execute and
deliver a counterpart signature page hereto
- 54 -
acknowledging its obligations hereunder as a party to this Agreement; and
provided, further, that such assignment shall not delay or adversely affect the
consummation of the Exchange Transactions. Whether or not any express assignment
has been made, the provisions of this Agreement which are for Luxco's benefit as
a purchaser or holder of ▇▇▇▇▇▇ Shares are also for the benefit of, and
enforceable by, any subsequent holder of such Common Stock.
10.8 Enforcement. The parties agree that irreparable damage would
occur in the event that any of the provisions of this Agreement were not
performed in accordance with their specific terms. It is accordingly agreed that
the parties shall be entitled to specific performance of the terms hereof, this
being in addition to any other remedy to which they are entitled at law or in
equity.
* * * * *
- 55 -
IN WITNESS WHEREOF, Luxco, Sirona and ▇▇▇▇▇▇ have caused this
Exchange Agreement to be signed by their respective officers thereunto duly
authorized, all as of date first written above.
SIRONA HOLDINGS LUXCO S.C.A., a societe en
commandite par actions, organized under the
laws of the Grand Duchy of Luxembourg
By: Sirona Holdings S.A.
Its: Manager
By: /S/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Its: A Director
By: /S/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Its: B Director
BLITZ 05-118 GMBH, a corporation organized
under the laws of the Federal Republic of
Germany
By: /S/ ▇▇▇▇ ▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇ ▇▇▇▇▇▇▇
Its: President and CEO
By: /S/ ▇▇▇▇▇▇ ▇▇▇▇▇
Name: ▇▇▇▇▇▇ ▇▇▇▇▇
Its: EVP and CFO
▇▇▇▇▇▇ TECHNOLOGIES, INC., a Delaware
corporation
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Its: Chief Executive Officer
Exhibit A
No. [o]/200[o] of the roll of deeds
Negotiated at [o] this [o] ([o]) of 200[o] (two thousand and [o])
Before me, the undersigned notary
[o]
notary in the district of the Higher Court of [o]
at [o], Germany, appeared today:
1. [o], German citizen, with business address at [o], identified by [o],
who declared that he was acting not in his own name, but solely in the name and
on behalf of
Sirona Holdings Luxco S.C.A., a partnership limited by shares (societe en
commandite par actions) organized under the laws of the Grand Duchy of
Luxembourg, registered with the with the trade and companies register of
the Grand Duchy of Luxembourg under B 109.399, with registered office at
▇-▇▇, ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇,
according to the attached power of attorney with notarial certification of
signature dated [o] 200[o],
2. [o], German citizen, with business address at [o], identified by [o],
who declared that he was acting not in his own name, but solely in the name and
on behalf of
▇▇▇▇▇▇ Technologies, Inc., a corporation organized under the laws of the
state of Delaware, USA, registered with the companies register under [o],
with registered office at ▇▇-▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇
▇▇▇▇▇, ▇▇▇,
according to the attached power of attorney with notarial certification of
signature dated [o] 2005.
1
The acting notary advised the persons appearing that a notary who or whose
partners in the law firm have formerly acted as legal advisors to one of the
parties involved in the matter to be notarized would not be entitled to take
office as a notary in the matter at hand pursuant to the so-called
"Vorbefassungsverbot" under the German Act of Notarization (ss. 3 Sect. 1(7)).
The acting notary states that he himself and his firm have not been involved in
the matter at hand in the meaning of said provisions. By approving the present
agreement, the Parties hereto shall confirm such statement of the acting notary.
The persons appearing requested this Deed including its Annexes to be recorded
in the English language. The acting notary who is in sufficient command of the
English language ascertained that the persons appearing are also in command of
the English language. After having been instructed by the acting notary, the
persons appearing waived the right to obtain the assistance of a sworn
interpreter and to obtain a certified translation of this Deed including the
Annexes hereto.
The persons appearing, acting as indicated, declared with request for notarial
recording the following:
SHARE TRANSFER AGREEMENT
between
1. Sirona Holdings Luxco S.C.A., a partnership limited by shares (societe en
commandite par actions) organized under the laws of the Grand Duchy of
Luxembourg, registered with the with the trade and companies register of
the Grand Duchy of Luxembourg under B 109.399, with registered office at
▇-▇▇, ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇,
- hereinafter referred to as the "Transferor" -,
and
2. ▇▇▇▇▇▇ Technologies, Inc., a corporation organized under the laws of the
state of Delaware, USA, registered with the companies register under [o],
with registered office at 30-00 47th Avenue, Long Island City, New York
11101, USA,
- hereinafter referred to as the "Transferee" -.
The Transferor and the Transferee are hereinafter also collectively referred to
as "Parties" and individually as a "Party".
PREAMBLE
(A) Whereas, the Transferor, being the only shareholder of ▇▇▇▇▇ ▇▇-▇▇▇ ▇▇▇▇,
a German corporation (Gesellschaft mit beschrankter Haftung) and to be
renamed Sirona Holding GmbH registered with the commercial register at the
local court (Amtsgericht) of Munich under HRB 157535 with a nominal share
capital of EUR 25,000 (the "Company"), holds two shares in the Company in
the nominal amount of EUR 24,750 and EUR 250 respectively (the "Shares");
(B) Whereas, the Parties have entered into an Exchange Agreement (as amended,
the "Exchange Agreement"), dated September __, 2005 (the "Exchange
Agreement Date") under which the Transferor is obliged to transfer the
Shares to the Transferee pursuant to the terms and conditions set forth
therein;
The Parties hereby agree as follows:
1
1. TRANSFER OF THE SHARES
Subject to the Receipt of the Closing Notice (as defined below in Clause
3) by the officiating notary, the Transferor transfers the Shares to the
Transferee with immediate effect. The Transferee accepts such transfer of
the Shares. The Shares are transferred to the Transferee with all rights
and obligations pertaining thereto, including all rights to undistributed
profits for previous business years and for the current business year.
2. NO REPRESENTATIONS OR WARRANTIES IN THIS AGREEMENT
The Transferor makes no representations or warranties, express or implied,
in this agreement to the Transferee regarding the Shares.
3. CLOSING NOTICE
The Parties will, upon satisfaction of the conditions precedents set out
in the Exchange Agreement, send by fax or registered mail a notice to the
officiating notary substantially in the form as attached as Annex 1 to
this agreement (the "Closing Notice"). The Closing Notice shall be deemed
to be received by the officiating notary (i) if sent by fax, if a sending
report with no error message has been printed on the fax machine of the
respective Party or (ii) if sent by registered mail, if a return receipt
has been received by the respective Party (each event being a "Receipt").
4. COSTS
All transfer taxes, fees, stamp duties and charges (including those
incurred with any merger control or other governmental approvals and
including notary fees) payable in connection with the execution and
implementation of this agreement shall be paid 50 % by the Transferor
and/or its subsidiaries and be paid 50 % by the Transferee and/or its
subsidiaries. Each Party shall pay its own costs and expenses, including
the fees of its advisers, incurred in connection with this agreement.
5. MISCELLANEOUS
(a) Any amendments, supplements to or a termination of this agreement
shall be made in writing unless notarial form is required. This
shall also apply to this Clause.
(b) No Party can assign any right or claim under this agreement to a
third party without the prior written consent of all other Parties.
(c) The headings in this agreement shall not affect the interpretation
thereof. English terms to which a German translation has been added
shall be interpreted
2
throughout this agreement in the meaning assigned to them by the
German translation.
(d) If not otherwise explicitly stated, this agreement shall be governed
by, and construed in accordance with, the laws of Germany, excluding
conflict of law rules and excluding the United Nations Convention on
Contracts for the International Sale of Goods of 11 April 1980.
(e) Should individual provisions of this agreement (or any agreements
made between the Parties in relation thereto) be or become invalid
or unenforceable in whole or in part, or should a gap in this
agreement (or any agreements made between the Parties in relation
thereto) become evident, this shall not affect the validity of the
remaining provisions. Instead of the invalid or unenforceable
provision, or in order to fill in the gap, such appropriate
regulation shall be deemed to be agreed which, to the extent legally
permissible, comes closest to what the Parties intended or would
have intended in view of the purpose of this agreement (and the
agreements made between the Parties in relation thereto) if they had
considered this point at the time of conclusion of this agreement.
This shall also apply if the invalidity or unenforceability is based
on the extent of performance or time stipulated. In such case, such
extent of performance or time as is legally permissible and comes as
close as possible to what had been intended shall replace the extent
stipulated.
* * *
The notary advised the Parties that, pursuant to sec. 16 of the German Limited
Liability Companies Act (Gesetz betreffend die Gesellschaften mit beschrankter
Haftung; GmbHG), in the event that a share is sold only the party whose
acquisition is notified to the company by providing evidence of the transfer of
the share will be deemed to be the buyer in relation to the company. The Parties
instructed and authorized the notary to notify the Company of the transfer of
the Shares after Receipt of the Closing Notice.
IN WITNESS THEREOF this Deed has been read aloud to the persons appeared. The
persons appeared then confirmed and approved this Deed and signed this Deed in
their own hands as set out below. The persons appearing declared that the
Company did not own any real estate. All this was done at the day here below
written in the presence of me, the notary, who also signed this Deed and affixed
my official seal.
3
Annex 1
From: Sirona Holdings Luxco S.C.A.
▇▇▇▇▇▇ Technologies, Inc.
To: [Notary]
Transfer Deed dated [o] 200[o] (your deed no. [o]/200[o])
Closing Notice
Dear Mr. [notary]
We hereby give you notice that the conditions precedent under the Exchange
Agreement have been satisfied.
We hereby instruct you and authorize you to notify the Company (as defined in
the abovementioned agreement) of the transfer of the Shares.
Yours sincerely,
----------------------------------
Sirona Holdings Luxco S.C.A.
Name:
Title:
----------------------------------
▇▇▇▇▇▇ Technologies, Inc.
Name:
Title:
4
Exhibit B
NOTE ASSIGNMENT INSTRUMENT AND CONSENT
THIS NOTE ASSIGNMENT INSTRUMENT AND CONSENT (this "Instrument"),
dated as of ________ __, 200_, is made by Sirona Holdings Luxco S.C.A., a
societe en commandite par actions, organized under the laws of the Grand Duchy
of Luxembourg ("Luxco") in favor of ▇▇▇▇▇▇ Technologies, Inc., a Delaware
corporation ("▇▇▇▇▇▇"). Each capitalized term used and not otherwise defined in
this Instrument has the meaning which the Exchange Agreement, dated as of
September __, 2005 (as in effect from time to time, the "Exchange Agreement") by
and among Luxco, ▇▇▇▇▇▇ and ▇▇▇▇▇ ▇▇-▇▇▇ ▇▇▇▇, a corporation organized under the
laws of the Federal Republic of Germany and to be renamed Sirona Holding GmbH
("Sirona") assigns to that term.
1. Pursuant to Section 1.2 of the Exchange Agreement, Luxco hereby
transfers to ▇▇▇▇▇▇ and its successors and assigns, and ▇▇▇▇▇▇ hereby accepts,
all of Luxco's right, title and interest in and to the Sirona Note, a copy of
which is attached hereto as Annex A.
2. To the extent any term or provision herein is inconsistent with
the Exchange Agreement, the terms and provisions of the Exchange Agreement shall
control.
3. The provisions of Article 10 of the Exchange Agreement shall
apply to this Instrument and are hereby incorporated herein by reference.
4. Except as expressly set forth in the Exchange Agreement, neither
Luxco nor any of its Affiliates or representatives makes any representations or
warranties, express or implied, regarding the Sirona Note and the transactions
contemplated hereby and Luxco hereby disclaims the same.
5. This Instrument may be executed in one or more counterparts, each
of which will be deemed an original but all of which taken together will
constitute one and the same instrument.
6. Sirona and Luxco hereby consent to the transfer of the Sirona
Note contemplated hereunder and waive any provision of the Sirona Note or any
other agreement to which they are a party that would restrict or prohibit the
transfer contemplated by this Instrument.
* * * * * *
IN WITNESS WHEREOF, the parties hereto have executed this Note
Assignment Instrument and Consent as of the date first above set forth.
SIRONA HOLDINGS LUXCO S.C.A., a societe en
commandite par actions, organized under the
laws of the Grand Duchy of Luxembourg
By:
----------------------------------------
Name:
Title:
▇▇▇▇▇▇ TECHNOLOGIES, INC., a Delaware
corporation
By:
Name:
Title:
For the purposes of paragraph 6 hereof only:
SIRONA HOLDING GMBH, (formerly known as Blitz 05-118 GmbH)
By:
-----------------------------
Name:
Title:
Annex A
PROMISSORY NOTE
(Euro)150,992,464 Issued: 30 June 2005
Due: 30 June 2015
FOR VALUE RECEIVED, ▇▇▇▇▇ ▇▇-▇▇▇ (▇▇▇▇ ("▇▇▇▇▇"), promises to pay to the
order of Sirona Holdings Luxco S.C.A., a societe en commandite par actions
organized under the laws of Grand Duchy of Luxembourg ("Payee"), in Euro in
immediately available funds, at such location as the Payee shall from time to
time designate, the principal sum of (Euro)150,992,464 (one-hundred fifty
million nine-hundred ninety-two thousand four-hundred sixty-four Euro), and
interest as set forth below.
From and after 15 July 2005, interest shall accrue on the outstanding
principal amount on a yearly basis at a rate equal to 7.5% per annum, compounded
annually on 30 June of each year (the "Annual Payment Date"), and shall become
due and payable on the Annual Payment Date, and if not so paid shall compound on
the Annual Payment Date.
The principal on this Note shall become due and payable ten (10) years
from the date of this Note (the "Final Payment Date"), unless prepaid in
accordance with the terms hereof.
Payor may prepay the outstanding principal amount of this Note together
with interest accrued at any time before the Final Payment Date without penalty
or premium.
Upon the commencement of any insolvency, reorganisation, arrangement,
adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or
similar proceeding of any jurisdiction relating to the Payor, the unpaid
principal amount hereof shall become immediately due and payable together with
any accrued but unpaid interest without presentment, demand, protest or notice
of any kind in connection with this Note.
This Note is not assignable.
All payments under this Note shall be made without offset, counterclaim or
deduction of any kind. Payee may at its sole discretion apply any payment on
this Note to accrued interest, principal, or reimbursable fees and expenses.
THIS NOTE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY ENGLISH
LAW.
Blitz 05-118 GmbH
By: /s/ [ILLEGIBLE]
--------------------------------
Name:
Exhibit C
[LOGO ▇▇▇▇▇▇]
CONTACT:
▇▇▇▇▇▇ Technologies
Media: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇/212-850-5600
▇▇▇ ▇▇▇▇▇▇▇▇/▇▇▇-▇▇▇-▇▇▇▇
Investors: ▇▇▇▇▇ ▇▇▇▇▇▇▇/212-245-4577
Sirona Dental Systems
Media: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇/011-49-221-9128-8719
▇▇▇▇▇▇ Technologies to Merge With Sirona Dental Systems
Transaction Valued At $1.9 Billion
o Merger creates a global leader in high-tech dental equipment,
with sales of approximately $500 million worldwide, including
over $180 million in North America
o Expands industry-leading global presence and product portfolio
and unites world-class R&D capabilities
▇ ▇▇▇▇▇▇ shareholders to receive $2.50 per share dividend
o Expected to be accretive to calendar 2006 cash EPS
NEW YORK/BENSHEIM, September 26, 2005 - ▇▇▇▇▇▇ Technologies, Inc. (OTC BB:
SCHK), an innovator in digital radiographic imaging systems and devices for the
dental industry, and Sirona Dental Systems, one of the world's leading
manufacturers of high-technology dental equipment, today announced that they
have entered into a definitive agreement to merge in a transaction valued at
$1.9 billion. The transaction will create a leading global player in dental
technology with strong product lines in all of the major dental segments. ▇▇▇▇▇▇
has a leading position in digital intra-oral imaging systems in North America,
while Sirona is a leading supplier of CEREC CAD/CAM restoration equipment,
panoramic and intra-oral imaging systems, treatment centers and instruments
worldwide.
1
[LOGO ▇▇▇▇▇▇]
Transaction Terms
The transaction is structured as a stock-for-stock tax-free exchange in which
▇▇▇▇▇▇ will issue Sirona's parent company 36.97 million new ▇▇▇▇▇▇ shares in
exchange for 100% of its economic interest in Sirona. Sirona's owners will have
an ownership interest in the combined company of 67%, with current ▇▇▇▇▇▇
shareholders holding the remainder. ▇▇▇▇▇▇ shareholders will also receive a
$2.50 per share cash dividend, which will be declared prior to closing. Based on
a September 23, 2005 ▇▇▇▇▇▇ closing market price of $25.10, the deal places the
total enterprise value of Sirona at $1.46 billion, including approximately $537
million in net debt. The merged company will be renamed Sirona Dental Systems,
Inc., with corporate headquarters located at Sirona's facilities in Bensheim,
Germany and U.S. headquarters at ▇▇▇▇▇▇'▇ facilities in New York. ▇▇▇▇▇▇ will
apply promptly for the listing of its common stock on the NASDAQ National
Market.
The merger has been unanimously approved by both companies' Boards of Directors
and is expected to close in the first calendar quarter of 2006. It is subject to
approval by ▇▇▇▇▇▇'▇ shareholders, clearance by appropriate regulatory agencies,
preparation of Sirona's financial statements in accordance with United States
GAAP and other customary closing conditions. Voting agreements in support of the
transaction have been signed by shareholders holding approximately 37% of
▇▇▇▇▇▇'▇ issued and outstanding common shares.
Sirona's Chief Executive Officer, ▇▇▇▇ ▇. ▇▇▇▇▇▇▇, will become Chairman,
President and Chief Executive Officer of the combined Sirona Dental Systems,
Inc. ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇▇'▇ President and Chief Executive Officer, will
become Executive Vice President of the combined company and Chief Operating
Officer of U.S. Operations. Sirona's Chief Financial Officer, ▇▇▇▇▇▇ ▇▇▇▇▇, will
become Executive Vice President and Chief Financial Officer of the combined
company. Sirona will hold seven seats on the combined company's board, with
▇▇▇▇▇▇ holding three seats.
Complementary Strengths, Synergies
The transaction will create a company with a strong global presence and breadth
of products based on complementary technologies, geographic coverage and channel
strengths. The combined company will have a broader product offering by virtue
of uniting ▇▇▇▇▇▇'▇ North American leadership in intra-oral digital radiography
with Sirona's four industry-leading product categories: dental CAD/CAM systems
(CEREC), imaging systems, treatment centers and instruments. Both companies'
brand awareness within the dental community and geographic fit will allow the
combined Sirona Dental Systems to capitalize on growth potential worldwide.
2
[LOGO ▇▇▇▇▇▇]
"This transaction represents a significant strategic growth opportunity for our
shareholders, partners and employees," said ▇▇▇▇▇▇ President and Chief Executive
Officer ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇. "We will create a company with a strong global
presence, an unrivaled breadth of products and excellence in R&D. Together with
Sirona, we command an extraordinary level of brand recognition around the world.
"We are excited about this merger and confident of the future growth of the
combined company. ▇▇▇▇▇▇ is a logical fit, complementing Sirona's strengths,
particularly in the United States," commented ▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Chairman,
President and Chief Executive Officer of Sirona. "Sirona and ▇▇▇▇▇▇ are two of
the true innovators in our sector, and our united R&D platform will benefit our
distribution partners, customers and patients."
The combined company will have 1,800 employees and, on a pro forma basis, for
the twelve months ended June 30, 2005, had revenue of approximately $500 million
worldwide, including over $180 million in North America. For the same period,
the combined company generated pro forma EBITDA of approximately $120 million
and operating cash flow in excess of $100 million. Following their combination,
the companies expect to achieve annual synergies of $5-7 million within 12-24
months after the close. The business combination is expected to be accretive to
▇▇▇▇▇▇'▇ calendar 2006 cash earnings per share.
Also commenting on the transaction was ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, Managing Director of
Madison Dearborn Partners, LLC and a director of Sirona: "We believe the
combination of these two strong companies will create significant shareholder
value and are excited to remain a major shareholder in Sirona Dental Systems."
Shareholder Approvals
The transaction will be presented for approval at a special meeting of ▇▇▇▇▇▇'▇
shareholders to be scheduled following the conversion of Sirona's financial
statements to U.S. GAAP. In connection with the shareholders meeting, ▇▇▇▇▇▇
will file proxy materials with the Securities and Exchange Commission. These
proxy materials will set forth additional details and other information
concerning the transaction, which investors should carefully read before making
a decision regarding the transaction.
3
[LOGO ▇▇▇▇▇▇]
Conference Call/Web cast Information
There will be an investor conference call conducted by both management teams to
discuss the transaction today at 11 a.m. EDT/8 a.m. PDT. Participants may dial
into the teleconference at ▇▇▇-▇▇▇-▇▇▇▇, pass code ▇▇▇▇▇▇▇▇. International
callers may access the teleconference at ▇▇-▇▇▇-▇▇▇-▇▇▇▇ with the same pass
code. A replay will be available until October 3, 2005 at 11:59 p.m. EDT at
▇▇▇-▇▇▇-▇▇▇▇, pass code ▇▇▇▇▇▇▇▇, and international callers may use
▇▇▇▇▇-▇▇▇-▇▇▇▇ with the same pass code. A live web cast of the conference call
will also be available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇.▇▇▇, with a replay available for those
unable to attend the live session.
UBS Investment Bank acted as exclusive financial advisor and ▇▇▇▇▇▇ & Whitney
LLP acted as legal advisor to ▇▇▇▇▇▇. ▇▇ ▇▇▇▇▇▇ acted as exclusive financial
advisor and ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇ LLP acted as legal advisor to Sirona.
About ▇▇▇▇▇▇
▇▇▇▇▇▇, an ISO 9001 certified company, designs, develops, and manufactures
innovative digital radiographic imaging systems and devices for the dental
market. ▇▇▇▇▇▇'▇ products, which are based on proprietary digital imaging
technologies, create instant high-resolution radiographs and offer significant
advantages over conventional x-ray devices. ▇▇▇▇▇▇'▇ headquarters are located in
Long Island City, New York. ▇▇▇▇▇▇'▇ sales were $57 million for the trailing 12
months through June 30, 2005, with earnings before interest, taxes, depreciation
and amortization of $22 million. Visit ▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇.▇▇▇ for more
information about ▇▇▇▇▇▇ and its products.
About Sirona
Recognized as one of the world's leading manufacturers of high quality dental
equipment and technologies, Sirona (formerly Siemens Dental) has served
equipment dealers and dentists worldwide for more than 125 years. Sirona
develops, manufactures, and markets a complete line of dental products,
including the CEREC CAD/CAM restoration equipment, digital and film-based
intra-oral, panoramic and cephalometric X-ray imaging systems, dental treatment
centers and handpieces. Sirona is committed to creating and supporting the most
advanced dental technologies in the marketplace. Sirona's worldwide headquarters
is located in Bensheim, Germany, with U.S. offices in Charlotte, North Carolina.
Sirona recorded sales of $441 million for the trailing 12 months to June 30,
2005, with earnings before interest, taxes, depreciation and amortization of $99
million. Sirona recently completed a management buyout with Madison Dearborn
Partners, LLC and Beecken ▇▇▇▇▇ ▇'▇▇▇▇▇ and Company, two leading Chicago-based
private equity firms. Visit ▇▇▇▇://▇▇▇.▇▇▇▇▇▇.▇▇▇ for more information about
Sirona and its products.
4
[LOGO ▇▇▇▇▇▇]
This press release may contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 (the "Act"). Words such as
"seek," "intend," "may," "believe," "will," "project," "plan," "estimate,"
"expect," "anticipate" and other similar statements of a forward-looking nature
identify forward-looking statements within the meaning of the Act. Some or all
of the results anticipated by these forward-looking statements may not occur and
are based on Sirona's and ▇▇▇▇▇▇'▇ current expectations and beliefs, and involve
a number of risks and uncertainties that could cause actual results to differ
materially from those stated or implied by the forward-looking statements. Those
risks and uncertainties include, but are not limited to: 1) the possibility that
the companies may be unable to obtain shareholder or regulatory approvals
required for the proposed transaction or that such approvals take longer to
obtain than expected; 2) difficulties in successfully integrating the businesses
and operations of the two companies; 3) unexpected costs in connection with the
proposed transaction; 4) the combined company may be unable to achieve
cost-saving synergies; 5) the businesses may suffer as a result of uncertainty
surrounding the proposed transaction; and 6) the industry may be subject to
future regulatory or legislative actions. In addition, the ability of Sirona and
▇▇▇▇▇▇ to achieve the projected revenues, accretion and synergy savings also
will be affected by the effects of competition (in particular the response to
the proposed transaction in the marketplace), the effects of general economic
and other factors beyond the control of Sirona and ▇▇▇▇▇▇, and other risks and
uncertainties described from time to time in ▇▇▇▇▇▇'▇ public filings with United
States Securities and Exchange Commission (the "SEC").
All Sirona financial statements are based on management accounts and German
GAAP, and have not been prepared in accordance with US GAAP. As a result,
Sirona's financial information may be materially different if Sirona's financial
statements were prepared in accordance with US GAAP. ▇▇▇▇▇▇ financial statements
have been prepared in accordance with US GAAP. All pro forma consolidated
financial information has been prepared by aggregating financial information
based on these different accounting standards and such financial information may
be materially different than the pro forma statements that would result from the
aggregation of financial statements in accordance with US GAAP. Further
information on ▇▇▇▇▇▇'▇ risk factors is contained in ▇▇▇▇▇▇'▇ Form 10-K and
other filings with the SEC. Sirona and ▇▇▇▇▇▇ assume no obligation and expressly
disclaim any duty to update information contained in this press release.
In connection with the proposed transaction, a registration statement including
a proxy statement will be filed with the SEC by ▇▇▇▇▇▇. Shareholders of ▇▇▇▇▇▇
are urged to read the Registration Statement/Proxy Statement and any other
relevant documents filed with the SEC because they will contain important
information about Sirona, ▇▇▇▇▇▇ and the proposed transaction. The final proxy
statement will be mailed to shareholders of ▇▇▇▇▇▇. Investors will be able to
obtain the documents free of charge at the SEC's website, ▇▇▇.▇▇▇.▇▇▇. In
addition, documents filed with the SEC by ▇▇▇▇▇▇ will be available free of
charge from ▇▇▇▇▇▇ Technologies, Inc., Attn: Legal Department, ▇▇-▇▇ ▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇▇▇, Tel: (▇▇▇) ▇▇▇-▇▇▇▇.
▇▇▇▇▇▇ Technologies, Inc. and its directors and executive officers and other
members of its management and employees, may be deemed to be participants in the
solicitation of proxies from
5
[LOGO ▇▇▇▇▇▇]
shareholders of ▇▇▇▇▇▇ in connection with the proposed transaction. Information
about the directors and executive officers of ▇▇▇▇▇▇ and their ownership of
▇▇▇▇▇▇ stock is set forth in ▇▇▇▇▇▇'▇ Annual Report on Form 10-K for the year
ended ▇▇▇▇▇ ▇▇, ▇▇▇▇.
# # #
▇
K&E Draft 9/20/05
Exhibit D
REGISTRATION AGREEMENT
THIS REGISTRATION AGREEMENT (this "Agreement") is made as of
_________ __, 200_,(1) by and between ▇▇▇▇▇▇ Technologies, Inc., a Delaware
corporation to be renamed Sirona Dental Systems, Inc. (the "Company"), and
Sirona Holdings Luxco S.C.A., a societe en commandite par actions, organized
under the laws of the Grand Duchy of Luxembourg (the "Investor").
The parties to this Agreement and ▇▇▇▇▇ ▇▇-▇▇▇ ▇▇▇▇, to be renamed
Sirona Holding GmbH, are parties to an Exchange Agreement, dated September __,
2005 (as amended, the "Exchange Agreement"). In order to induce the Investor to
enter into the Exchange Agreement, the Company has agreed to provide the
registration rights set forth in this Agreement. The execution and delivery of
this Agreement is a condition to the Closing under the Exchange Agreement.
Unless otherwise provided in this Agreement, capitalized terms used herein shall
have the meanings set forth in Section 10 hereof.
NOW, THEREFORE, in consideration of the mutual covenants contained
herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties to this Agreement hereby agree as
follows:
1. Demand Registrations.
(a) Requests for Registration. Subject to the terms and conditions
of this Section 1, at any time the holders of a majority of the Registrable
Securities may request, in writing, registration under the Securities Act of all
or any portion of their Registrable Securities on Form S-1 or any similar
long-form registration ("Long-Form Registrations") or on Form S-3 (including
pursuant to Rule 415 under the Securities Act) or any similar short-form
registration ("Short-Form Registrations") if available. All registrations
requested pursuant to this Section 1(a) are referred to herein as "Demand
Registrations". Each request for a Demand Registration shall specify the
approximate number of Registrable Securities requested to be registered, the
anticipated per share price range for such offering and the intended method of
distribution. The Company shall give written notice of such requested
registration to all other holders of Registrable Securities and, subject to the
terms of Section 1(d) hereof, shall include in such registration (and in all
related registrations and qualifications under state blue sky laws or in
compliance with other registration requirements and in any related underwriting)
all Registrable Securities with respect to which the Company has received
written requests for inclusion therein within 20 days after the receipt of the
Company's notice (the "Included Registrable Securities").
(b) Long-Form Registrations. The holders of Registrable Securities
shall be entitled to request three Long-Form Registrations in which the Company
shall pay all Registration Expenses. A registration shall not count as one of
the permitted Long-Form
----------
(1) Will be dated as of the Closing Date (as defined in the Exchange Agreement).
Registrations until it has become effective, and the last Long-Form Registration
shall not count as one of the permitted Long-Form Registrations unless the
holders of Registrable Securities are able to register and sell at least 90% of
the Registrable Securities requested to be included in such registration;
provided that in any event the Company shall pay all Registration Expenses in
connection with any registration initiated as a Long-Form Registration whether
or not it has become effective and whether or not such registration has counted
as one of the permitted Long-Form Registrations. Unless otherwise determined by
the holders of a majority of the Registrable Securities, all Long-Form
Registrations shall be underwritten registrations.
(c) Short-Form Registrations. In addition to the Long-Form
Registrations provided pursuant to Section 1(b), the holders of Registrable
Securities shall be entitled to request an unlimited number of Short-Form
Registrations in which the Company shall pay all Registration Expenses; provided
that the aggregate offering value of the Registrable Securities requested to be
registered in any Short-Form Registration must equal at least $20 million, based
on the anticipated per share price range (as specified in the request for such
registration) for such offering. Demand Registrations shall be Short-Form
Registrations whenever the Company is permitted to use any applicable short form
and if the managing underwriters (if any) agree to the use of a Short-Form
Registration. The Company shall use its best efforts to make Short-Form
Registrations on Form S-3 available for the sale of Registrable Securities. If
the Company, pursuant to the request of the holders of a majority of Registrable
Securities, is qualified to and has filed with the Securities and Exchange
Commission a registration statement under the Securities Act on Form S-3
pursuant to Rule 415 under the Securities Act (the "Required Registration"),
then the Company shall use its best efforts to cause the Required Registration
to be declared effective under the Securities Act as soon as practicable after
filing, and, once effective, the Company shall cause such Required Registration
to remain effective for a period ending on the earlier of (i) the date on which
all Included Registrable Securities have been sold pursuant to the Required
Registration, or (ii) the date as of which the holders of the Included
Registrable Securities (assuming such holders are affiliates of the Company) are
able to sell all of the Registrable Securities then held by them within a 90-day
period in compliance with Rule 144 under the Securities Act.
(d) Priority on Demand Registrations. Except for Common Stock
required to be included in such Demand Registration pursuant to the Existing
Registration Agreements, the Company shall not include in any Demand
Registration any securities which are not Registrable Securities without the
prior written consent of the holders of a majority of the Registrable Securities
included in such registration. If a Demand Registration is an underwritten
offering and the managing underwriters advise the Company in writing that in
their opinion the number of Registrable Securities and, if permitted hereunder,
other securities requested to be included in such offering exceeds the number of
Registrable Securities and other securities, if any, which can be sold in an
orderly manner in such offering within a price range acceptable to the holders
of a majority of the Registrable Securities requested to be included in such
registration, then the Company shall include in such registration prior to the
inclusion of any securities which are not Registrable Securities or Existing
Registrable Securities, the number of Registrable Securities and the number of
Existing Registrable Securities requested to be included which in the opinion of
such underwriters can be sold in an orderly manner within the price range of
such offering, pro rata among the respective holders thereof on the basis of the
amount of Registrable Securities and Existing Registrable Securities owned by
each such holder. Any Persons other than holders
-2-
of Registrable Securities or Existing Registrable Securities who participate in
Demand Registrations which are not at the Company's expense must pay their share
of the Registration Expenses as provided in Section 5 hereof.
(e) Restrictions on Long-Form Registrations. The Company shall not
be obligated to effect any Long-Form Registration within 90 days after the
effective date of a previous Long-Form Registration or a previous registration
in which Registrable Securities were included pursuant to Section 2 and in which
there was no material reduction in the number of Registrable Securities
requested to be included. Notwithstanding the foregoing, (i) the Company may
postpone for up to 90 days the filing or the effectiveness of a Long-Form
Registration for a Demand Registration if the Company shall furnish to the
holders of Registrable Securities a certificate signed by the Chief Executive
Officer of the Company stating that in the good faith judgment of the Company's
Board of Directors it would be seriously detrimental to the Company or its
stockholders for a registration statement to be filed in the near future and
setting forth the reasons for such judgment, and (ii) the Company shall not be
obligated to effect a registration pursuant to this Section 1 during the thirty
days prior to the Company's estimated date of filing a registration statement
for the account of the Company, provided that the Company is actually employing
in good faith its best efforts to cause such registration statement to become
effective; provided that in such event, the holders of Registrable Securities
initially requesting such Demand Registration shall be entitled to withdraw such
request and, if such request is withdrawn, such Demand Registration shall not
count as one of the permitted Demand Registrations hereunder and the Company
shall pay all Registration Expenses in connection with such registration. The
Company may delay a Demand Registration hereunder only once in any twelve-month
period.
(f) Selection of Underwriters. In connection with any underwritten
Demand Registration, the Company shall have the right to designate the managing
underwriter or underwriters, subject to the consent of the holders of a majority
of the Registrable Securities participating in the underwriting, which consent
shall not be unreasonably withheld or delayed if such underwriter or
underwriters are of recognized national standing.
(g) Other Registration Rights. Except for the Existing Registration
Agreements, the Company represents and warrants that it is not a party to, or
otherwise subject to, any other agreement granting registration rights to any
other Person with respect to any securities of the Company. As of the date of
this Agreement, no party to any Existing Registration Agreement has breached or
violated any such agreement and no such agreement has been amended, waived or
modified since the date of the Exchange Agreement. The Company has delivered
true and complete copies of each Existing Registration Agreement, each as
amended (including any assignments or transfers of rights or obligations related
thereto), to the Investor. The Company shall not amend, waive or modify the
terms and conditions of the Existing Registration Agreements without the prior
written consent of the holders of a majority of the Registrable Securities.
Except as provided in this Agreement, the Company shall not grant to any Persons
the right to request the Company to register any equity securities of the
Company, or any securities convertible or exchangeable into or exercisable for
such securities, without the prior written consent of the holders of a majority
of the Registrable Securities if, as a consequence of the granting of any such
rights, the rights of any holder of Registrable Securities could be adversely
affected.
-3-
2. Piggyback Registrations.
(a) Right to Piggyback. Whenever the Company proposes to register
any of its securities under the Securities Act (other than pursuant to a Demand
Registration) and the registration form to be used may be used for the
registration of Registrable Securities (other than a registration statement
relating either to the sale of securities to employees of the Company pursuant
to a stock option, stock purchase or similar plan or a Rule 145 transaction) (a
"Piggyback Registration"), the Company shall give prompt written notice (in any
event within five business days after its receipt of notice of any exercise of
demand registration rights other than under this Agreement) to all holders of
Registrable Securities of its intention to effect such a registration and,
subject to the terms of Sections 2(c) and 2(d) hereof, shall include in such
registration (and in all related registrations or qualifications under blue sky
laws or in compliance with other registration requirements and in any related
underwriting) all Registrable Securities with respect to which the Company has
received written requests for inclusion therein within 20 days after the receipt
of the Company's notice. The foregoing notwithstanding, the Company may, in its
discretion, withdraw any registration statement referred to in this Section 2
prior to the effectiveness thereof.
(b) Piggyback Expenses. The Registration Expenses of the holders of
Registrable Securities shall be paid by the Company in all Piggyback
Registrations.
(c) Priority on Primary Registrations. If a Piggyback Registration
is an underwritten primary registration on behalf of the Company, and the
managing underwriters advise the Company in writing that in their opinion the
number of securities requested to be included in such registration exceeds the
number which can be sold in an orderly manner in such offering within a price
range acceptable to the Company, then the Company shall include in such
registration (i) first, the securities the Company proposes to sell, (ii)
second, the Registrable Securities and the Existing Registrable Securities
requested to be included in such registration, pro rata among the holders of
such Registrable Securities and such Existing Registrable Securities on the
basis of the number of shares owned by each such holder, and (iii) third, other
securities requested to be included in such registration.
(d) Priority on Secondary Registrations. If a Piggyback Registration
is an underwritten secondary registration on behalf of holders of the Company's
securities, and the managing underwriters advise the Company in writing that in
their opinion the number of securities requested to be included in such
registration exceeds the number which can be sold in an orderly manner in such
offering within a price range acceptable to the holders of a majority of the
Registrable Securities requested to be included in such registration, then the
Company shall include in such registration (i) first, the securities requested
to be included therein by the holders requesting such registration (other than
Registrable Securities and Existing Registrable Securities) pursuant to demand
registration rights, (ii) second, the Registrable Securities and the Existing
Registrable Securities requested to be included in such registration, pro rata
among the holders of such Registrable Securities and such Existing Registrable
Securities on the basis of the number of shares owned by each such holder, and
(iii) third, other securities requested to be included in such registration.
-4-
(e) Selection of Underwriters. If any Piggyback Registration is an
underwritten offering, the Company shall have the right to designate the
managing underwriter or underwriters, subject to the consent of the holders of a
majority of the Registrable Securities participating in the underwriting, which
consent shall not be unreasonably withheld or delayed if such underwriter or
underwriters are of recognized national standing.
(f) Other Registrations. If the Company has previously filed a
registration statement with respect to Registrable Securities pursuant to
Section 1 or pursuant to this Section 2, and if such previous registration has
not been withdrawn or abandoned, then, unless such previous registration is a
Required Registration, the Company shall not file or cause to be effected any
other registration of any of its equity securities or securities convertible or
exchangeable into or exercisable for its equity securities under the Securities
Act (except on Form S-8 or any successor form), whether on its own behalf or at
the request of any holder or holders of such securities, until a period of at
least 180 days (or, in the case of a registration pursuant to Section 2.1 of the
Greystone Registration Agreement or Section 2.6 of the DVI Registration
Agreement, 90 days) has elapsed from the effective date of such previous
registration except if permitted to do so by the holders of a majority of the
Registrable Securities as to which registration has been requested.
3. Holdback Agreements.
(a) Each holder of Registrable Securities shall not effect any
public sale or distribution (including sales pursuant to Rule 144) of equity
securities of the Company, or any securities convertible into or exchangeable or
exercisable for such securities, during the seven days prior to and the 180-day
period beginning on the effective date of any underwritten Demand Registration
or any underwritten Piggyback Registration in which Registrable Securities are
included (except as part of such underwritten registration), unless the
underwriters managing the registered public offering otherwise agree.
(b) The Company (i) shall not effect any public sale or distribution
of its equity securities, or any securities convertible into or exchangeable or
exercisable for such securities, during the seven days prior to and during the
180-day period beginning on the effective date of any underwritten Demand
Registration or any underwritten Piggyback Registration (except as part of such
underwritten registration or pursuant to registrations on Form S-8 or any
successor form), unless the underwriters managing the registered public offering
otherwise agree, and (ii) to the extent not inconsistent with applicable law,
except as otherwise permitted by the holders of a majority of the Registrable
Securities, shall use its best efforts to cause each holder of at least 1% (on a
fully-diluted basis) of its Common Stock, or any securities convertible into or
exchangeable or exercisable for Common Stock, purchased or acquired from the
Company at any time after the date of this Agreement (other than in a registered
public offering) to agree not to effect any public sale or distribution
(including sales pursuant to Rule 144) of any such securities during such period
(except as part of such underwritten registration, if otherwise permitted),
unless the underwriters managing the registered public offering otherwise agree.
4. Registration Procedures. Whenever the holders of Registrable
Securities have requested that any Registrable Securities be registered pursuant
to this Agreement, the
-5-
Company shall use its best efforts to effect the registration and the sale of
such Registrable Securities in accordance with the intended method of
disposition thereof, and pursuant thereto the Company shall as expeditiously as
possible:
(a) prepare and file with the Securities and Exchange Commission a
registration statement, and all amendments and supplements thereto and related
prospectuses as may be necessary to comply with applicable securities laws, with
respect to such Registrable Securities and use its best efforts to cause such
registration statement to become effective (provided that before filing a
registration statement or prospectus or any amendments or supplements thereto,
the Company shall furnish to the counsel selected by the holders of a majority
of the Registrable Securities covered by such registration statement copies of
all such documents proposed to be filed, which documents shall be subject to the
review and comment of such counsel);
(b) notify in writing each holder of Registrable Securities of the
effectiveness of each registration statement filed hereunder and prepare and
file with the Securities and Exchange Commission such amendments and supplements
to such registration statement and the prospectus used in connection therewith
as may be necessary to keep such registration statement effective for a period
of not less than 180 days (or, if such registration statement relates to an
underwritten offering, such longer period as in the opinion of counsel for the
underwriters a prospectus is required by law to be delivered in connection with
sales of Registrable Securities by an underwriter or dealer) and comply with the
provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement during such period in
accordance with the intended methods of disposition by the sellers thereof set
forth in such registration statement;
(c) furnish to each seller of Registrable Securities such number of
copies of a prospectus or prospectus supplements and such other documents as
such seller may reasonably request in order to facilitate the disposition of the
Registrable Securities owned by such seller;
(d) use its best efforts to register or qualify such Registrable
Securities under such other securities or blue sky laws of such jurisdictions as
any seller reasonably requests and do any and all other acts and things which
may be reasonably necessary or advisable to enable such seller to consummate the
disposition in such jurisdictions of the Registrable Securities owned by such
seller (provided that the Company shall not be required to (i) qualify generally
to do business in any jurisdiction where it would not otherwise be required to
qualify but for this clause (d), (ii) subject itself to taxation in any such
jurisdiction or (iii) consent to general service of process in any such
jurisdiction);
(e) promptly notify in writing each seller of such Registrable
Securities, at any time when a prospectus relating thereto is required to be
delivered under the Securities Act, of the happening of any event as a result of
which the prospectus included in such registration statement (i) contains an
untrue statement of a material fact or omits any fact necessary to make the
statements therein not misleading or (ii) is otherwise not legally available to
support sales of Registrable Securities, and, at the request of the holders of a
majority of the Registrable Securities covered by such registration statement,
the Company shall promptly prepare a supplement or amendment to such prospectus
so that, as thereafter delivered to the purchasers of
-6-
such Registrable Securities, such prospectus shall not contain an untrue
statement of a material fact or omit to state any fact necessary to make the
statements therein not misleading;
(f) cause all such Registrable Securities to be listed on each
securities exchange on which similar securities issued by the Company are then
listed, if the listing of Registrable Securities is then permitted under the
rules of such exchange, or to secure listing of Registrable Securities on the
Nasdaq Stock Market as a "National Market System Security" within the meaning of
Rule 11Aa2-1 of the Securities and Exchange Commission or, failing that, to
secure listing on the Nasdaq Small Cap Market for such Registrable Securities
and, without limiting the generality of the foregoing, to arrange for at least
two market makers to register as such with respect to such Registrable
Securities with the National Association of Securities Dealers, Inc.;
(g) provide a transfer agent and registrar for all such Registrable
Securities not later than the effective date of such registration statement;
(h) enter into such customary agreements (including underwriting
agreements in customary form) and take all such other actions as the holders of
a majority of the Registrable Securities being sold or the underwriters, if any,
reasonably request in order to expedite or facilitate the disposition of such
Registrable Securities;
(i) make available for inspection by any seller of Registrable
Securities, any underwriter participating in any disposition pursuant to such
registration statement and any attorney, accountant or other agent retained by
any such seller or underwriter, all financial and other records, pertinent
corporate documents and properties of the Company, and cause the Company's
officers, directors, employees and independent accountants to supply all
information reasonably requested by any such seller, underwriter, attorney,
accountant or agent in connection with such registration statement;
(j) otherwise use its best efforts to comply with all applicable
rules and regulations of the Securities and Exchange Commission, and make
available to its security holders, as soon as reasonably practicable, an
earnings statement covering the period of at least twelve months beginning with
the first day of the Company's first full calendar quarter after the effective
date of the registration statement, which earnings statement shall satisfy the
provisions of Section 11(a) of the Securities Act and Rule 158 thereunder;
(k) permit any holder of Registrable Securities, which holder, in
its sole and exclusive judgment, exercised in good faith, might be deemed to be
an underwriter or a controlling person of the Company, to participate in the
preparation of such registration or comparable statement and to require the
insertion therein of material, furnished to the Company in writing, which in the
reasonable judgment of such holder and its counsel should be included and which
is reasonably acceptable to the Company;
(l) in the event of the issuance of any stop order suspending the
effectiveness of a registration statement, or of any order suspending or
preventing the use of any related prospectus or suspending the qualification of
any equity securities included in such registration
-7-
statement for sale in any jurisdiction, use its best efforts to promptly obtain
the withdrawal of such order;
(m) use its best efforts to cause such Registrable Securities
covered by such registration statement to be registered with or approved by such
other governmental agencies or authorities as may be necessary to enable the
sellers thereof to consummate the disposition of such Registrable Securities;
(n) obtain one or more cold comfort letters, dated the effective
date of such registration statement (and, if such registration includes an
underwritten public offering, dated the date of the closing under the
underwriting agreement), from the Company's independent public accountants in
customary form and covering such matters of the type customarily covered by cold
comfort letters as the holders of a majority of the Registrable Securities being
sold in such registered offering reasonably request (provided that such
Registrable Securities constitute at least 10% of the securities covered by such
registration statement); and
(o) provide a legal opinion of the Company's outside counsel, dated
the effective date of such registration statement (and, if such registration
includes an underwritten public offering, dated the date of the closing under
the underwriting agreement), with respect to the registration statement, each
amendment and supplement thereto, the prospectus included therein (including the
preliminary prospectus) and such other documents relating thereto in customary
form and covering such matters of the type customarily covered by legal opinions
of such nature.
5. Registration Expenses.
(a) Subject to Section 5(b) below, all expenses, other than
underwriting discounts and commissions, incident to the Company's performance of
or compliance with this Agreement, including all registration, qualification and
filing fees, fees and expenses of compliance with securities or blue sky laws,
printing expenses, messenger and delivery expenses, fees and disbursements of
custodians, and fees and disbursements of counsel for the Company and all
independent certified public accountants, underwriters (excluding discounts and
commissions) and other Persons retained by the Company (all such expenses being
herein called "Registration Expenses"), shall be borne as provided in this
Agreement, except that the Company shall, in any event, pay its internal
expenses (including all salaries and expenses of its officers and employees
performing legal or accounting duties), the expense of any annual audit or
quarterly review, the expense of any liability insurance and the expenses and
fees for listing the securities to be registered on each securities exchange on
which similar securities issued by the Company are then listed or on the NASD
automated quotation system.
(b) In connection with each Demand Registration and each Piggyback
Registration, the Company shall reimburse the holders of Registrable Securities
included in such registration for the reasonable fees and disbursements of one
counsel chosen by the holders of a majority of the Registrable Securities
included in such registration.
(c) To the extent Registration Expenses are not required to be paid
by the Company, each holder of securities included in any registration hereunder
shall pay those
-8-
Registration Expenses allocable to the registration of such holder's securities
so included, and any Registration Expenses not so allocable shall be borne by
all sellers of securities included in such registration in proportion to the
aggregate selling price of the securities to be so registered.
6. Indemnification.
(a) The Company agrees to indemnify and hold harmless, to the extent
permitted by law, each holder of Registrable Securities, its officers, partners,
managers and directors and each Person who controls such holder (within the
meaning of the Securities Act) against all losses, claims, actions, damages,
liabilities and expenses caused by (i) any untrue or alleged untrue statement of
material fact contained in any registration statement, prospectus or preliminary
prospectus or any amendment thereof or supplement thereto or any omission or
alleged omission of a material fact required to be stated therein or necessary
to make the statements therein not misleading, or (ii) any violation or alleged
violation by the Company of the Securities Act or any other similar federal or
state securities laws or any rule or regulation promulgated thereunder
applicable to the Company and relating to action or inaction required of the
Company in connection with any such registration, qualification or compliance,
and to pay to each holder of Registrable Securities, its officers, partners,
managers and directors and each Person who controls such holder (within the
meaning of the Securities Act), as incurred, any legal and any other expenses
reasonably incurred in connection with investigating, preparing or defending any
such claim, loss, damage, liability or action, except (x) insofar as the same
are caused by or contained in any information furnished in writing to the
Company by such holder expressly for use therein or by such holder's failure to
deliver a copy of the registration statement or prospectus or any amendments or
supplements thereto after the Company has furnished such holder with a
sufficient number of copies of the same and (y) amounts paid in settlement of
any such claim, loss, damage, liability or action if such settlement is effected
without the consent of the Company (which consent shall not be unreasonably
withheld or delayed). In connection with an underwritten offering, the Company
shall indemnify such underwriters, their officers, partners, managers and
directors and each Person who controls such underwriters (within the meaning of
the Securities Act) to the same extent as provided above with respect to the
indemnification of the holders of Registrable Securities.
(b) In connection with any registration statement in which a holder
of Registrable Securities is participating, each such holder shall furnish to
the Company in writing such information and affidavits as the Company reasonably
requests for use in connection with any such registration statement or
prospectus and, to the extent permitted by law, shall indemnify and hold
harmless the other holders of Registrable Securities and the Company, and their
respective directors, partners, managers and officers and each other Person who
controls the Company (within the meaning of the Securities Act) against any
losses, claims, damages, liabilities and expenses resulting from any untrue or
alleged untrue statement of material fact contained in the registration
statement, prospectus or preliminary prospectus or any amendment thereof or
supplement thereto or any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein not
misleading, but only to the extent that such untrue statement or omission is
contained in any information or affidavit so furnished in writing by such
holder; provided that the obligation to indemnify shall be individual, not joint
and several, for each holder and shall be limited to the net amount of proceeds
received by such holder from the sale of Registrable Securities pursuant to such
registration statement;
-9-
provided further that such indemnification shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or expense if such
settlement is effected without the consent of the holder providing such
indemnification (which consent shall not be unreasonably withheld or delayed).
(c) Any Person entitled to indemnification hereunder shall (i) give
prompt written notice to the indemnifying party of any claim with respect to
which it seeks indemnification (provided that the failure to give prompt notice
shall not impair any Person's right to indemnification hereunder to the extent
such failure has not prejudiced the indemnifying party) and (ii) unless in such
indemnified party's reasonable judgment a conflict of interest between such
indemnified and indemnifying parties may exist with respect to such claim,
permit such indemnifying party to assume the defense of such claim with counsel
reasonably satisfactory to the indemnified party. If such defense is assumed,
the indemnifying party shall not be subject to any liability for any settlement
made by the indemnified party without its consent (but such consent shall not be
unreasonably withheld). An indemnifying party who is not entitled to, or elects
not to, assume the defense of a claim shall not be obligated to pay the fees and
expenses of more than one counsel for all parties indemnified by such
indemnifying party with respect to such claim, unless in the reasonable judgment
of any indemnified party a conflict of interest may exist between such
indemnified party and any other of such indemnified parties with respect to such
claim. In such instance, the conflicting indemnified parties shall have a right
to retain one separate counsel, chosen by the holders of a majority of the
Registrable Securities included in the registration, at the expense of the
indemnifying party. Except as otherwise agreed by the holders of a majority of
the Registrable Securities, no indemnifying party, in the defense of such claim
or litigation, shall, except with the consent of each indemnified party, consent
to the entry of any judgment or enter into any settlement which does not include
as an unconditional term thereof the giving by the claimant or plaintiff to such
indemnified party of a release from all liability in respect to such claim or
litigation.
(d) The indemnification and contribution provided for under this
Agreement shall remain in full force and effect regardless of any investigation
made by or on behalf of the indemnified party or any officer, partner, manager,
director or controlling Person of such indemnified party and shall survive the
transfer of securities.
(e) If the indemnification provided for in this Section 6 is held by
a court of competent jurisdiction to be unavailable to an indemnified party or
is otherwise unenforceable with respect to any loss, claim, damage, liability or
action referred to herein, then the indemnifying party, in lieu of indemnifying
such indemnified party hereunder, shall contribute to the amounts paid or
payable by such indemnified party as a result of such loss, claim, damage,
liability or action in such proportion as is appropriate to reflect the relative
fault of the indemnifying party on the one hand and of the indemnified party on
the other hand in connection with the statements or omissions which resulted in
such loss, claim, damage, liability or action as well as any other relevant
equitable considerations; provided that the maximum amount of liability in
respect of such contribution shall be limited, in the case of each seller of
Registrable Securities, to an amount equal to the net proceeds actually received
by such seller from the sale of Registrable Securities effected pursuant to such
registration. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to
-10-
state a material fact relates to information supplied by the indemnifying party
or by the indemnified party and the parties' relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission.
(f) The parties hereto agree that it would not be just or equitable
if the contribution pursuant to this Section 6 were to be determined by pro rata
allocation or by any other method of allocation that does not take into account
such equitable considerations. The amount paid or payable by an indemnified
party as a result of the losses, claims, damages, liabilities or expenses
referred to herein shall be deemed to include any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating
or defending against any action or claim which is the subject hereof. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any Person who is not
guilty of such fraudulent misrepresentation.
7. Participation in Underwritten Registrations. No Person may
participate in any registration hereunder which is underwritten unless such
Person (i) agrees to sell such Person's securities on the basis provided in any
underwriting arrangements agreed upon between the Company and the underwriters
selected by the Company in accordance with this Agreement (including pursuant to
any over-allotment or "green shoe" option requested by the underwriters,
provided that no holder of Registrable Securities shall be required to sell more
than the number of Registrable Securities such holder has requested to include)
and (ii) completes and executes all questionnaires, powers of attorney,
indemnities, underwriting agreements and other documents reasonably required
under the terms of such underwriting arrangements; provided that no holder of
Registrable Securities included in any underwritten registration shall be
required to make any representations or warranties to the Company or the
underwriters (other than representations and warranties regarding such holder
and such holder's intended method of distribution) or to undertake any
indemnification obligations to the Company or the underwriters with respect
thereto, except as otherwise provided in Section 6 hereof.
8. Furnish Information. Upon request from time to time by the
Company, the holders of Registrable Securities shall furnish to the Company such
information regarding themselves, the Registrable Securities held by them, and
the intended method of disposition of such securities to the extent the Company
reasonably requires such information in order to undertake its obligations
pursuant to this Agreement.
9. Additional Parties; Joinder. In connection with the issuance of
additional equity securities of the Company, the Company, with the prior written
consent of the holders of a majority of the Registrable Securities, may permit
any Person who acquires Common Stock or rights to acquire Common Stock after the
date hereof (the "Acquired Common") to become a party to this Agreement and to
succeed to all of the rights and obligations of a "holder of Registrable
Securities" under this Agreement by obtaining an executed joinder to this
Agreement from such Person in the form of Exhibit 1 attached hereto, and upon
the execution and delivery of the joinder by such Person, such Person shall for
all purposes be a "holder of Registrable Securities" under this Agreement with
respect to the Acquired Common.
-11-
10. Definitions.
(a) "Common Stock" means any class of the Company's common stock.
(b) "DVI Registration Agreement" means the Registration Rights
Agreement between the Company and DVI Financial Services, Inc., dated as of
March 15, 2000, as amended by the First Amendment thereto, dated as of September
__, 2005.
(c) "Existing Registrable Securities" means Registrable Securities
(for this purpose only as defined in the DVI Registration Agreement) under the
DVI Registration Agreement and Registrable Securities (for this purpose only as
defined in the Greystone Registration Agreement) under the Greystone
Registration Agreement.
(d) "Existing Registration Agreements" means the DVI Registration
Agreement and the Greystone Registration Agreement.
(e) "Greystone Registration Agreement" means the Registration Rights
Agreement between the Company and Greystone Funding Corporation, dated as of
December 27, 1999, as amended by the First Amendment thereto, dated as of
September __, 2005.
(f) "Registrable Securities" means (i) any Common Stock issued
pursuant to the Exchange Agreement, (ii) any Common Stock issued or issuable
with respect to the securities referred to in clauses (i) above by way of a
stock dividend or stock split or in connection with a combination of shares,
recapitalization, merger, consolidation or other reorganization, and (iii) any
other Common Stock held by Persons holding securities described in clauses (i)
to (ii), inclusive, above. As to any particular Registrable Securities, such
securities shall cease to be Registrable Securities when they (i) have been
distributed to the public pursuant to an offering registered under the
Securities Act or in compliance with Rule 144 under the Securities Act (or any
similar rule then in force), (ii) except to the extent otherwise elected by a
holder of Registrable Securities, have been distributed or transferred to the
direct or indirect partners or other equity holders of such holder of
Registrable Securities or (iii) have been repurchased by the Company or any of
its subsidiaries.
(g) Unless otherwise stated, other capitalized terms contained
herein have the meanings set forth in the Exchange Agreement.
11. Miscellaneous.
(a) No Inconsistent Agreements. The Company shall not hereafter
enter into any agreement with respect to its securities which is inconsistent
with or violates the rights granted to the holders of Registrable Securities in
this Agreement.
(b) Adjustments Affecting Registrable Securities. The Company shall
not take any action, or permit any change to occur, with respect to its
securities which would adversely affect the ability of the holders of
Registrable Securities to include such Registrable Securities in a registration
undertaken pursuant to this Agreement or which would adversely affect the
marketability of such Registrable Securities in any such registration.
-12-
(c) Remedies. Any Person having rights under any provision of this
Agreement shall be entitled to enforce such rights specifically (without posting
a bond or other security), to recover damages caused by reason of any breach of
any provision of this Agreement and to exercise all other rights granted by law.
The parties hereto agree and acknowledge that money damages would not be an
adequate remedy for any breach of the provisions of this Agreement and that, in
addition to any other rights and remedies existing in its favor, any party shall
be entitled to specific performance and/or other injunctive relief from any
court of law or equity of competent jurisdiction (without posting any bond or
other security) in order to enforce or prevent violation of the provisions of
this Agreement.
(d) Amendments and Waivers. Except as otherwise provided herein, the
provisions of this Agreement may be amended or waived only upon the prior
written consent of the Company and holders of a majority of the Registrable
Securities. The failure of any party to enforce any of the provisions of this
Agreement shall in no way be construed as a waiver of such provisions and shall
not affect the right of such party thereafter to enforce each and every
provision of this Agreement in accordance with its terms.
(e) Successors and Assigns. All covenants and agreements in this
Agreement by or on behalf of any of the parties hereto shall bind and inure to
the benefit of the respective successors and assigns of the parties hereto
whether so expressed or not. In addition, whether or not any express assignment
has been made, the provisions of this Agreement which are for the benefit of
purchasers or holders of Registrable Securities are also for the benefit of, and
enforceable by, any subsequent holder of Registrable Securities.
(f) Severability. Whenever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be prohibited
by or invalid under applicable law, such provision shall be ineffective only to
the extent of such prohibition or invalidity, without invalidating the remainder
of this Agreement.
(g) Counterparts. This Agreement may be executed and delivered
simultaneously in two or more counterparts (including delivery by facsimile or
other electronic means), any one of which need not contain the signatures of
more than one party, but all such counterparts taken together shall constitute
one and the same Agreement.
(h) Descriptive Headings; Interpretation. The descriptive headings
of this Agreement are inserted for convenience only and do not constitute a
substantive part of this Agreement. The parties have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the parties and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any of
the provisions of this Agreement. Whenever required by the context, any pronoun
used in this Agreement shall include the corresponding masculine, feminine, or
neuter forms, and the singular form of nouns, pronouns, and verbs shall include
the plural and vice versa. The use of the word "including" in this Agreement
shall be, in each case, by way of example and without limitation. The use of the
words "or," "either," and "any" shall not be exclusive.
-13-
(i) Governing Law. All issues and questions concerning the
construction, validity, interpretation and enforcement of this Agreement and the
exhibits and schedules hereto shall be governed by, and construed in accordance
with, the laws of the State of Delaware, without giving effect to any choice of
law or conflict of law rules or provisions (whether of the State of Delaware or
any other jurisdiction) that would cause the application of the laws of any
jurisdiction other than the State of Delaware.
(j) Notices. All notices and other communications hereunder shall be
in writing and shall be deemed duly given (A) on the date of delivery if
delivered personally, (B) on the first Business Day following the date of
dispatch if delivered by a nationally recognized next-day courier service, (C)
on the third Business Day following the date of mailing if delivered by
registered or certified mail, return receipt requested, postage prepaid or (D)
if sent by facsimile transmission, with a copy mailed on the same day in the
manner provided in (A) or (B) above, when transmitted (with evidence of
transmission retained). All notices hereunder shall be delivered to the Company
or to the Investor as set forth below, or pursuant to such other instructions as
may be designated in writing by the party to receive such notice:
If to the Company:
Sirona Dental Systems, Inc.
▇▇-▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
with a copy to:
▇▇▇▇▇▇ & Whitney LLP
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇ ▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
If to the Investor:
Sirona Holdings Luxco S.C.A.
▇-▇▇, ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇
Facsimile: ▇▇▇▇ ▇▇▇-▇▇▇
-14-
and
Sirona Holdings Luxco S.C.A.
c/o Madison Dearborn Partners
Three First ▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
with copies to:
▇▇▇▇▇▇▇▇ & ▇▇▇▇▇ LLP
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. Perl, P.C.
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
and
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇, LLP
▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
(k) Mutual Waiver of Jury Trial. As a specifically bargained
inducement for each of the parties to enter into this Agreement (with each party
having had opportunity to consult counsel), each party hereto expressly and
irrevocably waives the right to trial by jury in any lawsuit or legal proceeding
relating to or arising in any way from this Agreement or the transactions
contemplated herein, and any lawsuit or legal proceeding relating to or arising
in any way to this Agreement or the transactions contemplated herein shall be
tried in a court of competent jurisdiction by a judge sitting without a jury.
* * * * *
-15-
IN WITNESS WHEREOF, the parties have executed this Registration
Agreement as of the date first written above.
▇▇▇▇▇▇ TECHNOLOGIES, INC.,
a Delaware corporation
BY:
--------------------------------
NAME:
ITS:
SIRONA HOLDINGS LUXCO S.C.A.,
a societe en commandite par actions,
organized under the laws of the Grand Duchy
of Luxembourg
BY: SIRONA HOLDINGS S.A.
ITS: MANAGER
BY:
----------------------------
NAME:
ITS:
BY:
----------------------------
NAME:
ITS:
Exhibit 1
REGISTRATION AGREEMENT
Joinder
The undersigned is executing and delivering this Joinder pursuant to
the Registration Agreement dated as of _______ __, 200_ (as the same may be
amended from time-to-time, the "Registration Agreement"), among Sirona Dental
Systems, Inc., a Delaware corporation formerly known as ▇▇▇▇▇▇ Technologies,
Inc. (the "Company"), and the other person(s) named as parties therein.
By executing and delivering this Joinder to the Company, the
undersigned hereby agrees to become a party to, to be bound by, and to comply
with the provisions of the Registration Agreement as a holder of Registrable
Securities in the same manner as if the undersigned were an original signatory
to the Registration Agreement, and the undersigned's ____ shares of Common Stock
shall be included as Registrable Securities under the Registration Agreement.
For purposes of Section 11(j) of the Registration Agreement, the undersigned's
address for notices is set forth below the undersigned's signature below.
Accordingly, the undersigned has executed and delivered this Joinder
as of the ___ day of ____________, 200__.
---------------------------------------
Signature of Stockholder
---------------------------------------
Print Name of Stockholder
Address for notices:
-------------------
-------------------
-------------------
-------------------
EXHIBIT E
CERTIFICATE OF AMENDMENT
TO
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
▇▇▇▇▇▇ TECHNOLOGIES, INC.
Pursuant to Section 242 of the Delaware General Corporation Law, ▇▇▇▇▇▇
Technologies, Inc., a Delaware corporation, hereby submits the following
amendments to its Amended and Restated Certificate of Incorporation:
1. The name of the corporation is ▇▇▇▇▇▇ Technologies, Inc. (the
"Corporation").
2. The Amended and Restated Certificate of Incorporation of the
Corporation is hereby amended by deleting article FIRST thereof in its entirety
and substituting in lieu of said article FIRST, the following new article FIRST:
"FIRST: The name of the corporation is Sirona Dental Systems,
Inc. (the "Corporation").
3. The Amended and Restated Certificate of Incorporation of the
Corporation is hereby amended by striking out the first paragraph of article
SIXTH thereof and by substituting in lieu of said first paragraph the following
new paragraph:
"SIXTH: CAPITAL STOCK
The aggregate number of shares of all classes of capital stock which
the Corporation shall have to issue is [____], of which [____] shall
be common stock, par value $.01 per share (the "Common Stock"), and
[_____] shall be preferred stock, par value $.01 per share (the
"Preferred Stock")."
4. The amendments of the Amended and Restated Certificate of Incorporation
herein certified has been duly adopted in accordance with the provisions of
Section 242 of the General Corporation Law of the State of Delaware.
* * * * *
The undersigned, on behalf of the Corporation, for the purpose of amending
the Corporation's Amended and Restated Certificate of Incorporation pursuant to
the Delaware General Corporation Law, does make this Certificate of Amendment,
hereby declaring and certifying that this is my act and deed on behalf of the
Corporation this ___ day of _______, 200__.
▇▇▇▇▇▇ TECHNOLOGIES, INC.
By:
------------------------------
Name:
------------------------------
Title:
------------------------------